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ABSTRACT
COURTNEY ELIZABETH KING. Role of the Oxytocin System in Alcohol
Consumption and Stress-Induced Alcohol Relapse-like Behavior (Under the direction
of HOWARD C. BECKER).
Alcoholism is a widespread public health concern with limited therapeutic
interventions available to help individuals battle relapse, moderate their use, and
sustain abstinence. While many variables contribute to relapse vulnerability, stress is
considered to play a prominent role in triggering relapse. The neuropeptide oxytocin
(OXT) has recently been implicated in a number of neuropsychiatric disorders,
including drug and alcohol use disorders. Given that OXT is known to interact with
brain reward systems and exert anxiolytic and anti-stress effects in humans and
rodents, the main overall hypothesis of this dissertation is that OXT (and OXT
receptor signaling) will be effective in reducing alcohol consumption and stressinduced alcohol relapse-like behavior. We demonstrate that systemic administration
of OXT reduced binge-like alcohol drinking, operant oral self-administration of
alcohol, and stress-induced relapse-like behavior in a dose-related manner in male
and female mice. Targeted chemogenetic activation of OXT neurons in the
paraventricular nucleus of the hypothalamus (PVN) reduced binge-like alcohol
drinking and operant oral self-administration in a similar manner as systemic
administration of the neuropeptide and this effect was reversed by pretreatment with
the centrally-active OXTR antagonist in males. Finally, administration of an OXTR
antagonist systemically and directly into the central amygdala blocked the effects of
OXT on stress-induced alcohol relapse-like behavior in male, but not female mice.
These data highlight potential sex differences in oxytocin receptor signaling and
support the therapeutic potential for OXT in treating alcohol use disorder.
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CHAPTER 1: Background and Significance
INTRODUCTION
Alcohol Use Disorder
Alcohol consumption represents a major social, economic and health
challenge that affects millions of people in the United States and around the
world. Alcohol intake, particularly heavy drinking, is identified as one of the most
relevant risk factors for disease, and premature disability and mortality
(Collaborators et al. 2015; Medina-Mora et al. 2016; Shield and Rehm 2019).
According to the most recent comparative risk assessment conducted by the
World Health Organization (WHO), alcohol consumption was the fifth highest
contributor to the global burden of disease and injury in most middle and highincome countries, exceeding many classical risk factors such as hyper-tension,
high cholesterol or tobacco use (WHO 2009). In the United States (U.S.) alone,
alcohol misuse is responsible for an approximately 88,000 deaths and 2.5 million
years of potential life lost (YPLL) annually from 2006-2010, making excessive
alcohol use the leading cause of premature mortality and the fourth highest
preventable cause of death (Stahre et al. 2014). However, one of the most
important consequences of alcohol use are alcohol use disorders (AUDs). As
currently defined by the Diagnostic and Statistic Manual, 5th Edition (DSM-V),
AUD (which encompasses both alcohol dependence (AD) and alcohol abuse) is
a heterogeneous disorder stemming from complex interactions of
neurobiological, environmental and genetic factors. This chronic, relapsing
disorder is characterized by compulsive and preoccupied alcohol use despite

negative consequences, loss of control over alcohol intake and the emergence of
a negative affective state (e.g. dysphoria, irritability, anxiety) when access of the
drug is prevented (Koob and Volkow 2016; Zorrilla et al. 2014). In the United
States, approximately 51% (120 million) of the population over the age of 12
reported as current alcohol users (Koob and Volkow 2010). Of these users,
approximately 13% (30 million) met the criteria for AUD (Grant et al. 2017).
Alcohol use disorder represents a staggering and substantial public health
concern, resulting in a myriad of medical, psychological, social and economic
problems.
Chronic alcohol use is extremely damaging to the human body. Indeed,
alcohol is a casual factor in more than 60 diseases, including liver cirrhosis and
cardiovascular disease and is involved in the etiology of more than 200 medical
conditions (WHO 2014a). Excessive alcohol use can have an effect on numerous
organs such as the gut, liver, pancreas and heart, contributing to endotoxemia,
advanced liver disease, pancreatitis, irregular heartbeat, stroke, high blood
pressure and cardiomyopathy (Souza-Smith et al. 2016). Further, increasing
research has documented a dose-relationship between alcohol consumption and
the development of cancer in different body locations, such as oral cavity,
pharynx, larynx, esophagus, colon/rectum and female breast (Medina-Mora et al.
2016; Rehm et al. 2018). Chronic alcoholism has also been associated with mild
to severe impairments in cognitive, behavioral and emotional functioning (Bates
et al. 2002) and has been shown to induce mood, anxiety, psychotic, sleep and
dementia disorders (Hayes et al. 2016).When left untreated, the co-occurrence of
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AUD and other psychiatric conditions (mood disorders, post-traumatic stress
disorder, schizophrenia and the use of other drugs; Petrakis et al. 2006) can
interact to further aggravate alcoholism’s effects on brain and behavior (Hasin et
al. 2007) and complicate treatment. Although dependent on the extent of
impairment at the time of drinking cessation, abstinent alcoholics have shown
improvements in neuropsychological functioning with continued sobriety (OscarBerman et al. 2014). However, up to 2 million people with an AUD development
permanent and debilitating conditions that require lifetime care (Oscar-Berman et
al. 2004; Oscar-Berman and Marinkovic 2003; Oscar-Berman et al. 1997)
Alcohol consumption may have a marked impact on others beyond the
health of the user. Alcohol-related harm affects families, neighbors, friends and
communities through risky behavior and negligence of drinkers while intoxicated.
Among a long list of consequences, harm to others includes (but is not limited
to): driving while impaired, family income loss, unemployment, work injuries,
increase in health expenses, property damage, absenteeism, domestic violence,
abuse, neglect and impact on family member’s mental health (depression,
anxiety), especially as a result of dysfunctional family environments affecting
normal child development (WHO 2014a). Harmful use of alcohol is also a major
contributor to violence; estimates suggest approximately 30% of total violent
deaths are attributable to alcohol (WHO 2011a). Additionally, increasingly
significant consequences of maternal drinking during pregnancy are pre-labor
complications and/or neurodevelopmental abnormalities, including fetal alcohol
syndrome (FAS) (Foltran et al. 2011)
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On average, alcohol dependence life-time prevalence rates are high
(roughly 15%; (Hasin and Grant 2004). Though treatment-seeking has been
found to increase rates of recovery from alcohol dependence, only a minority with
AUD seek and undergo formal treatment (Cohen et al. 2007). While some users
achieve long-term sobriety without active treatment, many individuals continue to
relapse despite multiple levels of intervention (Ferri et al. 2006). In fact, after a
single treatment episode, roughly only one in four patients will abstain from
alcohol in the first year (Miller et al. 2001). This may be due, in part, to many
different barriers to treatment such as stigma, not recognizing problems related
to alcohol, not acknowledging or perceiving a need for treatment, or wanting to
handle alcohol-related problems on one’s own (Cunningham et al. 1993; Glass et
al. 2017) In this regard, psychosocial interventions are perhaps the most utilized
and efficacious forms of intervention(Dawson et al. 2006) to achieve and
maintain recovery. Mutual help and self-help organizations, such as Alcoholics
Anonymous (AA), play a significant role in recovery for those interested in
reducing or ceasing drinking. However, while participation in AA or similar 12step group programs are often suggested as an adjunct for professional
treatment (and may have affiliations with treatment institutions) these groups are
not considered a formal treatment option (Medina-Mora et al. 2016; Sussman
2010). Clinical interventions, such as professional counseling, out-patient or inpatient programs can be costly (an additional barrier) and require high functional
social support to achieve program adherence (Dobkin et al. 2002). Thus, there
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remains a pressing need to develop lasting, successful and easily accessible
therapeutic strategies to prevent return to heavy alcohol drinking.
Pharmacological intervention is a potential treatment strategy to reduce
withdrawal symptoms and prevent relapse to alcohol drinking. Currently, there
are three drugs approved by the U.S. Food and Drug Administration (FDA) for
the treatment of AUD: Disulfiram (Antabuse), Naltrexone and Acamprosate
(Akbar et al. 2018). Although these pharmacotherapies have proven to be
beneficial for some people, success rates are variable and patient compliance is
poor due to deleterious medication side effects (Heilig and Egli 2006).
Additionally, there are a number of off-label medications (e.g., anticonvulsants,
antipsychotics, antidepressants, for review see (Akbar et al. 2018) for the
treatment of AUD targeting the physiological and negative affective symptoms of
withdrawal. However, there is currently no single medication or intervention that
boasts one hundred percent efficacy rate in supporting abstinence. Thus,
understanding the neurobiological underpinnings of alcohol addiction is critical to
the development of effective pharmacotherapeutics.

Addiction Neurocircuitry and Stages of Addiction
Addiction has been classically conceptualized as a cyclic brain disorder
composed of three general stages: ‘binge/intoxication’, ‘withdrawal/negative
affect’ and ‘preoccupation/anticipation’ (Koob and Volkow 2010). This composite
framework encompasses aspects of both impulse control disorders (positive
reinforcement mechanisms) and compulsive disorders (negative reinforcement
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mechanisms), in which impulsivity dictates the early stages of addiction and the
combination of impulsivity and compulsivity dominates the later stages (Koob and
Volkow 2010). While many individuals partake in occasional, controlled
substance use at some point in their lives, some substance users transition to
loss of control and chronic use. Research suggests that this transition by some
users in response to drug and/or alcohol use is mediated by neuroplastic
changes in brain reward-, stress- and executive function systems (Kalivas and
Volkow 2005; Koob 2008; Koob and Volkow 2010; Koob and Volkow 2016).
Alcohol and other drugs of abuse have both positive and negative
reinforcing properties. During the early stage of addiction (“binge/intoxication
stage”), drug use is motivated primarily by the acute reinforcing effects
(“positive”) of a substance mediated by mesocorticolimbic dopamine systems
(Koob 2013a). All addictive drugs have been shown to (directly or indirectly)
activate dopaminergic neurons originating in the ventral tegmental area (VTA).
These projections converge on targets in the limbic forebrain, including the
nucleus accumbens (NAc), which appears to be the primary region assigning
importance to the drug experience (Koob and Volkow 2010; Wise 1998). In
addition, alcohol has also been hypothesized to recruit non-dopaminergic
systems, particularly GABA and opioid peptides, to induce activity in the
mesolimbic system to signal reward (Nestler 2005; Tabakoff and Hoffman 2013).
Activation of dopamine systems by drugs of abuse sensitizes the reward system
and attaches incentive salience to both the substance and drug-related stimuli to
drive goal-directed (impulsive) behavior (Uhart and Wand 2009). The transition
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from controlled to compulsive drug taking has been associated with a shift in the
involvement of NAc to the dorsal striatum that is associated with habit formation
(Everitt and Robbins 2013; Volkow and Morales 2015).
As an individual continues further into the addiction cycle, neurochemical
systems other than those involved in the positive rewarding effects of drugs of
abuse are recruited by chronic activation of the reward system (Koob 2013a;
Koob 2013b; Koob and Le Moal 2005). The “withdrawal/negative affect” stage is
marked by the emergence of a negative emotional state (e.g., dysphoria, anxiety
and irritability) when access to the drug is prevented (Koob et al. 2004) and
primarily mediated by brain stress-systems (corticotrophin-releasing factor; CRF)
in the HPA-axis and extended amygdala (Koob 2008; Koob et al. 2004). Both
stress- and drug-induced activation of the HPA-axis allows glucocorticoids to
sensitize reward pathways, characterized by increases in reward thresholds
during withdrawal (Koob and Kreek 2007). As dependence and withdrawal
develop, brain “anti-reward” systems, such a CRF and dynorphin (DYN), are
recruited in the extended amygdala (Koob 2013a) contributing to dysphoria and
distress. Thus, the motivation to take drugs is not only driven by conditioned
response cues, but by negative emotional states.
The final stage of the addiction cycle (preoccupation/anticipation or
craving) is a key element of relapse and defines addiction as a chronic relapsing
disorder (Koob and Volkow 2010; Koob and Volkow 2016). In an addicted
individual, intense preoccupation with obtaining the abused substance develops
and often precedes the somatic signs of withdrawal. This behavior, commonly
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described as craving, represents a shift from goal-directed behavior to habitdriven (compulsive) behavior that results from drug-conditioned reinforcement,
altered incentive motivation and maladaptive stimulus-response learning (Koob
and Volkow 2010). In other words, continued heavy use becomes a conditioned
response to relieve and avoid withdrawal symptoms (ex. withdrawal-induced
seizures in alcoholics) (Tabakoff and Hoffman 2013).
This stage of addiction primarily involves loss of prefrontal cortical
executive control over intake (Everitt and Robbins 2005). Hypofunction of cortical
circuits is thought to play a permissive role in which subcortical structures that
drive addiction are no longer inhibited (Koob 2013a). In drug addicted individuals,
the ventromedial prefrontal cortex (including orbital frontal cortex (OFC) and
anterior cingulate cortex (ACC)) is hypofunctional in the absence of drug or drug
cues, but becomes hyperactive when exposed to drug or cues thereby enhancing
the reward salience (Volkow and Morales 2015). More specifically, exposure to
drug-associated cues results in activation of glutamatergic systems (projections
from the ventral prefrontal cortex, ventral hippocampus and amygdala) to striatal
regions that increase dopamine in the NAc and dorsal striatum (Volkow and
Morales 2015). Reduced dopamine signaling in the striatum contributes to
reduced activity of prefrontal cortical regions, particularly the OFC and ACC,
which represent brain regions essential for shifting behavior when a reward is no
longer reinforcing (Volkow and Morales 2015). As a result, circuits of the
extended amygdala that mediate enhanced reactivity to stressful stimuli,
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dysphoria, anhedonia and increased craving drive behavior, ultimately leading to
drug consumption (relapse).
In summary, during addiction the enhanced salience value of the abuse
substance in reward, motivation and learning/memory circuits overrides control
circuits. These circuits also interact with those involved in mood regulation,
including stress reactivity, which contribute to heightened awareness of craving
and drive vulnerability to relapse.

Disruption of Neurotransmitter Systems by Alcohol
Alcohol does not a have a specific receptor or site of action, which makes
it challenging to identify which specific factors are affected during the transition
from controlled to compulsive alcohol consumption. Alcohol is thought to impact
brain function through interaction with multiple neurotransmitter systems,
disrupting the delicate balance between inhibitory and excitatory
neurotransmission present under normal conditions. Acute alcohol exposure
enhances the function of inhibitory neurotransmitters and neuromodulators, such
as Gamma-aminobutyric acid (GABA), glycine and adenosine, and decreasing
the function of those involved in neuroexcitation, such as glutamate (OscarBerman 1994). More specifically, alcohol potentiates the effects of GABA through
the GABAA receptor subtype, increasing inhibition and sedation similar to
benzodiazepines (Nutt 1999). Chronic and repeated alcohol exposure reduces
the sensitivity of GABAA receptors to alcohol and GABA, such that more alcohol
is needed in order to achieve the same depressant and intoxicating effects.
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Additionally, alcohol increases the function of glycine receptors (inhibitory
neurotransmitter found in the brainstem and spinal cord) which may account for
some of alcohol’s behavioral effects (Valenzuela 1997).
Glutamatergic signaling is critically involved in the neuroplasticity that
occurs as dependence develops. Short-term alcohol exposure has also been
shown to interfere with some aspects of excitatory transmission by inhibiting Nmethyl-D-aspartate (NMDA) receptors that mediate post-synaptic excitatory
effects of glutamate (Nutt 1999; Tsai and Coyle 1998). Repeated cycles of
alcohol exposure and abstinence lead to elevated levels of extracellular
glutamate and/or dysregulation of glutamate transporters, particularly in the
amygdala and PFC (Bell et al. 2016) that contribute to craving that occurs in
abstinence (Pulvirenti and Diana 2001).
In response to prolonged exposure the brain undergoes compensatory
neuroadaptations to restore equilibrium. This includes the upregulation (hyperresponsiveness) of NMDA receptors and downregulation of GABAA receptors,
leading to tolerance. When alcohol consumption is abruptly discontinued or
reduced, the compensatory neuroadaptations are no longer in opposition to the
presence of alcohol, leading to hyperexcitability and development of alcohol
withdrawal syndrome, such as withdrawal-induced seizures, stroke, and
excitotoxicity (Tsai and Coyle 1998).
The mescorticolimbic dopaminergic system is altered in patients with
AUD. Alcohol directly stimulates the release of dopamine by disinhibiting
dopamine neurons in the VTA. These dopamine neurons project to medium spiny
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neurons (MSN) of the ventral striatum (VS) including those that express
dopamine D2 receptors in the NAc (Volkow and Morales 2015). Additionally,
alcohol intake enhances beta-endorphin release to stimulate mu-opioid receptors
in the VTA, resulting in the inhibition of GABAergic interneurons that normally
exert tonic inhibition of dopaminergic neurons in the VTA, resulting in a net effect
of enhanced dopamine release into the NAc (Di Chiara 1997; Di Chiara et al.
2004).
Alcohol exposure has also been shown to alter various aspects of
serotonin’s (5-HT) synaptic function (Lovinger 1997; Lovinger 1999). Acute
exposure has been shown elevate serotonin levels in regions that control
consumption (McBride et al. 1993) and appears to interfere with the function of
serotonin receptors. With prolonged exposure, serotonin receptors (ex. 5-HT2
subtype) undergo adaptive changes in response to increased serotonin activity,
and likely contribute increased anxiety during withdrawal (Lovinger 1997) and
development of co-occurring of mood disorders. Serotonin also plays a role in the
regulation of GABA-mediated transmission and dopaminergic activity, which may
also contribute to alcohol’s effect on the brain.

THE ROLE OF STRESS IN ALCOHOL USE AND RELAPSE
Stress and Alcohol
Stress, defined as any stimulus that disrupts the body’s internal balance
(i.e., physiological homeostasis), is recognized as a significant factor that
promotes alcohol drinking and, in particular, triggering relapse (Sinha 2001;
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Sinha 2008). Abnormal variations in the production of the stress hormone cortisol
are a risk factor for developing alcohol dependence (Blaine et al. 2016). Alcohol
serves as an effective anxiolytic (anxiety-reducing) agent and its ability to
alleviate stress may be a driving factor in the motivation to drink (i.e., selfmedication; Becker 2017). At the same time, alcohol-induced elevations in stress
hormones stimulate the HPA-axis at multiple levels, such that alcohol, itself, is a
stressor (Becker 2012; Becker 2017).This includes stimulating the release of
corticotrophin-releasing factor (CRF) from the hypothalamus (Sinha 2001; Smith
and Vale 2006), norepinephrine from the locus coeruleus (Koob 2008) as well as
other stress-related neuropeptides in extrahypothalamic stress circuits in the
brain (Koob 2009; Koob and Mason 2016). Repeated chronic alcohol exposure
and withdrawal can produce profound alterations in neuroendocrine function and
engage brain stress systems, which collectively contribute to increased alcohol
seeking and consumption (Koob and Kreek 2007; Lu and Richardson 2014;
Schank et al. 2012). Therefore, stress, alcohol and addiction are interconnected
in several ways. Stressful life events may predispose an individual to engage in
problematic drinking behavior (Sinha 2008), and excessive drinking may cause
activation of the HPA response, followed by sensitization of extrahypothalamic
CRF systems (Koob and Kreek 2007). Stress is reinforcing in certain contexts but
can also work to suppress the reward value of other (natural) reinforcers, which
contribute to negative affective states related to withdrawal (e.g., anxiety,
dysphoria, irritability) along with increased craving and drive to drink (Becker
2012; Heilig et al. 2010). The compulsive nature of alcohol seeking and use,
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along with high rates of relapse present a major challenge in the treatment of
alcohol addiction. Therefore, understanding brain mechanisms underlying
relapse and the influence of stress on drinking has emerged as a central issue in
addiction research. The following section presents what is known about stress as
it relates to alcohol abuse and the trajectory of dependence. Further, sex
differences in the role of stress reactivity and negative affect in initiating and
maintaining alcohol use will be discussed.

Alcohol, Stress and the Hypothalamic-Pituitary-Axis (HPA)
Many of the acute and chronic effects of alcohol are related to allostatic
adaptations in hypothalamic and extrahypothalamic stress regulation pathways.
Stress responses in relation to AUD includes the neuroendocrine responses of
the hypothalamic-pituitary axis (HPA), and two branches of the peripheral
autonomic nervous system (ANS), specifically the physiologic responses of the
sympathetic (SNS) and parasympathetic (PNS) arms (Boschloo et al. 2011). In
response to stress, neurons in the paraventricular nucleus (PVN) of the
hypothalamus releases two neurohormones, corticotrophin-release factor (CRF)
and arginine vasopressin (AVP) into the blood via a system of blood vessels at
the base of the brain (hypophysial portal system) connecting the hypothalamus
and the pituitary gland. Both hormones stimulate the anterior pituitary gland to
produce and secret adrenocorticotropic hormone (ACTH) into peripheral
circulation. The ACTH travels to the adrenal glands (atop the kidneys) and
induces glucocorticoid synthesis and release. The main glucocorticoid in humans
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is cortisol (termed corticosterone (CORT) in rodents). To protect the body against
prolonged activity, the HPA system is carefully controlled through negativefeedback loops designed to maintain precise hormone levels and homeostasis
(Stephens and Wand 2012). At the level of the anterior pituitary gland, PVN and
hippocampus, secretion of CRF, AVP and ACTH are in part controlled by
negative feedback exerted by cortisol (Herman and Tasker 2016; Stephens et al.
2012). There are two types of receptors for cortisol that participate in the
negative-feedback mechanism- mineralocorticoid (MR) and glucocorticoid (GR)
receptors (Herman et al. 2016). Cortisol has a higher affinity (i.e., binds more
readily) for MRs than GRs. This mechanism allows MRs to main low cortisol
levels circulating in the blood under normal conditions that rise and fall with a
daily circadian rhythm (Herman et al. 2016). In response to a stressful situation,
cortisol saturates MRs and binds to GRs with lower affinity, which terminates the
stress response. Basal and stress-induced cortisol are maintained carefully, as
correct regulation of cortisol levels is necessary for survival, and too little or too
much cortisol exposure can result in serious harm (Stephens and Wand 2012).
In addition to the HPA-axis, the also ANS plays a crucial role in the
maintenance of homeostasis. The ANS has two divisions: the SNS, which
mediates excitatory processes (“fight or flight”) and PNS which is responsible for
inhibitory processes (“Rest and Digest”). From the PVN, CRF-containing neurons
send projections to noradrenergic centers in the brain and spinal cord (Wehrwein
et al. 2016). More specifically, the locus coeruleus (LC) sends direct projections
to sympathetic preganglionic neurons in the spinal cord and to the
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parasympathetic preganglionic neurons in the brainstem and spinal cord. In
general, the LC modulates sympathetic and parasympathetic activity through a1adrenoreceptors and a2-adrenoreceptors, respectively (Karemaker 2017;
Wehrwein et al. 2016). The activation of the SNS in turn stimulates the release of
CRF by the hypothalamus, creating a direct feedback loop (McCorry 2007). The
principle neurotransmitters of the ANS are norepinephrine (NE), epinephrine (E)
and acetylcholine (ACh) (McCorry 2007). The sympathetic system controls
catecholamine synthesis and secretion (NE and E) from the adrenal medulla in
response to stressors (McCorry 2007). The SNS and PNS are meticulously
coordinated to maintain homeostasis. Under normal conditions, the PNS is
activated when a stressful situation is alleviated, however, in prolonged stress
experiences the SNS remains engaged, resulting in chronically high levels of
peripheral catecholamines (Karemaker 2017).
The relationship between stress and alcohol is complex and likely
changes throughout the trajectory of alcohol dependence. In the beginning
stages, direct activation of the HPA-axis likely contributes to the acute
physiological effects of alcohol (Becker 2012). Chronic CORT exposure in
rodents has been shown to reduce sensitivity to the subjective effects of alcohol
(Becker and Baros 2006; Besheer et al. 2012). In this regard, blunted subjective
feedback regarding intoxication may act as a permissive factor that promotes
increased levels of drinking (Becker 2012). Continued heavy drinking constitutes
a potent stressor, holding the HPA-axis in a constant state of activation that leads
to disturbances in HPA-axis functioning. Indeed, chronically high levels of alcohol
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consumption have been shown to produce overall elevation in blood
glucocorticoid levels, flattening of normal circadian fluctuations and dampening
HPA response to stress challenges (Becker 2012; Le et al. 2000; Wand and
Dobs 1991). Changes in basal HPA-axis activity (hyperactivity) is associated with
blunted responses to alcohol and stress related cues and increased craving
levels, which in turn, may result in high levels of alcohol intake to physiologically
normalize the HPA-axis (Sinha et al. 2011). Thus, allostatic adaptations in stress
systems in response to heavy consumption contribute to a state of incentive
sensitization and increase risk for relapse during periods of abstinence (i.e.,
withdrawal).
In conjunction with HPA-axis dysfunction, impaired autonomic regulation
may contribute to and perpetuate sympathetic dominance over central and
peripheral processes in alcohol dependent individuals (Blaine et al. 2016).
Chronically high levels of NE, acting on a1 receptors, are thought to induce
sympathomimetic states associated with withdrawal (Hawley et al. 1994). Altered
ANS activity, in the form of enhanced sympathetic tone, has also been
associated with dysfunctional emotional regulation (Boschloo et al., 2011) that
may contribute to the emergence of a negative affect state when access to
alcohol is prevented. Increased NE in circulation may further prime the brain to
depend on habit-based responding by holding bodily systems in the fight-or-flight
state (Blaine et al. 2016).
It is in this vein that the dynamic interplay between stress and alcohol
facilitates the transition to dependence. Alcohol may relieve stress, while at the
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same time provoke a stress response. Continued use perturbs the HPA-axis
beyond allostatic limits, leading to symptoms of chronic stress. Finally, alcohol
serves as a negative reinforcer, in that consumption leads to the removal of an
aversive state (physiological withdrawal, dysphoria, anxiety). Thus, continued
heavy alcohol consumption produces changes in neuroendocrine functioning that
may alter an alcohol-dependent individual’s response to stress, particularly with
respect to emotional regulation and motivation to consume alcohol, thereby
increasing the risk for relapse (Sinha 2012).

Alcohol, Stress and Extrahypothalamic Targets
As previously note, prolonged excessive alcohol consumption represents
a potent stressor. Persistent dysregulation of the HPA-axis resulting from chronic
alcohol exposure and withdrawal produces profound alterations in
neuroendocrine function and may activate brain stress systems outside of the
HPA-axis (Koob and Kreek 2007; Lu and Richardson 2014; Schank et al. 2012).
Indeed, it is well established that chronic alcohol alters CRF neurotransmission
independent of the physiological response to stress (Koob, 2013) and an
extensive body of research has emerged indicating the CRF plays a critical role
in alcohol addiction (Heilig and Koob 2007; Zorrilla et al. 2014). CRF-containing
neurons are found in numerous extrahypothalamic regions associated with brain
reward and stress systems, such as the central amygdala (CeA), bed nucleus of
the stria terminalis (BNST), VS and PFC. The actions of CRF are mediated
through interaction with two G-protein coupled receptor subtypes, CRF1 and
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CRF2 (Bale and Vale 2004). Chronic alcohol exposure results in increased
extracellular CRF and up-regulation of CRF1 receptors (associated with
increased stress-responsiveness; Koob and Heinrichs 1999) within the extended
amygdala and is thought to be a key element in the emergence of negative
emotional state during alcohol withdrawal (Koob, 2013). In support of this idea,
CRF receptor antagonists directly administered into the CeA have been shown to
reduce both alcohol withdrawal-induced anxiety-like behavior and alcohol selfadministration in alcohol-dependent rats (Agoglia and Herman 2018; Gilpin et al.
2015). Additionally, the recruitment of CRF in the CeA during early drinking
behaviors (before dependence) may initiate neuroplastic changes in the stress
system that intensify with repeated alcohol exposure (Haass-Koffler and Bartlett
2012; Lowery-Gionta et al. 2012). Evidence suggests that binge-drinking blunts
CRF-mediated GABAergic transmission (Lowery-Gionta et al. 2012), whereas
dependent animals show enhanced GABAergic transmission in the CeA (Roberto
et al. 2004).
Additionally, glucocorticoids secreted via alcohol-induced hypothalamic
activation modify reward-related behaviors by stimulating dopaminergic
transmission and increasing NE levels in the PFC (Piazza and Le Moal 1997).
Chronic a1 adrenoreceptor stimulation via NE in this region is known to impair
attentional processes by increasing “noise” and attenuating salient “signal”
(changing “signal” to “noise” ratio) (Birnbaum et al. 1999). This hinders the ability
of the PFC to distinguish between relevant and irrelevant stimuli, which may
contribute to mesolimbic control of behavior (Blaine et al. 2016). Therefore,
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persistent increases in NE in extrahypothalamic regions and in the PFC decrease
the ability of cortical pathways to inhibit habit-based responding to alcohol-related
cues (Volkow et al. 2010). Additionally, negative affective stimuli increase
amygdala activity, in part, through the release of NE, which leads to heightened
arousal, attention, and fear memory formation and anxiety. Chronically elevated
NE induced by long-term alcohol use can desensitize beta-adrenergic receptors
on GABAergic amygdala neurons, which may lead to the loss of inhibitory
signaling (Belmer et al. 2016). Interestingly, in animal models increased NE
signaling has been associated with enhanced stress-induced reinstatement to
alcohol following periods of abstinence (extinction) (Haass-Koffler et al. 2018).

Gender Differences in the Etiology of Stress-Related Alcohol Use
Stress- and reward- systems in the brain are influenced by sex hormones,
therefore, it is reasonable to suspect that the sex differences exist in the
development and expression of alcohol dependency. Historically, rates of AUD
have been higher in men (16.7%) compared to women (9%), though this gap has
been closing over the last decade (Grant et al. 2017; Peltier et al. 2019b).
Similarly, national data sources tracking trends in alcohol use in the U.S. have
shown changes in drinking patterns and substantial increases in the prevalence
of alcohol misuse and binge drinking in women (Grucza et al. 2018; Peltier et al.
2019a). Potential factors that may contribute to the increased rates of AUD in
women include drinking to regulate negative affect, increased experience of
negative emotions, stress and a greater sensitivity to alcohol-related health
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consequences (Agabio et al. 2016; Cole et al. 2006; Nolen-Hoeksema and Hilt
2006) While stress and negative affect are strongly associated with the
development of AUD for both men and women, these factors appear to be
especially crucial role for women (Peltier et al. 2019).
Increased rates of alcohol consumption in women are especially alarming
as women experience exacerbated alcohol-health related consequences
compared to men. While drinking is associated with significant health risks in
both sexes, women are more vulnerable to developing alcohol-related liver injury,
including liver cirrhosis and hepatitis, cancers and cardiovascular conditions than
men (Agabio et al. 2016; Agabio et al. 2017). Further, psychiatric comorbidities
such as depression, anxiety disorders and posttraumatic stress disorder (PTSD)
occur more often in women and are associated with problematic drinking (King et
al. 2003).
Compared to men, women begin problematic drinking later, consume less,
and drink less frequently (Greenfield 2002). However, female drinkers exhibit a
phenomenon known as “telescoping” in which they progress more rapidly,
compared to men, from drinking onset to serious-alcohol related problems and
dependence (Piazza et al. 1989). Although a number of factors associated with
biological differences (such as alcohol metabolism) may contribute to differential
alcohol use, sex differences in stress reactivity and negative affect may play a
key role in initiating and maintaining heavy drinking in women.
Women are more likely than men to drink heavily while experiencing
unpleasant emotions, psychological distress, or while in conflict with others in an
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effort to relieve internal tension (Peltier et al. 2019b). Consistent with these
observations, preclinical work has demonstrated that female rodents consume
more alcohol in models of depression and are more responsive to stress-induce
relapse (Bertholomey et al. 2016). In humans, several studies have found
increased prevalence of anxiety disorders, mood disorders (i.e., depression) and
PTSD in women (Brady and Back 2012; Brady and Randall 1999; Greenfield et
al. 2010), particularly in those with AUD. Compared to men, there is a stronger
correlation between negative affect associated with these co-morbid disorders
and alcohol-related measures, including overall consumption, binge-drinking,
craving and instances of dependence (Peltier et al. 2019b). Additionally, women
generally show a greater propensity to relapse in response to stress, and
demonstrate a sensitized response to stress during periods of alcohol withdrawal
(Becker and Koob 2016). Thus, chronic alcohol use may enhance vulnerability
for these disorders, and sex differences in the neuroendocrine adaptations that
occur in stress- and reward- systems in response to alcohol consumption may
mediated female susceptibility to alcohol abuse and relapse.

Animal Models for Stress, AUD and Relapse
The understanding of the neurobiology of addiction has largely progressed
through the study of animal models. Although no animal model of addiction can
fully emulate the human condition, they provide an avenue to investigate specific
aspects or symptoms associated with the psychopathological condition. Animal
models have been developed for various stages of the alcohol addiction cycle
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with a focus on the motivational effects of withdrawal, craving and relapse. Such
models provide a heuristic means with which to pursue the underlying
neurobiological basis of the disorder, particularly the acute and long-term
neuroadaptive changes in the brain that result in relapse.
Binge alcohol drinking is the most common form of alcohol consumption
and contributes to a host of long-term negative consequences, including anxiety
disorders and the formation of alcohol dependence (Koob, 2008). Repeated
episodes of binge-induced alcohol intoxication followed by periods of withdrawal
are hypothesized to cause aberrant plasticity in brain reward and stress systems
that drive increased alcohol consumption (Koob, 2008). One commonly used
model of voluntary alcohol consumption that mimics binge patterns in rodents is
the Drinking-in-the-Dark (DID) model. The DID procedure promotes high levels of
alcohol drinking in alcohol-preferring strains of mice by taking advantage of the
time in the animal’s dark cycle in which activity and nocturnal ingestive behaviors
are high (Thiele and Navarro 2014). A “binge” session, as defined by the National
Institutes on Alcohol Abuse and Alcoholism (NIAAA), is a pattern of drinking that
produces BECs exceeding 0.08% (80 mg/dL). Using this limited access
procedure, mice typically consume enough alcohol to reach BECs greater than
100 mg/dL and resulting in behavioral evidence of intoxication in a short period of
time (Sprow and Thiele 2012).
In the most common variation of the DID procedure, first implemented by
Rhodes et al. (2005), C57BL/6J mice are presented with a single bottle
containing 20% (v/v) alcohol in place of the home cage water bottle for 2hr, 3-hr
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after the beginning of the dark cycle, for 3 consecutive days. On the fourth day,
the drinking session is extended to 4 hr during which mice exhibit binge-like
behavior, consuming significant and physiologically relevant amounts of alcohol
(Rhodes et al. 2005). Several studies have characterized DID and have shown
that BECs of < 100mg/DL produce significant motor incoordination (Moore et al.
2007; Rhodes et al. 2007), tolerance to this effect after repeated binge-like
episodes (Linsenbardt et al. 2011) and increases in subsequent voluntary alcohol
drinking (Cox et al. 2013b). The DID model does not require training, prior
exposure to alcohol or inclusion of sweet compounds to motivate high levels of
alcohol intake. Further, in contrast to other models of binge-like drinking, DID
does not require alcohol to be administered by the experimenter as by gavage,
injection or ethanol vapor exposure (Becker and Lopez 2004), or by fluid
deprivation or inclusion of alcohol into an animals source of nutrients. Such
procedures may cause stress to the animal or other confounding variables,
calling into the question the motivation to drink alcohol (Thiele and Navarro
2014). Thus, DID provides a simple and effective high throughput tool for
characterization of potential pharmacotherapies and may provide a useful model
for studying binge patterns of consumption and the transition to alcohol
dependence.
The most direct procedure to evaluate the reinforcing properties of alcohol
is to test whether animals are willing to work to obtain it. One way to do this is
through oral operant alcohol self-administration procedures. Under this
procedure, operant responses reinforced by the acute reinforcing effects of
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alcohol provide information about voluntary intake and the motivation to obtain
reward. The first phase of this model is the acquisition of the operant behavior.
Animals are trained in a continuous reinforcement in which each response (lever
pressing) is reinforced with access to alcohol (via presentation of bottle or drop of
alcohol solution in a well). Typically, the alcohol reinforcement is paired with a
presentation of a stimulus (cue light or tone), which may become secondary
reinforcers through repeated pairing in the training process. In addition to an
“active” lever that results in alcohol delivery, a second “inactive” lever is
available. Response on this lever are measured but do not result in any
consequences, which allows for the measurement of differential responding and
(nonspecific) motor activation.
Once stable responding is achieved, an animal’s propensity to relapse can
be assessed using the extinction-based model of reinstatement. During this
phase, lever responding is extinguished (dramatically reduced) over repeated
trials in the absence of alcohol reward and alcohol-related cues. During the
reinstatement test, the resumption of alcohol- seeking behavior after extinction
training is assessed following exposure to the alcohol itself, cues or contexts
previously paired with alcohol reinforcement, or stressors (Shaham et al. 2003).
The reinitiating of responding on the previously extinguished lever is
hypothesized to reflect the motivation for drug-seeking behavior, which may
mimic the “craving” aspect of the preoccupation/anticipation stage of addiction.
This model is considered to have high face and construct validity (Leong et al.
2018; Markou et al. 2009) as factors that provoke relapse and craving in humans
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(re-exposure to drug, cues or stress) also reinstate alcohol-seeking in animals.
However, this “relapse-like” behavior does not involve return to drinking which
raises some questions about functional equivalence to human dependence.

OXYTOCIN
Neuropeptide Systems as Targets for the Treatment of Stress and AUD
Neuropeptides are short sequences of amino acids that are co-expressed
with neurotransmitters and widely expressed throughout the central nervous
system (Thiele 2017). A number of neuropeptides arise from the hypothalamus
and are of particular relevance to AUD due to their role in maintaining
physiological homeostasis, energy balance and ingestive behaviors (Thiele 2017)
such as galanin (GAL), melanin-concentrating hormone (MCH), neuropeptide Y
(NPY), orexin/hypocretin (OX), DYN and CRF (Barson and Leibowitz 2016).
These hypothalamic peptides can act locally (within the hypothalamus) or
project to extrahypothalamic regions to interact with other systems. The
mesolimbic dopamine reward system, for example, is heavily regulated by
neuropeptides most likely due to its involvement in acquiring natural reinforcers,
such as food, water and sex (Barson and Leibowitz 2016). Other neuropeptides
are produced within the extended amygdala (i.e., CRF, DYN) and are critical for
the integration of emotional behaviors (Koob and Le Moal 2001) These too can
signal locally or project elsewhere to modulate neurotransmission.
A growing body of literature has emerged implicating a crucial role for
neuropeptide systems in the modulation of the neurobiological response to
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alcohol. Neuropeptides are essential when the nervous system is trying to adapt
to various challenges and likely interact in multiple and complex ways. Repeated
alcohol exposure and withdrawal are thought to produce neuroplastic alternations
in these systems, contributing to allostatic shifts in activity and function (Koob &
Le Moal, 2001). During the progression of AUD, alterations of neuropeptide
activity in systems that modulate energy balance, reward, stress and emotional
function are thought to contribute to escalating consumption and anxiety aspects
the of addiction pathophysiology. Alcohol-induced adaptations of stress-related
neuropeptide systems within the extended amygdala, such as CRF, DYN and
NPY, promote the dysregulation of emotions that contribute to the emergence of
a negative affective state, especially during periods of withdrawal. Negative
affect, in turn, is thought to motivate alcohol intake as a way to alleviate adverse
symptoms (Koob & Le Moal, 2001). Thus, both hypothalamic and
extrahypothalamic systems are likely involved in the repeated periods of
abstinence following by return to heavy drinking that are reflective of
dependence.
The neuropeptide oxytocin (OXT) has recently emerged as a promising
therapeutic target for the treatment of alcohol use disorder. Oxytocin modulates
the adaptive processes associated with reward, tolerance, memory and stress
responses (Lee et al. 2016). Aside from its known hormonal role in parturition
and maternal behaviors, the nonapeptide has well-documented roles in
mammalian (pro) social behavior (e.g., pair-bonding, social reward processing,
aggression), which has been largely contributed to overlapping organization and
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projection sites in the midbrain dopaminergic system and direct modulation of
dopamine neurotransmission by OXT (Charlet and Grinevich 2017; Love 2014).
Convergent pathways within the mesocortiolimbic dopamine systems involved in
the processing of motivationally relevant stimuli not only has important
ramifications in social and maternal behavior, but may extend to influencing the
rewarding aspects of alcohol and other substances of abuse (Baskerville and
Douglas 2010; Burkett and Young 2012). Oxytocin is also known to exert potent
anti-stress and anxiolytic effects (Jurek et al. 2015; Peters et al. 2014; Slattery
and Neumann 2010) through interaction with the HPA-axis and extrahypothalamic stress-related brain regions, thereby enabling OXT to contribute to
the regulation of negative affect and stress-related behaviors relevant to
addiction. The following section will review the structure and function of the OXT
system, as well as discuss its role in the treatment of psychiatric and stressrelated disorders, including alcohol addiction.

Neuroendocrine and Neuropharmacological Function of the Oxytocin
System
Oxytocin is nine amino acid polypeptide that exerts a wide spectrum of
central and peripheral effects, ranging from the modulation of neuroendocrine
reflexes to the establishment of complex social behaviors (Gimpl and Fahrenholz
2001). Oxytocin synthesis within the central nervous takes place in magnocellular
neurons of the mammalian hypothalamus, specifically within the bilateral
paraventricular nucleus (PVN) and supraoptic nucleus (SON) (Jurek and
Neumann 2018). These neurons possess major axonal projections to the
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neurohypophysis by which OXT is released into the bloodstream for peripheral
distribution (Leng and Ludwig 2016; Quirin et al. 2011). In addition to the
magnocellular neurons of the SON and PVN, a small portion of magnocellular
OXT neurons can also be found in the accessory nuclei of the hypothalamus
(Jurek and Neumann 2018). Oxytocin is released from the posterior pituitary in
response to a variety of stimuli including suckling, parturition and stress (Gimpl
and Fahrenholz 2001). Moreover, OXT may also be synthesized in peripheral
tissue such as sexual organs, placenta, corpus luteum and the heart (Gimpl and
Fahrenholz 2001) for local release or release into the bloodstream.
Central OXT derives from at least three separate systems; magnocellular
neurons of the SON and PVN, and parvocellular neurons of the PVN. The
magnocellular neurons targeting the posterior pituitary develop axon collaterals
that extend long range projections to various forebrain regions, including the
PFC, anterior olfactory nucleus, NAc, lateral septum (LS), hippocampus, BNST
and amygdala (Stoop 2012). Oxytocin synthesis also occurs in smaller
parvocellular neurons of the PVN and to a small degree in selective extrahypothalamic neurons (Jurek and Neumann 2018). These neurons are distinct
from magnocellular populations in that they do not release OXT into blood
circulation (Knobloch and Grinevich 2014). Parvocellular OXT neurons project
mainly to the brainstem and spinal cord where they synapse to effect autonomic
functions, pain regulation and analgesia (Eliava et al. 2016). Since various
subgroups of OXT neurons may innervate distinct brain regions it has been
hypothesized that certain stimuli may activate select neuronal populations within
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specific intracerebral projections, in addition to OXT neurons projecting to the
posterior pituitary (Jurek and Neumann 2018). This enables OXT release to be
both stimulus- and region-dependent. Further, OXT neurons have been shown to
exhibit both axonal and dendritic release in which OXT binds to local OXT
receptors (OXTR) or may diffuse over long distances to bind to adjacent OXTRs
(Grinevich et al. 2016).
Many OXT processes contact the ventricle system and may interact with
cerebrospinal fluid (CSF) directly (Jurek and Neumann 2018) and a number of
OXT-receptive brain regions border the ventricular system and arachnoid spaces
(e.g. Amygdala, Hipp, BNST; (Gimpl and Fahrenholz 2001). Therefore, diffusion
of OXT within the fluid of extracellular space could be underlying the behavioral
effects of the neuropeptide (Knobloch and Grinevich 2014). To this idea, central
release of the peptide triggers OXT release from neighboring dendrites, inducing
a coordinated response from all OXT neurons in the activated brain region
(Veening and Olivier 2013). As a result, extracellular levels of oxytocin released
into the SON or PVN rapidly increase and reach the CSF by targeted release or
“spilling over” of EC-concentrations alongside the CSF compartments (Veening
et al. 2010). The half-life of oxytocin in CSF is considerably longer than in plasma
(28 minutes versus 2 minutes) and transport by ventricular CSF is relatively fast
(1-2 minutes). Thus, it has been hypothesized that CSF may be a ‘messagecarrier’ for endogenous OXT communication between hypothalamic regions and
receptive target areas in the CNS (Veening and Olivier 2013).
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Currently, there has been only one oxytocin receptor (OXTR) identified
(Gimpl and Fahrenholz 2001). Receptors are abundant throughout both central
and peripheral systems and are expressed in a sex- dependent and speciesspecific manner (Dumais and Veenema 2016). In the periphery, receptor
expression is observed in numerous tissues including mammary gland,
endometrium, ovary, testis, gastrointestinal tract, heart, kidney (Kimura et al.
2003). Centrally, OXTRs are expressed in brain regions that regulate learning
and memory, stress, mood, social and reward related behaviors, such as
prefrontal cortex (PFC), VTA, NAc, hippocampus, hypothalamus, ventral pallidum
(VP), amygdala and brainstem (Gimpl and Fahrenholz 2001).
The oxytocin receptor is a member of the family of the rhodopsin-type 1 G
protein-coupled receptor (GPCR) family and together with three vasopressin
receptor subtypes (V1a, V1b and V2) forms of subfamily of structurally related
receptors (Devost et al. 2008). The OXTR is diverse in its signaling pathways
(many of which remain unexplored) and the precise mechanisms by which OXT
exerts multiple biological actions have not been fully established (Devost et al.
2008). Nonetheless, OXT appears to be functionally coupled to the Gq/11mediated pathway, stimulating phospholipase C (PLC) to induce increased
intracellular calcium and inositol trisphosphate production (InsP3) (Vrachnis et al.
2011). However, depending on brain area and concentration, OXT also promotes
activation of Gi and Go coupled signaling cascades (Busnelli et al. 2012). While
the precise role for these OXTR signaling pathways within the brain is relatively
unknown, the promiscuity of OXTR (coupling to Gq or Gi/Go) most likely results in
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opposite effects on cell excitability (Gravati et al. 2010). One possible hypothesis
is that the local concentration reached by OXT may engage different signaling
pathways to allow for more finely tuned signaling mechanisms and behavioral
responses (Grinevich et al. 2016). Further, due to high structural homology OXT
can also bind to and activate the related vasopressin receptor subtypes (V1a,
V1b and V2) (Knobloch & Grinevich, 2014). Under some conditions, this may
constitute alternative targets for OXT, especially at high local concentrations and
in brain regions that have little or no OXTR expression (Grinevich et al. 2016).

Role of Oxytocin in Neuropsychiatric Disorders
Oxytocin has been shown to play a key role in the regulation of several
behaviors associated with neuropsychiatric disorders, including social
interactions, social attachment and social cognition, feeding behaviors, emotional
reactivity and threat perception, stress responsiveness and reward behaviors
(Shamay-Tsoory and Young 2016). Indeed, an increasing body of evidence
suggests that dysregulations of the oxytocinergic system may be involved in the
pathophysiology of numerous psychiatric disorders, particularly those
characterized by social deficits. These disorders include, but are not limited to:
autism, schizophrenia, mood and anxiety disorders, PTSD and substance use
disorders (Martinetz and Neumann 2016; Romano et al. 2015). The following
section will briefly discuss preclinical and clinical findings that evaluate the role of
the oxytocinergic system in some of these disorders.
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Oxytocin appears to be involved in number of complex social behaviors
across a range of species (Bosch and Neumann 2012). One of the most wellunderstood aspects of this behavior is the regulation of maternal bonding (Ross
and Young 2009). Oxytocin promotes maternal care behaviors and plays a
crucial role in the bond formation between mother and offspring (Ross and
Young 2009). Oxytocin is also involved in the development of adult-bonding,
including the formation of pair bonds (partner preference), social memory and
social recognition (Engelmann et al. 1998; Insel et al. 1998). The effects of OXT
on social behaviors are complex and may be dependent on the context in which
they occur. More specifically, OXT appears to promote sociality when social and
environmental cues are perceived as “safe”, whereas OXT may induce defensive
and/or aggressive behavior when cues are interpreted as “unsafe” (Olff et al.
2013). Genetic studies have reported associations between genetic
predisposition and social behavioral phenotypes. For example, one OXTR gene
variant has been associated with positive social traits, such as increased
empathy, optimism and trust, whereas carriers with the opposite allele appear to
display lower optimism and self-esteem, negative social perceptions, and higher
levels of psychological stress (Martinetz and Neumann 2016).
In this regard, it is not surprising that dysregulation in OXT signaling
mechanisms have been proposed to contribute to the socio-emotional
dysfunction seen in autism spectrum disorders (ASD) (Insel et al. 1998).
Decreases in plasma OXT levels have been reported in autistic children,
correlating to low social and communication skills (Modahl et al. 1992; Modahl et
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al. 1998). Further, several large-scale studies have demonstrated an association
between a specific OXTR gene single nucleotide polymorphism (SNP) and ASD
(Campbell et al. 2011; Jacob et al. 2007; Lerer et al. 2008). Interestingly, OXT
administration (intravenous (IV) or intranasal (IN)) has been shown to reduce
repetitive behaviors and improve social cognition in adult and adolescent patients
with ASD (Guastella et al. 2010; Hollander et al. 2007; Hollander et al. 2003).
Additionally, preclinical and clinical literature suggests OXT
neurotransmission may be involved in the regulation of cognitive deficits, as well
as the expression of both positive (hallucinations, delusions) and negative
(anhedonia, asociality) symptoms seen in schizophrenia (SCZ) (Feifel 2012).
Low plasma OXT has been associated with more severe symptoms across all
three domains of SCZ (Shilling and Feifel 2016) and genetic studies have
revealed multiple OXTR gene variants associated with both positive and negative
symptoms (Haram et al. 2015; Souza et al. 2010). In clinical trials, chronic coadministration of IN OXT and atypical antipsychotic medication in schizophrenic
patient populations has been reported to improve negative symptoms (Feifel et
al. 2010; Gibson et al. 2014; Modabbernia et al. 2013). Additionally, a single
dose of IN OXT was able to modulate the neural response (measured by fMRI) to
different facial emotions in patients with SCZ (Shin et al. 2015).
Perturbations of the OXT system may also be involved in the
pathophysiology of stress-related psychiatric disorders such as post-traumatic
stress disorder (PTSD) and Major Depressive Disorder (MDD). In terms of
PTSD, lower levels of salivary OXT were observed in men with PTSD (Frijling et
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al. 2015) and PTSD symptom severity has been associated with lower plasma
OXT levels during exposure to abandonment-related film scenes (Munro et al.
2013). PTSD is characterized by an exaggerated fear response which fails to
extinguish overtime and cannot be inhibited in “safe” contexts (Koch et al. 2016).
There is some evidence to suggest that deficits in OXT signaling contribute to
these processes and that increasing levels of OXT may be helpful for symptom
relief. For example, single doses of IN OXT have also been associated with a
variety of promising results in PTSD patients, including increased reward
responsivity (Nawijn et al. 2016; Nawijn et al. 2017) improved working memory
(Flanagan et al. 2018), reduced provoked PTSD symptoms (Sack et al. 2017),
and reduced amygdala reactivity (Koch et al. 2016). With respect to MDD, lower
levels of OXT have been observed in depressed pregnant women (Massey et al.
2016a; Massey et al. 2016b) and a negative correlation was observed between
serum OXT concentrations and depressive symptom severity in a clinical
population (Scantamburlo et al. 2007). Oxytocin administration has been shown
to be effective in enhancing the processing of affective cues and increased
motivation to affiliate (Sippel et al. 2017) and in an open trial, IN OXT was
reported to increase measures of life enjoyment and satisfaction in chronically
depressed patients who previously did not respond to treatment (Scantamburlo
et al. 2015).
Although OXT application appears to hold some promise in the treatment
of multiple psychiatric disorders, little is known about the mechanisms that
underlie these effects. One potential mechanism may be through interaction with
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serotonergic systems. Serotonergic neurons display OXTRs and OXT modulates
the release of serotonin (5-HT) within the dorsal raphe nucleus (Mottolese et al.
2014). Both OXT and 5-HT regulate various aspects of social behavior and may
interact in both MDD and ASD (Martinez and Neumann 2016). Additionally, it is
speculated that OXT may produce its anxiolytic effect, at least in part, by
modulation of 5-HT activity within the amygdala. Oxytocin interactions with
glutamatergic systems, specifically with mGluR5 in the lateral septum (LS), also
appears to be important in affiliative behavior and sociability. Furthermore, there
is strong evidence for interactions of OXT with dopaminergic systems, especially
within the NAc, where OXT modulates reward. This interaction will be discussed
more in depth in the next section. Finally, OXT is known to exert potent antistress and anxiolytic effects (Peters et al. 2014; Slattery and Neumann 2010) via
interaction with the HPA-axis. Oxytocin administration has been shown to
dampen increases in CORT levels and stress-induced HPA-axis activation, as
well as reduce behavioral responses in animal models of anxiety and depression
(Neumann et al. 2000; Windle et al. 2004; Windle et al. 1997). Conversely, mice
genetically engineered to lack the gene for OXT (OXTKO) display more anxietyrelated behavior and greater CORT response following exposure to stress
(Amico et al. 2004; Mantella et al. 2005; Mantella et al. 2004). Further, high
levels of OXT and OXTR mRNA expression are localized to forebrain regions,
such as the extended amygdala, that are critically involved in anxiety and stressresponsiveness (Dabrowska et al. 2011; Veinante and Freund-Mercier 1997),
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thereby enabling OXT to contribute to the regulation of anxiety, stress and
reward-related behaviors.

Oxytocin in Addiction
A large number of preclinical studies have investigated the effect of OXT
on various drug-induced behaviors throughout the phases of addiction pathology
(Lee et al. 2016; Lee and Weerts 2016; Leong et al. 2018). Oxytocin has been
shown to modulate the development of acute and chronic tolerance to multiple
drugs of abuse, including the analgesic effect of morphine and heroin (Kovacs et
al. 1984; Kovacs et al. 1987), physiological effects of alcohol (i.e., sedative,
ataxia and hypothermic; Szabo et al. 1987; Szabo et al. 1985; Szabo et al. 1989)
and sensitization to hyperactivity and stereotyped behavior associated with
psychostimulants (Sarnyai et al. 1992). With respect to self-administration
behavior, OXT has been shown to effectively decrease both acquisition and
maintenance of heroin (Ibragimov et al. 1987; Kovacs et al. 1985), alcohol
(Bowen et al. 2011; MacFadyen et al. 2016; Peters et al. 2013; Peters et al.
2017; Stevenson et al. 2017a), cocaine (Leong et al. 2017; Leong et al. 2016;
Sarnyai and Kovacs 1994; Zhou et al. 2014), methampethamine (Carson et al.
2010a; Carson et al. 2010b; Qi et al. 2009) and nicotine (Lee et al. 2017a;
Manbeck et al. 2014). Additionally, a number of studies have also been
conducted investigating the ability of OXT to attenuate relapse-like behavior.
These studies will be discussed in the following sections.
The mechanism by which OXT interacts with the development and
maintenance of addiction is not fully understood. However, OXT appears to
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modulate reward signaling in the mesolimbic dopamine system through direct
interaction with various neurotransmitter systems. Oxytocin projections from the
PVN synapse on dopaminergic cells within the NAc (Knobloch and Grinevich
2014) and OXTRs are present on VTA dopaminergic projection neurons that
target the NAc and mPFC (Knobloch and Grinevich 2014; Peris et al. 2017).
Indeed, central OXT administration has been shown to inhibit drug- and alcoholinduced increases in dopamine in mesolimbic regions, particularly the NAc
(Kovacs et al. 1998; Peters et al. 2017). Additionally, recent studies have
characterized the presence of OXT/dopamine heteroreceptor complexes
(OXTR/D2R) within the NAc and CeA (de la Mora et al. 2016; Fuxe et al. 2012;
Romero-Fernandez et al. 2013) in which OXT-induced OXTR activation cause
increases in D2 receptor signaling. Interestingly, the D2 receptor subtype is
downregulated following chronic drug- exposure and activation of DR2 has been
shown to reduced drug-seeking behavior (Volkow and Morales 2015). Thus,
OXT, serving as an allosteric agonist to increase D2R affinity in the NAc, may
reduce drug-seeking behavior.
There is also some evidence to suggest that OXTRs may also interact
with a2 adrenergic receptors (a(2A)ARs) in a similar fashion (Fuxe et al., 2012).
More specifically, OXT via signaling at OXTR-a(2A)AR heteroreceptor complex
may act as an allosteric antagonist to reduce adrenergic signal transduction
(Diaz-Cabiale et al. 2000a; Diaz-Cabiale et al. 2000b). It is also likely that
a(2A)ARs can also modulate OXTRs through reciprocal receptor-receptor
interaction (Fuxe et al., 2012). Interestingly, OXTR-(2A)AR heterodimers have
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been located within hypothalamic and amygdala regions as well as the nucleus
of the solitary tract (NTS), which is well situated to mediate both central and
autonomic stress effects (Fuxe et al. 2012; Diaz-Cabiale et al. 2000) that may be
involved in withdrawal-related symptoms.
Oxytocin receptors have also been localized on GABAergic interneurons
in the NAc (Dolen et al. 2013), CeA (Huber et al. 2005), hippocampus (Zaninetti
and Raggenbass 2000) and PFC (Li et al. 2016; Nakajima et al. 2014). There is
also some evidence that OXTR-expressing cells contain GABA (Yoshida et al.
2009), implicating a role for OXT in the modulation of inhibitory tone. Indeed,
OXT administration has been shown to effect GABAergic transmission in multiple
brain regions critical to the addiction process and may regulate both drugseeking and anxiety-related behaviors through interactions with its own receptor.
Additionally, there is some evidence to suggest that OXT may also modulate
GABA via direct interaction with GABAA receptors (Bowen et al. 2015; Dong et al.
2017), particularly in regard to the acute physiological effects of alcohol (Bowen
et al. 2015).

Oxytocin and Alcohol Use
Oxytocin signaling in brain has been shown to be altered by both acute
and chronic exposure to alcohol. Results from human postmortem studies shed
some light on the effects of alcohol consumption on the OXT system. In male
patients with AUD, OXT peptide immunoreactivity was decreased in both the
SON and PVN compared to controls (Sivukhina et al. 2006). More recently, Lee
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et al. (2017b) reported a significant increase in OXT peptide mRNA in the PFC of
human post-mortem AUD subjects compared to controls (Lee et al. 2017b). In
addition, the authors report hypertrophy of OXT producing neurons in the
hypothalamus in AUD patients, in concordance with previous evidence to
suggest that this is an effect of chronic alcohol exposure (Madeira et al. 1993). In
congruence, a loss of hypothalamic OXT neurons after prolonged alcohol intake
has been reported in animal studies (Silva et al. 2002; Stevenson et al. 2017b).
Finally, following repeated cycles of chronic intermittent alcohol vapor exposure
to induce dependence in rats, Hansson et al. (2018) demonstrated that OXT
mRNA was reduced in the NAc by acute alcohol and during early withdrawal, but
increased after prolonged (3 weeks) abstinence, suggesting dynamic
dependence-related neuroadaptation of the OXT system. Additionally, after 3
weeks of abstinence, dependent rats showed increases in OXT receptor mRNA
and protein levels in prefrontal cortex, striatal, amygdala and hippocampal
regions, and a reduction in OXT mRNA and peptide expression in hypothalamic
nuclei. These data provide evidence that chronic alcohol exposure produces
compensatory neuroadaptive changes in the endogenous OXT system in brain
regions specifically involved in the addiction process (Hansson et al. 2018).
Preclinical evidence indicates that OXT administration influences a number of
behavioral and physiological effects of alcohol (Lee and Weerts 2016). The early
seminal body of research in this area focused on the effect of OXT on tolerance
to the physiological effects of alcohol. Repeated systemic administration (ip.) of
OXT prevented the development of tolerance to the hypothermic, hypnotic and
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ataxic effects of alcohol (Jodogne et al. 1991). Oxytocin treatment was also
found to modulate the severity of alcohol withdrawal symptoms (Szabo et al.,
1987). Additionally, central administration of OXT (icv.) was shown to block rapid
tolerance to the effects of alcohol (Szabo et al. 1989). Central administration was
found to be more efficacious than peripheral administration, pointing to a
centrally mediated mechanism. In this regard, interactions with dopamine and
serotonin neurotransmission were postulated to mediate this effect of OXT
(Szabo et al. 1989).
In more recent reports, systemic administration of OXT has been shown to
reduce alcohol preference and intake in a variety of voluntary drinking models in
rats (Bowen et al. 2011; McGregor and Bowen 2012) and mice (King et al. 2017;
Peters et al. 2013). Specifically, McGregor and Bowen (2012) found that a single
dose of OXT (1 mg/kg) produced a long-lasting reduction in preference for an
alcohol-containing solution compared with a nonalcoholic sweet solution.
Additionally, treatment with OXT for 2 weeks prior to the induction of a two-bottle
free-choice paradigm resulted in lower alcohol preference in OXT-treated rats
compared to controls. MacFadyen et al. (2016) reported that systemic
administration of a lower dose range of OXT (0.1-0.5 mg/kg, ip.) reduced operant
alcohol self-administration in rats. Peripheral OXT treatment in a higher dose
range (1-10 mg/kg) reduced alcohol consumption in male and female prairie
voles that had two-bottle choice free-access to 15% alcohol (Stevenson et al.
2017a). In a continuous access paradigm, systemic OXT administration
decreased alcohol intake in the first hours after treatment but had no significant
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effect on consumption over a 24-hour period (Stevenson et al. 2017a). Most
recently, Tunstall et al. (2019) demonstrated that both systemic (ip.) and central
(icv.) OXT administration blocked escalated alcohol drinking and the enhanced
motivation for alcohol in alcohol-dependent but not nondependent rats. This
effect was also replicated with IN administration of OXT (Tunstall et al. 2019).
While this evidence implicates a role for OXT in AUDs, the mechanisms by
which OXT reduces alcohol consumption is not fully understood. In a recent study,
direct (icv.) administration of OXT reduced alcohol consumption and alcoholinduced dopamine efflux in the NAc (Peters et al. 2017). Additionally, OXTRs have
been identified on neurons in the VTA projecting to the NAc (Peris et al. 2017).
Thus, it is possible that OXT reduces alcohol self-administration by altering
mesolimbic dopamine activity that ordinarily signals alcohol-related reward.
However, few studies have examined the role of OXTRs in mediating the
neuropeptide’s effect on the motivational actions of alcohol. Recent reports
showed that viral-mediated overexpression of OXTRs in NAc reduced alcoholinduced conditioned place preference and alcohol consumption in mice (Bahi
2015; Bahi et al. 2016). Additionally, ICV, but not peripheral, administration of an
OXTR agonist that does not cross the blood brain barrier (therefore, would not
diffuse into the periphery) decreased alcohol drinking, suggesting that OXT
reduced alcohol consumption through interaction with its own receptor via a central
mechanism of action (Tunstall et al. 2019). Although the OXTR appears to be
involved in the rewarding effects of alcohol, it is important to note that Bowen and
colleagues showed that attenuation of sedative and ataxic effects by central OXT
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administration was mediated by GABAA receptors (Bowen et al. 2015). Thus, while
additional studies are necessary to further investigate the conditions and
mechanisms by which OXT reduces alcohol consumption, the growing body of
literature investigating the effect of OXT on the neurobehavioral response to
alcohol points to the OXT system as a promising target for the therapeutic
intervention of alcohol use disorders.

Oxytocin, Stress and Relapse
Due to the strong link between stress, alcohol use and relapse, the ability
of OXT to modulate stress processes has generated growing interest in its
potential as a treatment for substance use disorders. Indeed, preclinical evidence
suggests that OXT administration is effective in attenuating reinstatement of drug
seeking to conditioned cues, drug- or stress- prime. In general, systemic injection
of OXT has been shown to reduce drug-primed reinstatement in models
investigating heroin (Georgiou et al. 2015), cocaine (Zhou et al. 2014) and
methamphetamine (Carson et al. 2010a; Cox et al. 2017; Cox et al. 2013a)
related behaviors. Additionally, OXT directly applied into the NAc blocked methinduced conditioned place preference (CPP; Baracz et al. 2012) and attenuated
meth-primed reinstatement of meth-seeking behavior (Baracz et al. 2015; Baracz
et al. 2016). In regard to cued reinstatement, systemic OXT decreases
reinvigoration of drug-seeking behavior (lever responding) for cocaine (Bentzley
et al. 2014; Leong et al. 2017) and methamphetamine (Bernheim et al. 2017)
provoked by stimuli previously associated with drug reward. Similar results were
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found when OXT was administered centrally. More specifically, icv. infusion of
OXT reduced cue-induced reinstatement of cocaine-seeking behavior in both
male (Morales-Rivera et al. 2014) and female rats (Leong et al. 2016). In
congruence with the aforementioned regions, direct infusion of OXT into NAc
(Weber et al. 2018) and the subthalamic nucleus (STN), a downstream projection
of the accumbens (Leong et al. 2017), attenuated cocaine-seeking behavior.
To our knowledge, only one published study has investigated the effects
of OXT administration on alcohol relapse-like behavior in animal models.
Following repeated cycles of chronic intermittent alcohol vapor exposure to
induce dependence in rats, Hansson and colleagues (2017) injected (icv.) OXT in
alcohol-dependent and non-dependent rats trained to orally self-administer
alcohol using operant conditioning procedures. Central administration of OXT
reduced cue-induced alcohol relapse-like behavior in alcohol-dependent rats, but
not in non-dependent rats (Hansson et al. 2017).
Additionally, OXT has also been shown to reduce stress-related relapselike behavior to other drugs of abuse. Systemic administration of OXT decreased
methamphetamine-seeking behavior following predator odor exposure (Ferland
et al. 2016) and yohimbine administration (Cox et al. 2013) in rats. In mice,
centrally administered OXT (icv.) attenuated reinstatement of methamphetamine
CPP induced by restraint stress (Qi et al. 2009; Han et al. 2014), and systemic
administration of the OXT analog, carbetocin, reduced the effects of forced-swim
stress on reinstatement of morphine-induced CPP (Zanos et al. 2014). While
there are currently no studies that examine the effect of OXT on stress-induced
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reinstatement of alcohol-seeking behavior, exogenous OXT administration may
help to attenuate the effects of stress associated with heavy drinking and drug
use. In support of this hypothesis, Peters and colleagues demonstrated that OXT
administration attenuated stress-induced increase in alcohol consumption in rats
(Peters et al. 2013).
Clinically, OXT administration has shown some efficacy in attenuating
craving and withdrawal-related symptoms across multiple drugs of abuse. In the
context of stress, a single dose of IN OXT was shown to reduce stress-induced
craving and anxiety in cannabis-dependent individuals (McRae-Clark et al. 2013).
However, Reed and colleagues demonstrated that IN OXT produced an increase
in subjective stress compared to placebo in female cannabis users, whereas IN
OXT produced a small (but non-significant) decrease in subjective stress in males
(Reed et al. 2019). The authors found no differences in stress-related cannabis
craving, though female cannabis users demonstrated a longer latency to selfadminister and used less cannabis overall compared to males (Reed et al. 2019).
These data indicate differential effects of OXT in males and females, particularly
in regard to stress-related behavior and highlight the importance of adequately
assessing sex differences. In a study by Lee et al. (2014) a single dose of IN OXT
reduced the desire to use drug in cocaine-dependent subjects, though OXT
treatment had no effect on cue-induced cocaine craving (Lee et al. 2014). In
patients with a dual diagnosis of PTSD and AUD, IN OXT attenuated cortisol
reactivity in response to a stress provocation (Flanagan et al. 2019). Further, IN
OXT treatment decreased alcohol withdrawal symptoms in treatment-seeking

44

patients compared to placebo and significantly reduced anxiety in dependent
subjects following cessation of drinking (Pedersen 2017; Pedersen et al. 2013).
Taken together, OXT treatment may be a useful therapeutic to reduce stressrelated physiological responses (e.g. anxiety, craving) relevant to drug and alcohol
use and relapse.

Summary
Alcoholism is a chronic, relapsing disorder that represents a substantial and
disabling public health concern. Excessive alcohol consumption is linked to a
number of diseases, including cancers, cardiovascular disease, liver cirrhosis,
FAS and neuropsychiatric disorders (Rehm et al. 2009). The Center for Disease
Control places excessive alcohol use/abuse as the third leading cause of
preventable deaths in the U.S. (Mokdad et al. 2004). Economically, alcohol misuse
is estimated to cost the U.S. roughly $249 billion per year. Despite the significant
personal, social and economic burden AUDs present, there are few effective
pharmacotherapies available to help curb alcohol addiction. The neuropeptide
OXT has emerged as a promising novel therapeutic target in the treatment of a
number of neuropsychiatric disorders, including alcohol addiction. Oxytocin may
provide therapeutic value for the treatment of AUD through its anxiolytic, stressand reward- related properties by acting directly through its own receptor and
through interactions with other neurotransmitter systems within addiction circuitry.
The present PhD dissertation aims to add to the knowledge about OXT’s
interaction with alcohol consumption and expand upon the current findings to
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investigate a role for OXT in stress-induced alcohol relapse-like behavior. Further,
we examine potential mechanisms that underlie the ability of OXT to reduce
alcohol consumption and attenuate reinstatement of alcohol-seeking behavior in
male and female mice.
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CHAPTER 2: Oxytocin Decreases Alcohol Consumption
INTRODUCTION
As discussed in Chapter 1, a growing body of literature suggests that OXT
plays a role in several neuropsychiatric disorders that involve deficits in social
behaviors, including drug and alcohol addiction (Baskerville and Douglas, 2010;
Lee and Weerts, 2016). For example, while alcohol use initially promotes prosocial behaviors, continued excessive drinking can lead to long-term social
deficits associated with alcohol dependence, a negative consequence that may
be mediated, at least in part, by adaptations in the OXT system (McGregor and
Bowen, 2012; Stauffer and Woolley, 2014; Young et al., 2014). In a recent
clinical study, Pedersen and colleagues demonstrated that IN OXT treatment
attenuated alcohol withdrawal symptoms in treatment-seeking human subjects
compared to placebo (Pedersen et al. 2013). Further, a number of preclinical
studies provide support for a role of OXT in modulating alcohol preference and
consumption. In a recent study, OXT was shown to reduce operant responding
for alcohol in Sprague-Dawley rats (MacFadyen et al. 2016). Acute OXT
treatment also produced a significant and lasting decrease in preference for an
alcohol-containing solution versus a non-alcoholic sucrose solution in alcoholpreferring “P” rats (McGregor and Bowen 2012). Additionally, Bowen and
collegues demonstrated that chronic exposure to exogenous OXT in
adolescence decreased alcohol consumption in adult rats (Bowen et al. 2011).
Thus, administration of exogenous OXT has been shown to alter a number of
alcohol effects, including its motivational effects.
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Many of the OXT PVN projections in brain overlap with dopamine systems
critically involved in processing motivationally relevant stimuli. An emerging
literature suggests that OXT can alter dopaminergic neurotransmission within
mesocorticolimbic dopamine systems, thereby altering motivational aspects of
not only social and maternal behavior, but also alcohol/drug addiction
(Baskerville and Douglas 2010; Burkett and Young 2012; Groppe et al. 2013;
Love 2014). For example, direct (icv.) infusion of OXT blocked alcohol-induced
increases in dopamine release in the NAc and reduced voluntary alcohol
consumption in Wistar rats (Peters et al. 2016). Additionally, viral-mediated
overexpression of OXTRs in the NAc reduced alcohol-induced CPP and alcohol
consumption in C57BL/6J mice (Bahi 2015; Bahi et al. 2016). Taken together,
accumulating evidence suggests that the OXT system may represent a promising
target for the treatment of AUDs (Lee et al. 2016; Lee and Weerts 2016).
However, few studies have examined the broad efficacy and specificity of
systemically administered OXT in reducing voluntary alcoholl consumption, and
whether oxytocin influences the motivational effects of alcohol. In the present
study, we investigated the effects of systemic administration of OXT on alcohol
self-administration in a binge-like drinking model, in a two-bottle choice paradigm
and in a model involving operant conditioning procedures. Specificity of OXT
effects in the operant studies was examined by conducting parallel studies with
sucrose solutions. It was hypothesized that OXT would selectively decrease
alcohol consumption in these models at doses that would not affect sucrose
consumption under similar testing conditions.
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MATERIALS AND METHODS
Subjects
Adult male C57BL/6J mice (25-30g) were obtained from Jackson
Laboratories (Bar Harbor, ME). Mice arrived at 9-10 weeks of age and were
acclimated to the experimental housing rooms for a minimum of 1 week prior to
the start of experiments. Mice were individually housed under a 12 hr reversed
light/dark cycle in an AAALAC accredited facility. All testing was conducted
during the dark phase of the circadian cycle. Mice were provided free access to
food and water, except at the start of operant oral self-administration training. All
experimental protocols were approved by the Medical University of South
Carolina Institutional Animal Care and Use Committee and consistent with
guidelines of the NIH Guide for the Care and Use of Laboratory Animals.

Binge-Like Ethanol Consumption
The effect of OXT on binge-like ethanol consumption was examined in
C57BL/6J mice (n= 40) using the drinking-in-the-dark (DID) paradigm (Rhodes et
al. 2005). Mice were presented in the home-cage with a single 15-ml graduated
bottle of 20% (v/v) ethanol 3 hr into the dark phase of the circadian light cycle.
Mice were provided access to ethanol for 2 hr/day for 3 consecutive days. On the
fourth day, access to ethanol was extended to 4 hr. Vehicle injections were
given 30 min prior to the 2-hr drinking sessions during the first three days to
acclimate mice to handling and the injection procedure. On Day-4, separate
groups of mice were injected intraperitoneally (ip.) with OXT (0, 1, 3, or 10
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mg/kg) 30 min prior to the 4 hr drinking session. These OXT doses and the route
of administration were selected based on previous work in rodents (e.g. Bahi
2015; Bowen et al. 2011; McGregor and Bowen 2012; Peters et al. 2013).
Immediately following this test session, blood samples were collected to measure
blood ethanol concentration (BEC) using an Analox Instrument analyzer
(Lunenburg, MA).
Since results from the previous study indicated that the 3 and 10 mg/kg
doses of OXT were similarly efficacious in reducing ethanol consumption, a
follow-up study was conducted to extend these findings to a lower dose range for
OXT. Additionally, to assess the temporal distribution of ethanol consumption
during the 4 hr session, a separate group of mice (n= 24) was tested in the DID
model, with the ethanol bottles fitted with lickometers as previously described
(Griffin et al. 2009). Briefly, contacts (i.e., “licks”) with the ethanol tube
completed a circuit grounded to the stainless steel grid floor inside of the home
cage. The metal drinking spouts were covered with plastic shrink-wrap coating to
limit extraneous contacts. The metal cage floor and tubes were connected
through lickometer circuits (Med Associates, Inc., St. Albans, VT), and contacts
were monitored and recorded by a computer outside of the testing room. Mice
were acclimated to the lickometers in their home cage by providing drinking
water (24 hr/day) in bottles connected to the lickometer for one week prior to DID
testing. As in the previous experiment, vehicle injections were given to all mice
30 min before the 2-hr drinking sessions and on the fourth day, separate groups
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of mice were injected (ip.) with OXT (0, 0.3, 1, or 3 mg/kg) 30 min prior to the 4hr test session.
Finally, to investigate whether exogenous OXT administration was
exerting its effects on alcohol consumption in the DID model via actions at the
OXTR, a separate cohort of mice (n= 40) was pretreated with the selective brain
penetrant, nonpeptide OXTR antagonist L-368,899 (10 mg/kg) (Borthwick 2010;
Kuteykin-Teplyakov and Maldonado 2014; Olszewski et al. 2013) or vehicle
(0.9% saline) 15 min prior to OXT (1 mg/kg) or vehicle (saline) administration
(ip.), which was given 30 min before the start of the 4-hr test drinking session.
Two-Bottle Choice Ethanol Drinking
Mice (N= 12) were provided unlimited daily access to two drinking bottles
in the home cage containing either 20% (v/v) ethanol or tap water. Since OXT
has been reported to reduce general fluid intake in rats (Arletti et al. 1990), a
separate group of mice (N= 9) was given two bottles containing water throughout
the study to assess potential effects of OXT treatment on general water intake.
The position of the bottles was alternated daily to avoid a side preference. Mice
were weighed weekly and fluid intake was measured at 4 hr and 24 hr. After
establishing stable daily alcohol and water intake over 3 weeks, half the mice in
the alcohol vs. water and water vs. water groups were injected (ip.) with 1 mg/kg
OXT while the remaining mice in each group received a saline injection.
Following an additional 3 days when all mice were treated with saline, mice were
tested again with the alternative drug (1 mg/kg OXT or saline). Data were
collapsed across dose condition for analyses.
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Locomotor Activity
Following the DID study involving use of lickometer circuitry, mice were
left undisturbed for 4 weeks and then tested for effects of OXT on locomotor
activity. The mice (n= 24) were injected (ip.) with the same doses of OXT (0, 0.3,
1, or 3 mg/kg) 30 min before the start of the test session. Injections occurred 2.5
hr into the dark phase of the circadian cycle to match the DID procedure.
Locomotor activity in an open field arena was assessed using Med Associates
(St. Albans, VT, USA) activity chambers (27 × 27 × 20 cm; ENV-510) situated in
sound-attenuating cubicles with a ventilation fan. Animal movement was tracked
through the use of 16 horizontal infrared photo beams, located on both the X and
Y-axes for positional and rearing detection. Photo beam breaks were recorded
and converted to distance traveled using activity-monitoring software (Activity
Monitor 5.0; Med Associates).

Operant Self-Administration
Operant Conditioning Chambers
Mice were tested in standard operant chambers configured with two
retractable levers, a centrally located well for liquid reinforcers, house light, and a
tone generator and stimulus light above the well. The chambers were situated in
sound-attenuating cubicles with a ventilation fan (Med Associates, St. Albans,
VT). One lever was assigned as the “active” lever, with responses resulting in
access to alcohol or sucrose reinforcement paired with a light and tone stimulus
(80 dB). Alcohol or sucrose reinforcement (20 ul) was delivered to the well by an
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infusion pump (activated for 2 sec). Responses on the ‘inactive lever” were
recorded but did not result in any stimulus consequences or reinforcement
delivery. Stimulus events and responses were controlled and monitored using
Med PC, Version IV software (Med Associates, Inc., St. Albans, VT). At the end
of each session, any residual fluid left in the well was collected with a pipette,
measured, and subtracted from the total volume of reinforcer delivered. The
corrected volume was used to calculate g/kg ethanol or ml/kg sucrose intake
during the sessions.

Ethanol and Sucrose Self-Administration Procedure
Mice were trained to orally self-administer ethanol or sucrose using a postprandial consumption procedure to facilitate acquisition of the behavior. One
hour prior to the beginning of initial self-administration sessions, water bottles
were removed from the cages and mice were given access to standard home
cage chow for 15 min. Water bottles were returned to the home cage following
the conclusion of the behavioral session. During the post-prandial manipulation
(2-3 weeks), weights were monitored, and food was provided after the behavioral
session to maintain weight at 90-95% pre-training body weight. Mice were
trained to respond on a fixed-ratio (FR)-1 schedule for access to 12%
unsweetened ethanol or 5% sucrose solution in 20 min sessions. Once mice
acquired stable rates of responding, the response requirement was increased to
FR2 and then FR4 over 1-3 weeks. When mice demonstrated stable responding
on the FR4 schedule, they were returned to ad libitum food and water access for
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the remainder of the study. Experiments were initiated after response rates had
stabilized (<15% variability over 3 consecutive days). To assess the effects of
oxytocin administration on operant self-administration of ethanol (n= 13) or
sucrose (n= 18), mice were injected (ip.) with different doses of OXT (0, 0.1, 0.3,
or 1 mg/kg) 30 min before self-administration sessions. Each mouse received all
treatment conditions in a Latin-square design, counter-balanced to avoid an
order of treatment bias. Baseline levels of responding were re-established
without drug pre-treatment for a minimum of 3 days between treatments.

Progressive Ratio Testing
The effect of oxytocin on motivation to seek ethanol or sucrose reward
was assessed in a subset of the animals trained to self-administer ethanol (n=
10) or sucrose (n= 12) using a progressive ratio paradigm. To avoid any residual
drug effects, mice were left undisturbed in the home cage for four consecutive
weeks prior to re-establishing baseline lever responding. After stable baseline
(FR4) responding was re-established (<15% variability over 3 consecutive days),
animals were tested on a progressive ratio (PR) schedule. Mice were injected
(ip.) with either OXT (0.3 mg/kg) or vehicle 30 min prior to testing using a
crossover design over two test sessions spaced 7 days apart. The PR schedule
followed an arithmetic series, with the response requirement to obtain ethanol or
sucrose reinforcement increased by four (i.e., FR 4, 8, 12, 16, 20, etc.).
Breakpoint was defined as the highest ratio value reached during the session.
The session was terminated following any 5-min period of inactivity on the active
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lever. Maximum session length was 3 hr, at which point the session was
terminated.

Drugs and administration
Synthetic human OXT (CellSciences, Canton, MA) and the OXTR
antagonist, L-368,899 hydrochloride (Tocris Bioscience, Minneapolis, MN) were
dissolved in 0.9% saline, which served as the vehicle. Injections were
administered intraperitoneally at a volume of 0.01 ml/g body weight in all
experiments. Ethanol (95%) was obtained from AAPER (Shelbyville, KY) and
diluted with tap water to the appropriate concentration. Sucrose was also diluted
to the appropriate concentration with tap water (5% w/v). The ethanol and
sucrose solutions were prepared daily and presented at room temperature.

Statistical Analysis
Primary dependent variables were ethanol intake (g/kg), BEC (mg/dl),
sucrose intake (mL/kg), ethanol lick contacts, and distance traveled (cm) for the
binge-drinking studies. Ethanol intake (mL; g/kg), water intake (mL), total fluid
intake (mL), and ethanol preference ratio (24 hr) were analyzed in the 2-bottle
choice ethanol drinking study. Dependent measures for the operant studies
included lever responses and ethanol/sucrose intake, as well as break points on
the PR schedule. Data were analyzed by analysis of variance (ANOVA), with
Dose as a between-subjects factor (DID model studies) or a within-subjects
factor (2-bottle choice drinking and operant conditioning studies). The factor Time
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served as a repeated measure in analyses of lick responses and locomotor
activity. Breakpoint data from PR testing were analyzed by t-tests. Further
analyses were conducted using Newman-Keuls test, when appropriate. For all
analyses, significance levels were set at p< 0.05, and data are presented as
mean ± standard error of the mean (SEM).

RESULTS
Effect of Oxytocin on Binge-Like Ethanol Consumption
Oxytocin significantly reduced ethanol consumption and resultant blood
ethanol concentrations (BEC) in a dose-related manner. ANOVA revealed a
significant effect of Dose [F(3,36)= 12.31, p< 0.0001] on ethanol intake, and post
hoc analysis indicated a significant decrease in consumption following 1 mg/kg, 3
mg/kg, and 10 mg/kg OXT compared to vehicle (Figure 2.1a). Analysis of BEC
data indicated a similar profile of results, with ANOVA indicating a significant
effect of Dose [F(3,36)= 4.86, p< 0.01]. Further analysis indicated that 3 and 10
mg/kg OXT doses significantly reduced BEC compared to the vehicle condition,
with a trend for reduction at the 1 mg/kg dose (Figure 2.1b).
In a follow-up study with a separate cohort of mice, a lower OXT dose
range was examined on ethanol intake in the DID model. Additionally, lickometer
circuitry was employed to examine the temporal pattern of ethanol intake in the
study. As in the previous study, ANOVA revealed a significant effect of OXT
Dose [F(3,19)= 35.18, p< 0.0001] on ethanol consumption during the 4-hr
drinking session. Post hoc analysis revealed that 0.3, 1, and 3 mg/kg OXT doses
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significantly decreased ethanol intake compared to the vehicle condition, and the
two higher doses of OXT were more effective than the lowest (0.3 mg/kg) OXT
dose in reducing ethanol intake (Figure 2.1c). Further, OXT administration
decreased licking responses at the ethanol bottle in a dose-related manner
(Figure 2.1d). Whereas mice treated with vehicle evidenced relatively consistent
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Figure 2.1. Effect of oxytocin on binge-like ethanol drinking. Oxytocin
reduced ethanol intake (g/kg) (a) and resulting blood ethanol concentrations
(BEC) (b) in the DID model in a dose-related manner. (N= 10/group). Using a
lower range of doses, OXT also reduced ethanol consumption (g/kg) (c) and
decreased as well as delayed ethanol bottle lick contacts over the 4-hr drinking
session (d) in the DID model in a dose-related manner. Values for ethanol intake
are mean ± s.e.m. and mean lick responses are plotted as a function of 10-min
intervals (N= 5-6/group). Values are mean ± s.e.m. (N= 10/group). Significantly
differs from vehicle condition: * (p< 0.05); ** (p< 0.01); *** (p< 0.001).
Significantly differs from 0.3 mg/kg OXT dose: ^ (p< 0.05).
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intake over the entire 4-hr session with cumulative licks increasing steadily over
time, mice treated with OXT exhibited significant delay in contact with the ethanol
bottle, only beginning to drink 1 to 2 hours after bottles were available. This was
supported by ANOVA of the lick data, which revealed significant main effects of
OXT Dose [F(3,18)= 30.88, p< 0.0001] and Time [F(23,414)= 57.10, p< 0.0001],
and a Dose x Time interaction [F(69,414)= 5.03, p< 0.0001]. Analysis of total
cumulative lick responses indicated a significant effect of OXT Dose [F(3,18)=
14.39, p< 0.001] and post hoc analyses indicated that all three OXT doses (0.3,
1, and 3 mg/kg) significantly decreased ethanol lick contacts compared to vehicle
over the entire 4-hr drinking session. Further, there was a trend for the highest
OXT dose to reduce ethanol bottle contacts more than the two lower doses (p<
0.07).
Reversal of Oxytocin Effect on Ethanol Consumption by Oxytocin Receptor
Antagonist
To determine whether OXT reduced ethanol consumption via its receptor,
separate groups of mice were treated with a selective OXT receptor antagonist,
L368,889, before OXT or vehicle (saline) administration. As previously observed,
OXT (1 mg/kg) significantly reduced ethanol consumption in the DID model.
However, this effect was blocked in animals that were pretreated with the OXTR
antagonist (Figure 2.2). These observations were supported by ANOVA, which
revealed a significant main effect of OXT Dose [F(1,36)= 9.08, p< 0.005] and an
OXT x Antagonist interaction [F(1,36)= 10.36, p< 0.003]. Post hoc analysis
indicated that OXT alone significantly reduced ethanol intake and that
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Figure 2.2. Oxytocin-induced reduction in binge-like ethanol consumption
is blocked by pretreatment with an oxytocin receptor antagonist. Oxytocin
(1 mg/kg) reduced ethanol intake in the DID model and this effect was reversed
by pretreatment with the OXTR antagonist L368,889 (10 mg/kg). Values are
mean ± s.e.m. (N= 10/group). Significantly differs from the vehicle-saline
condition: *** (p< 0.001).
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ethanol intake was significantly greater in OXT-treated mice that received L368,889 (10 mg/kg) compared to mice that received saline pretreatment. The
OXT receptor antagonist did not alter ethanol consumption when given alone.

Effect of Oxytocin on Locomotor Activity
The reduction in ethanol consumption by OXT in concert with the delayed
temporal pattern of ethanol intake prompted additional examination of whether
the OXT-induced decrease in ethanol intake is due to a general sedative effect of
the neurohormone. Within 5 min following administration, OXT decreased
locomotor activity in a dose-related manner. While this difference relative to the
vehicle condition rapidly dissipated for the lower (0.3 and 1 mg/kg) OXT dose
groups, reduced activity produced by the highest dose tested (3 mg/kg) persisted
for a longer period of time during the test session (Figure 2.3). ANOVA of activity
data (distance traveled in the open field) indicated significant main effects of
Dose [F(3,19)= 9.87, p< 0.0001] and Time [F(11,209)= 12.76, p< 0.0001] as well
as the Dose x Time interaction [F(33,209)= 3.90, p< 0.0001]. Overall, activity
decreased across the testing session for all groups. Further, all OXT doses
significantly decreased distance traveled compared to the vehicle group within
the first 5 min of the test. However, while activity for mice treated with 0.3 and 1
mg/kg OXT doses was similar to the vehicle group within 10 min, recovery to
control (vehicle) levels required approximately 40-45 min for mice treated with 3
mg/kg OXT.
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Figure 2.3. Effects of oxytocin on locomotor activity. Oxytocin (0.3, 1, or 3
mg/kg) or vehicle was injected (ip.) 30 minutes before locomotor activity was
recorded in an open field during a 4-hr session. Shown are mean ± s.e.m. Values
for distance traveled during first hour of locomotor activity measurement (N= 56/group). Significantly differs from the vehicle condition: * (p< 0.05); + (p< 0.01);
# (p< 0.001).
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Effect of Oxytocin on 2-Bottle Choice Ethanol Drinking
Oxytocin treatment reduced ethanol consumption without significantly
altering total fluid intake under continuous access conditions (Table 1). At 4 hr
following injection, OXT (1 mg/kg) significantly reduced ethanol intake (mL:
[F(1,11)= 5.92, p< 0.05] and g/kg: [F(1,11)= 6.16, p< 0.05]), while not altering
total fluid intake [F1,11)< 1.0]. Similarly, OXT (1 mg/kg) reduced ethanol intake
over 24 hr (mL: [F(1,11)= 20.39, p< 0.001] and g/kg: [F(1,11)= 20.87, p< 0.001]).
The decrease in ethanol consumption was accompanied by increased water
intake [F(1,11)= 6.51, p< 0.05], resulting in no change in total fluid intake
[F(1,11)< 1.0]. OXT treatment also significantly reduced ethanol preference
[F(1,11)= 12.80, p< 0.01] (Table 1). In animals given access to only water, OXT
did not alter intake at 4 hr [F(1,8)= 1.37, p> 0.1] or 24 hr [F(1,8)= 0.07, p> 0.1].

Effect of Oxytocin on Operant Ethanol Self-Administration
After reaching the criteria for stable responding for ethanol, the effect of
OXT on operant oral self-administration was assessed. For these studies, we
omitted the higher doses (3 and 10 mg/kg) from the previous experiments and
included a lower dose (0.1 mg/kg) of OXT. Preliminary analyses indicated no
significant effect of dosing order on the main dependent variables: active lever
responses and ethanol (g/kg) intake [F(5,46)< 1.6 for both variables]. Thus, data
was collapsed across this variable to analyze OXT effects on ethanol selfadministration behavior.
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Table 1. Two-Bottle Choice Ethanol and Water Intake Following Vehicle or Oxytocin Treatment
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in a dose-related fashion OXT reduced responding for ethanol on the active lever
(Figure 2.4a) and the amount of ethanol (g/kg) self-administered (Figure 2.4b).
These observations were supported by significant effects of OXT Dose for active
lever responding [F(3,36)= 7.58 p< 0.001] and ethanol intake [F(3,36)= 8.41 p<
0.001]. Post hoc analyses indicated that all doses of OXT significantly reduced
ethanol responding and intake compared to the vehicle condition. Analysis of
inactive lever responding indicated no significant effect of OXT Dose (Figure
2.4a).
To investigate the effect of OXT on motivation to seek ethanol
reinforcement, a subset of the same mice (n= 10) were challenged using a
progressive ratio (PR) self-administration schedule. OXT decreased overall
active lever responding during the PR sessions. Further, analysis of breakpoint
data indicated that OXT (0.3 mg/kg) significantly reduced breakpoint ratio
achieved for ethanol reward compared to vehicle [t(8)= 2.82, p< 0.03] (Figure
2.4c).

Effect of Oxytocin on Sucrose Self-Administration
To investigate whether OXT administration influences self-administration
of a natural reward, a separate cohort of mice was trained to respond for sucrose
reinforcement. One mouse was excluded from the final analysis due to receiving
incorrect doses in the Latin-square design. Preliminary analyses indicated that
dosing order did not have a significant effect on active lever responding or ml/kg
sucrose intake [F(4,66)< 2.4 for both dependent measures]. However, ANOVA
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Figure 2.4. Effects of oxytocin on oral operant ethanol self-administration
and progressive ratio responding for ethanol. Oxytocin reduced active lever
responding (a) and ethanol consumption (g/kg) (b) in a dose-related manner (N=
13/group). Oxytocin (0.3 mg/kg) reduced breakpoint values (c) for progressive
ratio responding. Values are mean ± s.e.m. (N=5/group). Significantly differs from
vehicle condition: * (p< 0.05); ** (p< 0.01); *** (p< 0.001).
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Figure 2.5. Effects of oxytocin on operant sucrose self-administration and
progressive ratio responding for sucrose. Oxytocin reduced active lever
responding (a) and sucrose consumption (ml/kg) (b) at only the highest dose
tested (1 mg/kg). (N= 18/group). Oxytocin (0.3 mg/kg) did not significantly alter
breakpoint values for progressive ratio responding. Values are mean ± s.e.m.
(N=6/group).Significantly differs from vehicle condition: * (p< 0.05).
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revealed a marginal OXT Dose effect on active lever responding [F(3,51)= 2.48,
p< 0.07] (Figure 2.5a) and a significant effect on ml/kg intake [F(3,51)= 3.33, p<
0.05] (Figure 2.5b). Post hoc analysis revealed that the highest dose of OXT (1
mg/kg) significantly reduced ml/kg intake of sucrose compared to vehicle. OXT
treatment did not significantly alter inactive lever responding (Figure 2.5a).
A subset of mice (n=12) from the sucrose self-administration experiment
were then tested for responding under a PR schedule. OXT (0.3 mg/kg) did not
significantly alter responding for sucrose during PR sessions and analysis of
breakpoint data indicated no significant difference between OXT and vehicle
conditions [t(10)= 1.31, p> 0.20] (Figure 2.5c).

DISCUSSION
Results from the present study demonstrate that systemic administration
of OXT reduces alcohol consumption in a binge-like drinking model, 2-bottle
choice drinking paradigm, and in a model that employs operant selfadministration procedures (Table 2). Oxytocin decreased alcohol consumption in
a dose-related manner, and the ability of OXT to reduce alcohol intake did not
appear to be related to nonspecific (e.g., sedation, antidipsogenic) effects.
Further, OXT reduced motivation to respond for ethanol at doses that did not
alter responding for a natural reward (sucrose). These results are generally
consistent with other reports indicating that systemic administration of OXT
reduces ethanol intake in a variety of drinking models in rats (Bowen et al. 2011;
MacFadyen et al. 2016; McGregor and Bowen 2012) and mice (Peters et al.
2013). These data also complement a recent report showing that direct
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Table 2. Summary of Oxytocin Effects on Ethanol Behaviors

69

icv. infusion of the neuropeptide reduced ethanol consumption in Wistar rats
(Peters et al. 2016). Oxytocin reduced relatively high levels of ethanol intake
along with resultant blood ethanol concentrations in the binge-like DID model.
Use of lickometers provided an opportunity to analyze the effects of OXT on the
temporal pattern of ethanol drinking during the final (fourth day) of the DID
procedure. Results showed vehicle-treated mice initiated licking contacts at the
ethanol bottle within the first 5-10 min of the drinking period and maintained a
relatively steady pace of drinking throughout the entire 4-hr session. In contrast,
OXT treatment delayed ethanol bottle contacts until 1-2 hours into the session.
This profile suggests oxytocin reduced motivation to seek and consume ethanol
under these testing conditions.
Alternatively, the delay in initiating drinking produced by OXT could be due
to a sedative effect of the neuropeptide. Oxytocin has been shown to reduce
locomotor activity in rats (Klenerova et al. 2009). In the present study, OXT
reduced locomotor actvity in an open field in a dose-related manner. However,
this effect was transient, with activity returning to levels registered in vehicletreated mice within 10 min for mice treated with low doses of OXT (0.3 and 1
mg/kg). In contrast, reduced activity produced by a high OXT dose (3 mg/kg) did
not recover to control levels until at least 40-45 min into the test session. These
results are congruent with other reports indicating that low-dose anxiolytic effects
of OXT can be distinguishd from sedative effects produced by higher doses of
the neuropeptide (Bahi et al., 2016; Klenerova et al., 2009). Interestingly, central
(icv.) administration of OXT was shown to attenuate ethanol-induced sedative
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effects in an open-field locomotor test (Bowen et al. 2015). Taken together, it
does not seem likely that the reduction in alcohol drinking produced by low doses
of OXT can be simply attributed to a nonspecific sedative effect of the
neuropeptide. Additionally, while OXT has been reported to produce an
antidipsogenic effect in rats (Arletti et al. 1990), in the present study OXT did not
alter general fluid intake. In fact, reduced alcohol consumption was compensated
by increased water intake. Further, in mice offered only water, OXT treatment did
not alter total fluid intake. Thus, it is unlikely that reduced alcohol consumption in
the various drinking models can be simply attributed to OXT decreasing general
fluid intake.
Using operant conditioning procedures, OXT was shown to reduce alcohol
responding and intake in a dose-related fashion. Moreover, this effect was
produced at doses that did not alter self-administration of a natural reward
(sucrose). The highest OXT dose tested in these operant self-administration
studies (1 mg/kg) reduced responding for both alcohol and sucrose. Other
studies have shown OXT given either systemically or centrally (infused into the
VTA) reduced sucrose intake in rats (Mullis et al. 2013; Zhou et al. 2015). While
the present studies were conducted in only male mice, there is some evidence
that females may be more sensitive than males to the supressant effects of OXT
on sucrose consumption (Zhou et al. 2015). Nevertheless, it is noteworthy that in
the present study low doses of OXT reduced alcohol responding and intake
without altering sucrose self-administration. The fact that responding on an
“inactive” lever in both alcohol and sucrose experiments was not significantly
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altered by OXT also supports the notion that reduced alcohol self-administration
is not related to a general sedative effect of the neuropeptide.
Results from progressive ratio testing further support a selective effect of
OXT in decreasing motivation to self-administer alcohol. Oxytocin (0.3 mg/kg)
reduced breakpoint value for alcohol while not altering this measure for sucrose.
Similarly, a recent study in rats showed 1 mg/kg OXT did not alter progressive
ratio responding or breakpoint for sucrose pellets (Cox et al. 2013). While it is
possible that higher doses of OXT may reduce motivation to respond for a
natural reward, results from the present study demonstrate that at a low dose,
OXT can selectively reduce responding for alcohol. Collectively, these results
align with a growing body of literature demonstrating efficacy for OXT to reduce
alcohol/drug seeking and consumption (Lee et al. 2016).
The mechanism by which systemically administered OXT reduces alcohol
consumption is not fully understood. Peripheral administration (ip. injection) of
OXT was shown to produce a rapid rise in plasma and brain dialysate levels of
OXT in mice (Neumann et al. 2013). While penetration of the neuropeptide
through the blood-brain barrier is limited, passage of a small, yet physiologically
relevant amount of exogenous OXT is thought to influence central OXT activity
(Landgraf and Neumann 2004; Neumann and Landgraf 2012; Neumann et al.
2013). There is evidence indicating that OXT can facilitate its own release in the
hypothalamus (Moos et al. 1984; Rossoni et al. 2008; Theodosis 2002). This
feed-forward loop may explain, at least in part, how acute and chronic
systemically administered OXT can produce enduring functional and behavioral
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effects. For example, Bowen and colleagues showed that repeated injections of
OXT in adolescent rats resulted in upregulated oxytocin receptor mRNA
expression in the hypothalamus in adult rats, which was accompanied by
reduced alcohol consumption (Bowen et al. 2011). Nevertheless, whether
reduced alcohol intake produced by systemic administration of OXT in the
present studies can be attributed to direct effects of the exogenous neuropeptide
in the brain or indirect effects on release of endogenous OXT in brain is unknown
and will require further investigation.
Oxytocin projections are known to influence mesolimbic dopamine activity
in mediating the rewarding aspects of social behaviors (Young et al., 2014). The
relatively high expression of OXTRs within structures such as the NAc suggests
that modulation of mesolimbic dopamine pathways may underlie the ability of
OXT to influence the rewarding effects of alcohol and other substances of abuse.
In a recent study, direct (icv.) administration of OXT reduced ethanol
consumption and ethanol-induced dopamine efflux in the NAc of Wistar rats
(Peters et al. 2016). Thus, it is possible that OXT reduced ethanol selfadministration in the present study by blunting mesolimbic dopamine activity that
ordinarily signals ethanol-related reward.
In the present study, the ablity of OXT to reduce binge-like drinking was
blocked by pretreatment with an OXTR antagonist, suggesting that OXT reduced
ethanol consumption via an interaction with its receptor. Few studies have
examined the role of OXTRs in mediating the neuropeptide’s effects on
motivational actions of alcohol. Recent studies involving viral-mediated

73

overexpression of OXTRs in the nucleus accumbens core (NAcc) have
implicated a role for these receptors in ethanol drinking and conditioned reward
(Bahi, 2015; Bahi et al. 2016). However, it is noteworthy that OXT was shown to
block ethanol-induced ataxic and sedative/hypnotic effects via an apparent direct
interaction with delta-subunit containing GABAA receptors (Bowen et al. 2015).
Thus, there remains some abiguity as to the role of OXTRs in mediating the
neuropeptide’s effects on physiological effects of ethanol and, in particular,
ethanol-related reward and self-administration behavior.
Differing by only two amino acids from the related nonapeptide arginine
vasopressin (AVP), it is possible that OXT reduced the motivational effects of
ethanol through actions at vasopressin receptors (Neumann and Landgraf,
2012). The two hypophyseal neuropeptide systems generally produce opposing
physiological actions. Interestingly, the arginine vasopressin 1b (V1b) receptor
antagonist SR149415 was shown to reduce ethanol drinking in genetically high
alcohol-preferring rats (Zhou et al. 2011) and dependent Wistar rats (Edwards et
al. 2012). However, results from a study demonstrating that the synthetic OXTR
agonist carbetocin, which exhibits low affinity for V1b (and V1a) receptors
compared to OXTRs (Passoni et al. 2016), effectively reduced ethanol-induced
conditioned reward supports a role for OXTRs (Bahi 2015). Further investigation
is needed to determine the relative role of these related neuropeptide receptors
in mediating the ability of OXT to reduce ethanol reward and drinking.
In summary, results from this study provide support and extend evidence
demonstrating the ability of OXT to reduce the motivational effects of ethanol.
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The present results indicate OXT is effective in reducing ethanol consumption in
a model of binge-like drinking, an effect reversed by pretreatment with an OXTR
antagonist. Oxytocin also decreased 2-bottle choice drinking in the home cage as
well as ethanol responding and intake in an oral self-administration model
involving operant conditioning procedures. Further, OXT reduced responding for
ethanol under fixed- and progressive- ratio schedules at doses that did not alter
responding for a natural reward (sucrose). Collectively, these and other recent
reports provide support for the theraputic potential of this neuropeptide as a
treatment for AUDs. A limited number of clinical studies have shown OXT to have
some efficacy in decreasing craving for alcohol and other drugs of abuse (Lee et
al. 2016). For example, Pedersen and colleagues recently demonstrated that IN
OXT attenuated alcohol withdrawal symptoms in treatment seeking human
subjects compared to placebo (Pedersen et al. 2013). Thus, the OXT system
may be a promising target for therapeutic intervention of AUDs, though additional
studies are necessary to establish its clinical efficacy and further investigate the
conditions and mechanisms by which OXT reduces alcohol consumption.
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CHAPTER 3: Chemogenetic Activation of Hypothalamic
Oxytocin-Containing Neurons Reduces Alcohol Consumption
INTRODUCTION
As previously noted, a growing number of preclinical studies has shown
that systemic administration of OXT attenuates alcohol consumption in a variety
of models. However, the mechanisms by which exogenous OXT, especially OXT
delivered in the periphery, reduces the motivational effects of alcohol is not fully
understood. Historically, peripherally administered OXT was not thought to
bypass the blood-brain-barrier in quantities sufficient to alter behavior (OpackaJuffry and Mohiyeddini 2012) but rather, impact behavior via a feed-forward
mechanism stimulating release of endogenous OXT (Ludwig et al. 2002; Rossoni
et al. 2008; Ermisch et al. 1985). Recent evidence has emerged to support
increased central OXT levels following systemic administration (Bowen 2019;
Tanaka et al. 2018; Bustion et al. 2016; Neumann et al. 2013; Freeman et al.
2016; Dal Monte et al. 2014), though only a handful of these studies has
addressed whether the observed increase in OXT was due to exogenous OXT
crossing the BBB or peripherally stimulated release of central OXT (Smith et al.
2019). Lee et al. (2018) recently demonstrated in nonhuman primates that d5denatured OXT (which can be distinguished from endogenous OXT)
administered through IN and IV routes reached the CSF but did not activate a
feed-forward mechanism to elevate OXT. Additionally, Smith and colleagues
reported detectable concentrations of OXT in amygdala and hippocampus of
OXT null mice following both IN and IP administration of the neuropeptide (Smith
et al. 2019). These data validate that the source of measured OXT (by
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microdialysis) originates solely from exogenous administration, as the knockout
mice do not produce endogenous OXT. Thus, while studies are largely
consistent regarding elevated OXT in the CNS following peripheral
administration, the mechanism by which systemic administration simulates
prolonged activation of the central OXT system sufficient to activate OXTRs and
alter behavior remains ambiguous. This void in the literature raises the question
as to whether direct activation of endogenous OXT can produce a similar effect
as exogenous OXT administration on behavior, especially in regard to reducing
alcohol consumption.
Although exogenous OXT may be capable of crossing the blood-brainbarrier (Smith et al. 2019; Neumann et al. 2013), the behavioral effects of
systemic OXT administration may also involve OXTR signaling in the periphery.
Oxytocin receptors are found throughout the periphery where binding mediates
the neuropeptide’s role in a number of behaviors including uterine contraction
during parturition, milk-let down during lactation, feeding behavior and sexual
reflexes in both males and females (Iwasaki et al. 2015; Gimpl and Farenholz
2001). Endogenous OXT is secreted from hypothalamic magnocellular neurons
targeting both the periphery via axon terminals in the posterior pituitary and
extrahypothalamic brain regions via axon collaterals (Knobloch et al. 2012). A
number of receptor binding sites in the periphery are found in areas that could
reasonably contribute to the behavioral effects of OXT on appetitive behavior and
anxiety, including the gut, heart, vascular system and vagus nerve (Gimpl and
Farenholz 2009). However, studies investigating the relative contributions of
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peripheral versus central OXT signaling have yielded mixed results. While there
is evidence to suggest that peripheral OXT directly interacts with vagal afferents
to decrease appetitive behavior in mice (Iwasaki et al. 2015), Tunstall et al.
(2019) demonstrated that peripherally restricted OXTR antagonist, L-371,257, did
not alter the effects of intranasal OXT in reducing alcohol consumption in
dependent rats. Thus, the central versus peripheral contribution to OXT’s effect
on alcohol consumption also remains an important question.
Studies in this chapter will address these important questions. Specifically,
we utilize pharmacological and chemogenetic approaches to selectively activate
OXT-containing neurons within the hypothalamus (PVN) to examine the effect of
endogenous OXT on anxiety-like behavior and alcohol consumption in both a
binge-like-drinking model and in a model involving operant conditioning
procedures. Additionally, through the use of BBB penetrant and peripherally
restricted OXTR antagonists (L-368,899 and Atosiban, respectively), we test the
hypothesis that activation of OXT+ neurons reduces motivation for alcohol via
central, not peripheral, actions. Collectively, these results indicate that
OXT/OXTR activity play a role in regulating anxiety-like behavior and alcohol
consumption, and that this effect is mediated, at least in part, by central, rather
than peripheral, OXTR signaling.
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MATERIALS AND METHODS
Animals and housing
Adult male Oxt-IRES-Cre (Oxt-Cre) mice at least 10 weeks old were used
for all in vivo chemogenetic experiments. These transgeneic mice express Cre
recombinase under the control of the OXT promotor. The breeding colony was
established by back-crossing homozygote Oxt-Cre male mice with C57BL/6J
female mice, both obtained from Jackson Labororaties (Bar Harbor, ME). All
offspring were positive for the expression of Cre recombinase under the control
of the OXT promoter as determined by standard polymerase chain reaction
(PCR) genotyping protocols.
Mice were individually housed under a 12-hour reverse light/dark cycle in
an AAALAC-accredited facility. All testing was conducted during the dark phase
of the circadian cycle. Mice were provided free access to food and water
throughout the duration of the experiment. All experimental protocols were
approved by the Medical University of South Carolina Institutional Animal Care
and Use Committee and consistent with guidelines of the NIH Guide for the Care
and Use of Laboratory Animals.

Drinking in the dark (DID) procedure
Ethanol consumption was assessed using a standard 4-day drinking in the
dark (DID) protocol (Rhodes 2005), as previously described in Chapter 2. Briefly,
mice were presented in the home cage with a single bottle of 20% (v/v) ethanol
approximately 3 hours into the dark cycle for 2 hours on days 1-3 (baseline), and
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for 4 hours on day 4 (test). On test day, intake was recorded at timepoints 0-2hr
and 2-4hr. Vehicle injections were given 30 minutes prior to the 2-hr drinking
session during the first 3 days to acclimate mice to handling and the injection
procedure.

Locomotor Activity and Open Field
Following experiment 2, mice were left undisturbed for 4 weeks and then
tested on the effect of activation of endogenous OXT on anxiety behavior and
locomotor activity. Locomotor activity and anxiety behavior in an open field arena
were assessed using Med Associates (St. Albans, VT, USA) activity chambers
(27 × 27 × 20 cm; ENV-510) situated in sound-attenuating cubicles with a
ventilation fan. Animal movement was tracked through the use of 16 horizontal
infrared photo beams, located on both the X and Y-axes for positional and
rearing detection. Mice were placed in the center of the box and allowed to
explore the arena for 10 minutes. The box was uniformly light under bright light.
Time spent in the periphery of the chamber was compared with time spent in the
center (5x5 cm) to quantify anxiety-like behavior. For locomotor activity,
photobeam breaks were recorded during the same session and converted to
distance traveled using activity-monitoring software (Activity Monitor 5.0; Med
Associates).
Operant Self-Administration
Mice were tested in standard operant chambers, as previously described
in Chapter 2. Briefly, mice were trained to respond on a fixed-ratio (FR)-4
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schedule for access to 12% ethanol solution (20ul delivered into well) in 20minute sessions. At the end of each session, any residual fluid left in the well was
collected with a pipette, measured, and subtracted from the total volume of
alcohol delivered. The correct volume was used to calculate g/kg alcohol intake
during the daily sessions. Experimental tests were initiated after response rates
and intake had stabilized (<15% variability over 3 consecutive days). Vehicle
injections were given 30 minutes prior to all 20-minute drinking sessions to
acclimate mice to handling and the injection procedure.

Drugs and administration
Clozapine-N-oxide (CNO; Tocris Bioscience, Minneapolis, MN), synthetic
human OXT (CellSciences, Canton, MA), and the OXTR antagonists L-368,899
hydrochloride (Tocris) and Atosiban (Tocris), were dissolved in 0.9% saline,
which served as the vehicle. Injections were administered intraperitoneally (ip.) at
a volume of 0.01ml/g body weight in all experiments. Ethanol (95%) was
obtained from AAPER (Shelbyville, KY) and diluted with tap water to the
appropriate concentration. The ethanol solution was prepared daily and
presented at room temperature.

Surgical procedures
Male Oxt-Cre mice were anesthetized with isoflurane and received
bilateral infusion of Cre-dependent virus obtained from Addgene (Cambridge,
MA). To target hypothalamic OXT containing neurons, mice received bilateral
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infusion of AAV8-hSyn-DIO-hM3Dq-mCherry (excitatory) or AAV8-hSyn-DIOmCherry (control virus) into the PVN using stereotaxic coordinates (AP: -0.78
mm, ML: ± 0.2 mm, DVL -5.2 mm) (Wei et al. 2015; Franklin and Paxinos 2008;
adjusted based on pilot data). Viral infusion was delivered over 5 minutes for a
total volume of 0.25 µL followed by a 5 min wait for diffusion. The injector was
slowly withdrawn at a rate of 250 microns every 15 seconds, and after fully
removed, the process repeated on the opposite side. Experiments were
conducted 3-4 weeks after viral injections to allow for recovery and adequate
expression.

Experimental procedures
Effect of Chemogenetic Activation of Hypothalamic Oxytocin-Containing Neurons
on Alcohol Drinking in Binge-like Consumption Model
Previous evidence suggests that Gq-coupled Designer Receptors
Exclusively Activated by Designer Drugs (DREADDs) cause selective activation
of OXT-containing neurons (via administration of otherwise inert ligand CNO)
when virus expression is restricted by the OXT promotor (Penagarikano et al.
2015; Wei et al. 2015). Similarly, the use of OXT-IRES-Cre transgenic mice
enables selective targeting of OXT neurons in the PVN via infusion of Credependent virus containing excitatory DREADD virus (Krashes et al. 2014). To
examine the effect of chemogenetic activation of hypothalamic OXT-containing
neurons on alcohol consumption, adult male Oxt-IRES-Cre mice were infused
with a virus containing an excitatory DREADD (AAV8-hSyn-DIO-hM3DqmCherry) (N=12) or control virus (AAV8-hSyn-DIO-mCherry) (N=11) targeting the
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PVN. Subjects were left undisturbed for three weeks to allow for viral infection
prior to the start of weekly DID cycles. At 30 minutes prior to the 4-hr test
sessions during two consecutive weekly DID cycles, mice were injected with
vehicle (saline) and CNO (3mg/kg). A within-subjects crossover design was
used, with order of drug treatment (saline vs. CNO) counter-balanced across the
two test sessions.
To examine whether systemic OXT administration produced the expected
effects on drinking in this transgenic mouse line (as previously demonstrated in
C57BL/6J mice, see Chapter 1), a separate group of male Oxt-IRES-Cre mice
(n=9) that did not receive viral infusions was injected with vehicle (saline) or OXT
(1 mg/kg) 30 minutes prior to the 4-hr test sessions during two consecutive
weekly DID cycles. Testing in this group was conducted in the same way as
described above. Mice were run concurrently with Oxt-IRES-Cre mice harboring
excitatory DREADD and control virus.
Following the conclusion of DID cycles in Experiment 1, a subset of mice
was left undisturbed for 4 weeks and then tested for effects of activation of
endogenous OXT on anxiety behavior and locomotor activity. Mice (n= 20) were
injected (ip.) with the same doses of CNO (0 or 3 mg/kg) 30 min before the start
of the 10 minute test session. Injections occurred 2.5 hr into the dark phase of
the circadian cycle to match the DID procedure. Data were collected for both
locomotor activity and anxiety behavior in the open field arena within the same
10 minutes.
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Effect of Pharmacological Antagonism of Oxytocin Receptors in Brain on the
Ability of Endogenous Oxytocin to Reduce Alcohol Consumption
To examine whether chemogenetic activation of OXT+ containing neurons
was exerting its effects on alcohol consumption via actions at OXTRs, a separate
cohort of Oxt-Cre mice that received infusion of an excitatory (Gq) DREADD
(AAV8-hSyn-DIO-hM3Dq-mCherry, N=6) or control virus (AAV8-hSyn-DIOmCherry, N=6) was pretreated with the selective brain penetrant nonpeptide
oxytocin receptor antagonist L,368,899 (10mgkg) (King et al. 2017) 15 minutes
prior to CNO (3 mg/kg) or vehicle (saline) administration (ip.) which was given 30
minutes before the start of the 4 hour test session during two consecutive weekly
DID cycles. A within-subjects crossover design was used for oxytocin receptor
antagonist dose with order of drug treatment (Saline or 10mg/kg L368,899)
counter-balanced across the two test sessions. Activation of oxytocin containing
neurons by systemic administration of CNO was treated as a between-subjects
factor, such that animals that received CNO (or saline) in test 1 received the
same drug treatment in est 2.
Effect of Pharmacological Antagonism of Peripheral Oxytocin Receptors on the
Ability of Endogenous Oxytocin to Reduce Alcohol Consumption
To investigate whether the reduction in alcohol drinking produced by
targeted chemogenetic activation of OXT-containing neurons in PVN was related
to signaling at peripheral OXTRs, a separate cohort of Oxt-Cre mice that
received infusion of an excitatory (Gq) DREADD (AAV8-hSyn-DIO-hM3DqmCherry, n=12) or control virus (AAV8-hSyn-DIO-mCherry, n=10) was pretreated
with peripherally restricted OXTR antagonist Atosiban (ATO; 1 mg/kg or saline)
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15 minutes prior to CNO (3 mg/kg) or vehicle (saline) administration (ip.), which
was given 30 minutes before the state of the 4-hour test drinking session. Similar
to Experiment 3, a within-subjects crossover design was used for OXTR
antagonist dose with order of drug treatment (Saline or 1mg/kg ATO) counterbalanced across the two test sessions, while activation of OXT-containing
neurons by systemic administration of CNO (or saline) was treated as a betweensubjects factor.
Effect of Chemogenetic Activation of Hypothalamic Oxytocin-Containing Neurons
on Oral Operant Alcohol Self-Administration
To assess the effects of chemogenetic-induced activation of hypothalamic
OXT+ neurons on operant self-administration of alcohol, Oxt-Cre mice that
received infusion of an excitatory (Gq) DREADD (AAV8-hSyn-DIO-hM3DqmCherry, n=7) or control virus (AAV8-hSyn-DIO-mCherry, n=4) were injected
(ip.) with CNO (3 mg/kg) or vehicle (saline) 30 minutes before self-administration
session. Mice received both treatment conditions in a Latin square design,
counterbalanced to avoid an order of treatment bias. Baseline levels of
responding were re-established without drug pretreatment for a minimum of
5 days between treatments.
To examine whether systemic OXT administration produced similar effects
on oral operant self-administration in this transgenic mouse line (as previously
demonstrated in C57BL/6J mice, see Chapter 1), Oxt-IRES-Cre mice (n=8) that
did not receive viral infusions were injected with vehicle (saline) or OXT (1
mg/kg) 30 minutes prior to a 20-minute daily session. Testing in this group was
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conducted in the same way as described above. Mice were run concurrently with
Oxt-IRES-Cre mice harboring excitatory DREADD and control virus.

Immunohistochemistry
At the conclusion of Experiments mice were transcardially perfused with
ice-cold saline followed by 4% paraformaldehyde (PFA). After extraction, brains
were post-fixed in 4% PFA solution overnight and then transferred to 20%
sucrose in PBS for an additional 24hrs. Brains were frozen on dry ice and sliced
on a cryostat at 50 µm. Slices were blocked 10% normal donkey serum (NDS) in
PBS. Sections were incubated in primary antibody (Rat-Anti-mCherry 1:1000,
Millipore #, Mouse Anti-Oxytocin 1:1000 Clone 4G11, Millipore #MAB5296) in
PBS-TX with 2% NDS for 48hrs at 4 degrees C, followed by 2hr incubation at
room temperature in secondary antibodies (Alexa Flour 555 at Donkey-Anti Rat,
biotinylated donkey anti-mouse, Jackson Immuno). Finally, sections were
incubated in Alex Flour 647-conjugated streptadivdin (1:250, Invitrogen) in PBSTx for 30 minutes. Stained sections were mounted on Superfrost plus slides
(Fischer, Pittsburgh, PA, USA) and cover slipped using Vectashield Mounting
Medium (Vector Laboratories, Burlingame, CA, USA). Images were acquired
using EVOS Cell Imaging Systems (Thermo Fisher Scientific)

Statistical Analysis
Alcohol intake (g/kg) at 2-hr and 4-hr time points during the Day 4 test
sessions in Experiments 1 was analyzed by ANOVA, with Drug (saline vs. CNO)
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and Time (2hr vs. 4hr) as a repeated measure. Data from mice that received
infusions of excitatory DREADD virus or control virus were analyzed separately.
Cumulative intake over the 4 hour test was analyzed as a separate ANOVA for
each of the experimental groups. Total Distance and Time in Center data for
Experiment 1 were analyzed by unpaired t-tests. In Experiment 3 and 4, the
effect of OXTR antagonist pretreatment on alcohol intake during the Day-4 test
sessions was analyzed separately in mice that receive infusions of excitatory
DREADD virus or control virus by ANOVA, with Treatment (saline, CNO, saline +
Antag, CNO+Antag) and Time as repeated factors. In Experiment 5 data were
analyzed by ANOVA, with Drug (saline vs. CNO) and Time (Baseline versus
Test) as a repeated measure. Statistical analyses were carried out using SPSS
software package. Post-hoc comparisons were performed when appropriate
(Newman-Keuls) and significance level for all analyses was p <0.05.

RESULTS
Chemogenetic Activation of Hypothalamic Oxytocin-Containing Neurons
Reduces Alcohol Drinking in Binge-like Consumption Model
Data from one mouse infused with active virus was excluded from analysis
after histological evaluation indicated misplaced viral expression. Mice that
received intra-PVN infusion of excitatory DREADD virus and injected with CNO
consumed significantly less alcohol compared to the same mice that were
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injected with saline. This was supported by ANOVA, which revealed a significant
main effect of Drug [F(1,20) = 9.816, p<0.01]. Further, alcohol consumption
following CNO injection was similarly reduced at 0-2-hr and 2-4-hr time points, as
Drug x Time interaction was not significant [F(1,20) = 2.324, p > 0.10], although a
separate ANOVA revealed a significant main effect of Drug [F(1,20) = 8.50, p >
0.001] for total intake consumed during the 4-hour session (Figure 3.1b). In
contrast, CNO injection did not significantly alter alcohol intake in mice that
harbored the control virus (Drug: [F(1,20) = 0.01, p>0.1] and Drug x Time
[F(1,20) = 0.769, p > 0.1]) (Figure 3.1c).
In a follow up study in a separate cohort of mice, we next examined
whether systemic administration of oxytocin produced comparable effects in OxtIRES-Cre mice that did not receive viral infusion. Analysis of alcohol intake
during the Day-4 test session indicated a significant main effect of Time[F(1,16) =
11.23, p<0.01], with reduction in intake greater at the 0-2hr compared to 2-4hr
measurement. ANOVA also revealed a significant main effect of Drug [F(1,16) =
3.711, p<0.01], although Drug x Time interaction reached only trend level
significance [F(1,16) = 4.04, p=0.06]. This indicates that systemic administration
of oxytocin decreased alcohol consumption compared to mice that received
saline, and this effect was similar at the 0-2-hr and 2-4-hr time points.
Additionally, a separate ANOVA revealed a significant main effect of
Drug[[F(1,16) = 7.437, p<0.05], indicating that total intake across the 4-hr test
session was decreased in mice treated with OXT compared to those treated with
saline (Fig. 3.1d)
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Figure 3.1. Chemogenetic activation of hypothalamic oxytocin-containing neurons
reduces alcohol consumption. (a) Sample image PVN in OXT-IRES-Cre mouse taken
from coronal brain slice depicted mCherry-positive neurons in red (scale bar = 150 µM).
Fluorescence expression was confirmed for all mice used in experiments for panels b-f.
(b) chemogenetic activation of PVN OXT+ neurons reduced total alcohol consumption.
Measurement at 0-2hr timepoint reached trend level significance (p=0.06) (c) Systemic
CNO (3 mg/kg) administration had no effect on drinking in animals harboring control
virus (d) systemic administration of OXT (1 mg/kg) decreased alcohol drinking in the first
2 hours (0-2hr) of the test session, as well total ethanol intake over 4hrs (e) CNOinduced activation of OXT+ neurons increase time in center in open field and (f) this
effect does not appear to be due to changes in locomotor activity (distance traveled).
Values are mean ± s.e.m (N=11-12/group) *p<0.05 versus VEH
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Next, we examined whether acute chemogenetic activation of PVN-OXT
neurons resulted in reduced anxiety-related behavior and/or locomotor activity.
Mice that received intra-PVN infusion of excitatory DREADD virus and injected
with CNO spent significantly more time in the center of the open field arena
compared to mice treated with saline [t(9)= 2.33, p<0.05], suggesting a decrease
in anxiety-like behavior. In mice harboring control virus, CNO injection did not
alter time spent in center compared to mice injected with saline [t(7)= 0.02,
p>0.05] (Fig. 3.1e). The anxiolytic effect observed following activation of
oxytocin-containing neurons by CNO injection is not related to increased
locomotor activity, as there was no significant difference in total distance
travelled in the open field arena in mice with excitatory DREADD [t(9)= 1.09,
p>0.05] or control virus [t(7)= 0.42, p>0.05] during the 10 minute test session
(Fig. 3.1f)

Pharmacological Antagonism of Oxytocin Receptors in Brain Reverses the Ability
of Endogenous Oxytocin to Reduce Alcohol Consumption
To determine whether chemogenetic-induced activation of PVN OXTcontaining neurons reduced ethanol consumption via action at the OXTR, mice
with excitatory DREADD or control virus were treated with a selective blood brain
barrier penetrant OXTR antagonist, L368,889, before CNO or vehicle (saline)
administration. As previously observed, CNO (3 mg/kg) significantly reduced
ethanol consumption in animals harboring excitatory DREADD virus (VEH versus
CNO). However, this effect was blocked in animals that were pretreated with the

90

b
4

VEH
CNO
L368,899
L368,899+CNO

3
2
1
0

Ethanol Intake (g/kg)

Ethanol Intake (g/kg)

a

*

*
0-2hr

2-4hr

Total

4
3

VEH
CNO
L368,899
L368,899+CNO

2
1
0

0-2hr

2-4hr

Total

Figure 3.1. Brain penetrant oxytocin receptor antagonist, L368,899,
reverses the chemogenetic-induced reduction in drinking (a) In mice
harboring excitatory DREADD, CNO-induced activation of OXT+ neurons
decreased alcohol consumption at 0-2hr and total relative to vehicle and
pretreatment with L368,899 (10 mg/kg) reversed this effect. (b) No effect was
observed in animals harboring control virus. Values are mean ± s.e.m
(N=6/group) *p<0.05 versus VEH
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OXTR antagonist (CNO versus L368,899; Fig. 3.2a). These observations were
supported by ANOVA, which revealed a significant main effect of Drug [F(3,20)=
6.40, p< 0.01] and significant Drug x Time interaction [F(3,20)= 3.70, p< 0.05].
Post hoc (Newman-Keuls) analysis indicated that reduced drinking produced by
activation of excitatory DREADD with CNO was completely reversed when mice
were pretreated with OXTR antagonist L368,899 (10mg/kg), and the OXT
receptor antagonist did not alter ethanol consumption when given alone (VEH
versus L368,899). This effect was also shown in the total ethanol intake (g/kg)
across the four hour test session (significant main effect of Drug [F(3,20)= 6.96,
p< 0.01]. Similarly, the lack of a significant main effect of Drug [F(3,18)= 0.959,
p> 0.05] in mice with control virus indicates neither injection of CNO or
pretreatment with L368,899 had an effect on alcohol consumption during the test
session (Fig. 3.2b)

Pharmacological Antagonism of Peripheral Oxytocin Receptors Does Not
Reverse the Ability of Endogenous Oxytocin to Reduce Alcohol Consumption
Next, we examined the role of peripheral OXTR signaling in the observed
decrease in alcohol drinking via chemogenetic inducted activation of PVN OXTcontaining neurons. Data from one mouse infused with active virus and two mice
infused with control virus were excluded from the analyses after histological
evaluation indicated misplaced viral expression. Mice with excitatory DREADD or
control virus were treated with peripherally restricted (expected to not cross the
BBB) OXTR antagonist, Atosiban, before CNO or vehicle (saline) injection. In
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Figure 3.2. Peripherally restricted oxytocin receptor antagonist, Atosiban,
did not reverse chemogenetic-induced reduction in drinking (a) In mice
harboring excitatory DREADD, CNO-induced activation of OXT+ neurons
decreased alcohol consumption at 0-2hr and total relative to vehicle.
Pretreatment with Atosiban (1 mg/kg; ATO) did not affect alcohol consumption in
vehicle (ATO) or CNO (ATO+CNO) groups (b) No effect of CNO or ATO was
observed in animals harboring control virus. Values are mean ± s.e.m
(N=10/group) *p<0.05 versus VEH
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mice harboring excitatory DREADD, CNO treatment significantly reduced
drinking whether mice were pretreated with either vehicle or with the peripherally
restricted OXTR antagonist Atosiban (Drug: [F(3,17)= 3.985, p< 0.05], Fig. 3.3a).
Lack of significant Time x Drug interaction ([F(3,17)= 1.936, p> 0.1]), indicates
that pretreatment with ATO had no effect no alcohol drinking at either timepoint.
However, analysis of total ethanol intake (g/kg) for mice with Excitatory DREADD
revealed that main effect of Drug F(3,17)= 3.023, p= 0.056]) reached only trend
level significance. Further, ATO did not significantly alter drinking in mice
harboring control virus (Drug: [F(3,12)= 0.249, p>0.1], For total Intake: Drug:
[F(3,12)= 0.215, p>0.1] , Fig. 3.3b)

Activation of Hypothalamic Oxytocin-Containing Neurons Reduces Oral Operant
Alcohol Self-Administration
After reaching the criteria for stable responding for EtOH, the effect of
chemogenetic-induced activation of OXT+ neurons on operant oral selfadministration was assessed. Mice that received intra-PVN infusion of excitatory
DREADD virus and injected with CNO demonstrated a decrease in responding
for alcohol compared to animals injected with saline, as well as the average
responding during the last 3 days of baseline (Fig. 3.4a). This was supported by
ANOVA, which revealed a significant main effect of Drug [F(1,12) = 10.113,
p<0.01] and significant Drug x Time interaction [F(1,20) = 2.324, p > 0.10].
Analysis revealed similar results for ethanol intake ( Drug [F(1,12) = 10.113,
p<0.01] and Drug x Time [F(1,12) = 7.99, p < 0.05]; Fig. 3.4b) In contrast, CNO
injection did not significantly alter responding (Fig. 3.4c) or alcohol intake (Fig.
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Figure 3.3. Chemogenetic activation of PVN oxytocin- neurons on oral
operant alcohol self-administration (a) chemogenetic activation of PVN OXT+
neurons reduced lever responding and (b) alcohol intake in mice harboring
excitatory virus compared to vehicle and the average of the last 3 days of
baseline responding prior to testing. In contrast, administration of CNO had no
effect on (c) lever responses and (d) alcohol intake in mice that received infusion
of control virus. For comparison, systemic OXT (1 mg/kg) also reduced (e) lever
responding and (f) alcohol intake. Values are mean ± s.e.m (N= 7 /group Gq and
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3.4d) in mice that harbored the control virus (Responding: Drug: [F(1,6) = 0.04,
p>0.1] and Drug x Time [F(1,6) = 0.204, p > 0.1], Intake: Drug: [F(1,6) = 0.043,
p>0.1] Drug x Time [F(1,6) = 0.218, p > 0.1]).
In the same cohort of mice, we next examined whether systemic
administration of oxytocin produced comparable effects on lever responding and
alcohol intake. For this study, we used a single dose of OXT (1 mg/kg) previously
shown to be effective in decreasing lever responding and ethanol intake (King et
al., 2017, see Chapter 2). As expected, lever responding was reduced during the
test session compared to baseline AVG (significant main effect of Time[F(1,20) =
12.804, p<0.01]). ANOVA also revealed a significant main effect of Drug [F(1,20)
= 8.377, p>0.01] and Drug x Time interaction [F(1,20) = 9.437, p<0.01], reflecting
significantly reduced lever responding for alcohol in mice treated with OXT (1
mg/kg) compared to vehicle (Base versus CNO, VEH versus CNO, all post hocs
p <0.05; Fig. 3.4e). Similar results were obtained for alcohol intake (Time[F(1,20)
= 34.774, p<0.001], Drug[F(1,20) = 18.167, p<0.001], and Drug x Time [F(1,20) =
25.715, p<0.001]; Base versus CNO, VEH versus CNO, all post hocs p <0.05
Fig. 3.4f)

DISCUSSION
A growing body of evidence has established a role for the OXT system in
various aspects of alcohol and drug addiction. However, much of this work has
centered around exogenous peripheral administration (i.e., intraperitoneal,
intravenous, intranasal) of the neuropeptide or synthetic analog, carbetocin. The
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precise mechanism by which peripherally applied OXT crosses the blood-brain
barrier and facilitates release within the brain remains unclear, prompting the
question as to whether activation of endogenous OXT can produce a similar
effect as exogenous OXT administration. Here we report that direct activation of
OXT-containing neurons in the PVN via targeted expression of excitatory
DREADD (and systemic injection of CNO) decreases total alcohol consumption
in a binge-like model. Activation of OXT-containing neurons decreased anxiety
behavior in the open field test and this effect was not due to changes in
locomotor activity. Further, using pharmacological and chemogenetic
approaches, we demonstrate that the effects of activation of PVN OXTcontaining neurons on alcohol consumption can be reversed with a blood-brainbarrier penetrant OXTR antagonist, while peripheral administration of an OXTR
antagonist that does not cross the blood-brain-barrier did not reverse this effect.
Finally, chemogenetic-induced activation of OXT+ neurons reduced lever
responding and ethanol intake in a model that employs operant selfadministration procedures. Together, these data suggest a central mechanism
for OXT’s effect on alcohol drinking and anxiety-like behavior and implicate
OXTR neurotransmission as a potential mechanism of action.
In the present study, activation of PVN OXT+ neurons decreased alcohol
consumption and anxiety-like behavior. These findings are consistent with
previous reports that OXT decreases alcohol drinking (Tunstall et al. 2019;
Hansson et al. 2018; Stevenson et al. 2017; King et al. 2017; Peters et al. 2017;
Bowen et al. 2011; McGregor & Bowen 2012) and anxiety-like behavior (Lee et
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al. 2017; Li et al. 2016; Bredewoid and Veenema 2018) in rodents. While data
from Experiment 1 demonstrates a reduction in total intake in mice that
experienced CNO-induced activation of OXT+ containing neurons, the decrease
in alcohol consumption measured at the different time points (0-2hr and 2-4hr)
was not significantly different compared to mice treated with vehicle. Regardless,
these data corroborate the previous finding (Chapter 2) that systemic OXT
treatment decreased binge-like ethanol consumption over the four hour test
period. The current data included investigation of the systemically administered
OXT on drinking, as previous experiments in our lab using the DID model did not
involve measurements of intake at different time points.
Systemic administration of OXT demonstrated a more robust reduction in
alcohol drinking in the first two hours (0-2hr; reached significance) in comparison
to acute chemogenetic activation of PVN-OXT neurons. This effect may be
related to the fact that activation of DREADD receptors in OXT+ neurons is
driving the endogenous OXT system and therefore is restricted by physiological
limits (such as availability of OXT, rate of neuropeptide synthesis. etc).
Administration of exogenous OXT, however, may push the system beyond
physiological relevant doses and reveal a more exaggerated effect on behavior.
In congruence with previous data (see Chapter 2), the ability of activation
of PVN OXT+ containing neurons to reduce alcohol consumption was reversed
by pretreatment with a brain penetrant OXTR antagonist, suggesting that OXT
neurotransmission reduced alcohol consumption via an interaction with its
receptor. Oxytocin receptors have been identified in a number of reward- and
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anxiety-associated brain regions that are integral to motivational effects of
alcohol, including PFC, striatal, and limbic regions (Grinevich et al. 2016).
Further, changes in OXTR expression in a number of these regions (e.g.,
prelimbic cortex, NAc core and shell, CeA) have been demonstrated as a direct
result of alcohol experience (Hansson et al. 2018). Oxytocin may directly impact
reward signaling by altering mesolimbic dopamine activity via OXTR located on
VTA neurons projecting to the NAc (Peris, et al. 2017; Peters et al. 2016).
Moreover, recent reports showed that viral-mediated overexpression of OXTRs in
NAc reduced alcohol-induced CPP and alcohol consumption in mice (Bahi 2015;
Bahi et al. 2016).
Using a chemogenetic approach, results from the present work also
provide evidence to support the hypothesis that OXT’s effect of reducing alcohol
drinking is likely centrally mediated. However, OXT-containing neurons in the
PVN secrete OXT into the bloodstream via axon terminals in the posterior
pituitary as well as target extrahypothalamic brain regions via axon collaterals
(Knobloch et al. 2012). Therefore, chemogenetic-induced activation of these
neurons could potentially lead to secretion of OXT into the periphery and produce
effects through signaling at peripheral OXTRs. The present study provides
evidence that peripheral receptors did not a make a major contribution to the
effect of activating OXT+ neurons in the PVN on alcohol consumption. More
specifically, pretreatment with nonbrain penetrant OXTR antagonist, Atosiban,
had no effect on activation of OXT+ neurons in the PVN on alcohol consumption.
Whereas pretreatment of brain penetrant OXTR antagonist, L368,899, reversed
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this effect. These results are consistent with a recent report by Tunstall et al.
demonstrating icv. administration of a large molecule OXTR agonist, PF06655075, that does not cross the BBB, significantly reduced alcohol drinking in
dependent rats. However, the same compound administered systemically (not
expected to enter the CNS) did not have an effect. The authors also showed that
application of nonbrain penetrant OXTR antagonist L-371,257 did not reverse the
ability of intranasal OXT to reduce alcohol drinking in dependent rats (Tunstall et
al. 2019). Taken together, these data suggest that OXTR signaling in the brain
reduces alcohol consumption independent of OXTR binding in the periphery.
While the mechanism by which OXT reduces alcohol consumption
remains unknown, one possible explanation is through interaction with
GABAergic neurotransmission. Oxytocin has been reported to interact with
GABAergic signaling to modulate limbic reward, fear and anxiety circuits (Dolen
et al. 2013; Yoshida et al. 2009; Knobloch et al. 2012; Viviani et al. 2010; Sabihi
et al. 2017) and may block the acute effects of alcohol (Bowen et al. 2015).
Specifically, in the CeA, OXT has been shown decreased GABAergic signaling in
both dependent and nondependent rats (Tunstall et al. 2019). However, there is
evidence to support both OXTR independent (via direct interaction with δ
subunit-containing GABAA receptors; Bowen et al. 2015), and OXTR dependent
(Sabihi et al. 2017) mechanisms to regulate behavior. Interestingly, some
OXTR-expressing cells contain GABA (Yoshida et al. 2009) and OXTRs have
been shown to be located on GABAergic interneurons in the CeA (Huber et al.
2005), as well as mPFC (Nakajima et al. 2014) that may attenuate activity of
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downstream limbic regions, including the amygdala (Berretta et al. 2005, Gabbott
et al. 2005). Thus, the effects of OXT neurotransmission on GABAergic signaling,
particularly in the CeA, may contribute to the acute reinforcing effects of alcohol,
as well as the negative affective state associated with chronic alcohol use.
However, since the OXTR antagonist L368,899 was systemically administered,
we cannot impy that OXTR activity in any brain region independently mitigates
the effects of targeted chemogenetic-induced activation of OXT+ neurons.
Further studies involving local OXTR blockade will be required to more directly
address this issue.
One important limitation of the present work is that the studies were
conducted exclusively in male Oxt-IRES-Cre mice. In the present investigation
female Oxt-IRES-Cre mice were run concurrently with males (See Appendix).
However, systemic injection of CNO reduced alcohol consumption in female mice
harboring control virus (with no active DREADD receptor) across several studies,
suggesting that CNO had off-target effects. Thus, data from mice infused with
excitatory DREADD virus are challenging to interpret. This is unfortunate
especially considering sex-specific OXTR distribution (Dumias and Veemena
2016). Although very few studies have examined the potential sex-related
differences in OXT modulation of alcohol intake, there is some evidence that
female mice may be more sensitive to the behavioral effects of OXT (Kohtz et al.
2018). Thus, this is an issue that will require further investigation.
Another issue regards the specificity of the peripherally restricted OXTR
antagonist, Atosiban. Atosiban is an OXT analogue (competitive antagonist) that
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also acts as an antagonist of the vasopressin receptor V1a (Vrachnis et al.
2011). This raises some concern, as a role for vasopressin (AVP) has been
implicated in the transition to dependence (Zhou & Kreek, 2018) and AVP
receptor antagonism has been shown to decrease alcohol consumption in
humans and rodents (Zhou et al. 2018; Edwards et al. 2012; Katz et al. 2016;
Ryan et al. 2017). However, these effects appear to be mediated largely by the
vassopressin V1b receptor (Zhou et al. 2018; Edwards et al. 2012). Regardless,
an association between V1a receptor subtype and alcohol drinking has also been
established. Both heterozygous and homozygous mouse knockout of the V1a
receptor increased alcohol consumption (Sanbe et al. 2008, Caldwell et al.
2006), and a modest association was found between a V1a receptor SNP and
maximum drinks per day in humans (Maher et al. 2011). However, a recent study
investigating the role of AVP in alcohol-associated anxiety, showed that V1b, but
not V1a, antagonism was effective in reducing alcohol-related behaviors
(Dannenhoffer et al. 2018). Further, in peripheral tissue, the V1a receptor is
expressed in a variety of vascular walls in arteries, arterioles and veins and
regulates vascular contraction, glucocorticoid release from the adrenal gland and
renin production in the kidney (Morel et al. 1992; Vrachnis et al. 2011). While
unlikely, these physiological functions may contribute to the observed reduction
in alcohol consumption. Nonetheless, the results of the present study are in
congruence a recent report that showed a more selective non-BBB penetrant
OXTR antagonist, L-371,257, did not reverse the effects of OXT administration
on alcohol consumption (Tunstall et al. 2019). Thus, while other OXTR
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antagonists, such as esGly–NH2,d(CH2)5[Tyr(Me)2,Thr4]OVT, 5, desGly–
NH2,d(CH2)5[D-Tyr2,Thr4]OVT, and L-371,257 offer clear advantages for in vivo
studies requiring the discrimination of OXT versus V1a receptors in rodents
(Manning et al. 2008), the current examination provides some evidence that
peripheral OXTR do not contribute to the effect of chemogenetic induced
activation of OXT+ containing neurons on alcohol consumption.
In sum, results from the present study provide new evidence indicating a
role for OXT/OXTR system activity and, in particular, central activity of this
neuropeptide system in the regulation of motivated alcohol drinking. These
findings implicate the OXT system as a potential therapeutic target in treatment
designed to reduce alcohol consumption and anxiety-related behaviors.
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CHAPTER 4: Oxytocin Attenuates Stress-Induced Reinstatement
of Alcohol-Seeking
INTRODUCTION
The compulsive nature of alcohol seeking and use, along with high rates
of relapse present a major challenge in the treatment of alcohol addiction. Stress
is a common trigger for relapse, yet mechanisms by which stress provokes
relapse and promotes excessive levels of alcohol consumption are not fully
understood. Thus, understanding brain mechanisms underlying relapse and the
influence of stress on drinking has emerged as a central issue in addiction
research.
Understandably, the ability of OXT to modulate both stress and
motivational processes has generated growing interest in its potential as a
treatment for substance use disorders. For example, in a recent clinical study, IN
OXT was shown to alleviate alcohol withdrawal symptoms in treatment-seeking
subjects (Pedersen et al. 2013). Additional support comes from a growing
number of studies showing that systemic administration of OXT reduces alcohol
consumption in rodents (Bowen et al. 2011; MacFadyen et al. 2016; McGregor
and Bowen 2012). Further, direct brain (icv.) infusion of OXT, or manipulation of
OXTR expression in brain reduced alcohol reward and consumption (Bahi 2015;
Bahi et al. 2016; Peters et al. 2017). Recent work in our laboratory demonstrated
that systemic administration of OXT reduced binge-like alcohol drinking and oral
self-administration of alcohol using operant conditioning procedures in male
C57BL/6J mice in a dose-related manner (King et al. 2017; See Chapter 2).
Importantly, OXT reduced alcohol consumption at doses that did not significantly
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alter sucrose intake. Taken together, accumulating evidence suggests that the
OXT system may represent a promising target for the treatment of alcohol use
disorders.
While evidence supports a role for OXT in regulating alcohol consumption,
few studies have examined the effects of OXT on alcohol relapse-like behavior.
The present study aimed to examine the ability of systemic OXT to attenuate
stress-induced reinstatment of alcohol-seeking behavior in male and female
mice. Two different stress procedures were employed: brief exposure to a
predator odor and acute challenge with the pharmacological stressor yohimbine.
Given that OXT is know to function as an anti-stress neuropeptide (Landgraf and
Neumann 2004; Windle et al. 2004), it was predicted that systemic OXT
administration would attenuate stress-induced reinstatement of alcohol-seeking
behavior in a dose-related manner in male and female mice. Further, since there
is some evidence to suggest that gonadal hormones can influence the functional
activity of OXT (Ivell and Walther 1999), it was predicted that females would
exhibit a greater response to OXT treatment compared to males.

MATERIALS AND METHODS
Animals and Housing
Adult male and female C57BL/6J mice (25 to 30 g) were obtained from
Jackson Laboratories (Bar Harbor, ME) at 9 to 10 weeks of age and were
acclimated to the experimental housing rooms for a minimum of 1 week prior to
the start of experiments. Male and female mice were group housed (4 per cage)
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in the same colony room, but with males and females on separate racks. The
animals were maintained under a 12-hour reversed light/dark cycle in an
AAALAC-accredited facility. All testing was conducted during the dark phase of
the circadian cycle. Mice were provided free access to food and water, except at
the start of operant oral self-administration training. All experimental protocols
were approved by the Medical University of South Carolina Institutional Animal
Care and Use Committee and consistent with guidelines of the NIH Guide for the
Care and Use of Laboratory Animals.

Operant Conditioning Chambers
Mice were tested in standard operant conditioning chambers configured
with 2 retractable levers, a centrally located well for liquid reinforcers, house light,
a tone generator, and a stimulus light above the well. The chambers were
situated in sound-attenuating cubicles with a ventilation fan (Med Associates;
Fairfax, VT). One lever was assigned as the “active” lever, with scheduled
responses activating an infusion pump that delivered alcohol (12% v/v ethanol)
reinforcement (20 µl) into the well along with activating a light and a tone stimulus
(80 dB). Responses on the “inactive lever” were recorded but did not result in any
stimulus consequences or reinforcement delivery. The position of the “active”
lever (left vs. right of well) was counterbalanced across subjects. Stimulus events
and responses were controlled and monitored using Med PC, Version IV
software (Med Associates). At the end of each session, any residual fluid left in
the well was collected with a pipette, measured, and subtracted from the total
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volume of alcohol delivered. The corrected volume was used to calculate g/kg
alcohol intake during the 20-min daily sessions. Male and female mice were
tested in separate chambers throughout the experiments (8 chambers/sex).

Operant Alcohol Self-Administration
Mice were trained to self-administer alcohol using standard operant
conditioning procedures, as previously described (King et al. 2017). Briefly, mice
were first trained to respond for alcohol reinforcement under a fixed ratio-1 (FR1)
schedule. Response requirements were gradually increased until mice achieved
stable lever responding under a FR4 schedule of reinforcement (<15% variability
across 3 consecutive daily sessions). Once stable baseline alcohol
responding/intake was established, mice entered into the extinction phase of the
study. During daily extinction sessions, responding on the “active” lever no longer
had stimulus consequences and alcohol reinforcement was no longer delivered.
After 14 days of extinction (when responding has reached <15% of baseline
responding), all mice were tested for stress-induced reinstatement of alcohol
responding.

Study 1: Predator Odor-Induced Reinstatement Testing
Mice were transferred to a chamber and exposed to a predator odor
(2,3,5-Trimethyl-3-thiazoline; TMT) for 15 min. This stressor, a synthetically
derived component of fox feces, was selected because of its ethological
relevance and validity (Janitzky et al. 2015), as well as the fact that we have
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successfully used TMT to produce robust relapse-like behavior in our preliminary
studies. TMT (0.03 mL; 1% v/v; Ferland et al. 2016) was placed on a gauze pad
in a weigh boat in the chamber such that mice could not manipulate it. After the
15-min exposure period, mice were immediately placed into self-administration
chambers to examine alcohol-seeking behavior under extinction conditions. At 30
min prior to the reinstatement test session (15 min prior to TMT exposure),
separate groups of mice were injected (ip.) with vehicle (saline) or OXT (0.1, 0.5,
1 mg/kg) (N= 8-10/group).

Study 2: Yohimbine-Induced Reinstatement Testing
Mice were injected with yohimbine (0.3, 0.625 mg/kg; ip.) 60 min prior to
the reinstatement test session. At 30 min post-yohimbine injection, mice are
injected (ip.) with vehicle (saline) or OXT (1 mg/kg). Reinstatement testing was
conducted under extinction conditions 30 min after OXT injection. Results from a
series of pilot studies indicated that the 60 min pretreatment time for yohimbine
administration was optimal for triggering reinstatement responding (unpublished
data). In this case, OXT was administered after yohimbine treatment to keep the
pretreatment time for the neuropeptide consistent with that used in the TMT
study (Study 1). Each mouse received both yohimbine doses in a
counterbalanced order with one week of extinction responding between tests.
Male and female cohorts were tested separately (N= 7-10/group/sex).
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Drugs
Synthetic human OXT (CellSciences, Canton, MA) and yohimbine (Tocris
Bioscience, Minneapolis, MN), were dissolved in 0.9% saline, which served as
the vehicle. Injections were administered intraperitoneally in a volume of
0.01 ml/g body weight in all experiments. Alcohol (95% ethanol) was obtained
from AAPER (Shelbyville, KY) and diluted with tap water to the appropriate
concentration. The alcohol solution was prepared daily and presented at room
temperature.

Statistical Analysis
The primary dependent variable analyzed was lever responses during
different phases of the studies. Lever responses were averaged over the last
three daily sessions of baseline alcohol self-administration and the last 3 days of
extinction testing prior to reinstatement testing. Number of reinforcers earned and
amount of alcohol intake (g/kg) averaged over the last three self-administration
sessions were also analyzed. For Study 1, lever responses, reinforcers earned,
and alcohol intake in male and female mice were analyzed by t-tests. Responses
during reinstatement testing were analyzed by ANOVA, with Sex and Dose as
between-subject factors. For Study 2, since male and female mice were not
tested simultaneously, reinstatement responding for males and females was
separately analyzed by ANOVA, with OXT Dose as a between-subject factor and
yohimbine Treatment as a repeated measure. Initial analyses also included order
of yohimbine dose as a factor but since this variable did not significantly interact
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with the other variables, data were presented and analyzed as collapsed over
this factor. Post-hoc analyses (Newman-Keuls) were conducted when
appropriate. For all analyses, significance levels were set a p < 0.05.

RESULTS
Oxytocin Effects on TMT-Induced Reinstatement of Alcohol-Seeking in Male and
Female Mice
All animals demonstrated stable and preferential responding on the active
lever. Males and females did not significantly differ in responding on the active
lever [t(66)= 0.08, p> 0.1] and inactive lever [t(66)= 0.95, p> 0.1] (Figure 4.1a),
and there was no sex-related difference in the number of alcohol reinforcers
earned [t(66)= 0.25, p> 0.1] (Figure 4.1b). However, average alcohol intake was
significantly higher in females compared to males [t(66)= 2.87, p< 0.01] due to
differences in body weight (Figure 4.1c).
During reinstatement testing, TMT exposure significantly increased
alcohol-seeking behavior, and OXT treatment significantly reduced this stressinduced relapse-like responding in both male and female mice in a dose-related
manner (Figure 4.1d). ANOVA revealed a significant main effect of Dose
[F(3,63)= 8.39, p< 0.001], indicating that OXT was effective in reducing alcohol
responding in both males and females. While it appears that females may have
been more sensitive to the effects of OXT, this was not supported by the
analysis, as the Dose x Sex interaction did not achieve statistical significance.
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Figure 4.1. Effects of oxytocin on TMT-induced reinstatement of alcoholseeking behavior. Lever responding, alcohol reinforcers and alcohol Intake
during self-administration. (a) Males and females did not significantly differ in
responding on the active lever, and there was no sex-related difference in the
number of (b) alcohol reinforcers. (c) Average alcohol intake was significantly
higher in females compared to males. Systemic OXT attenuates TMT-induced
reinstatement of alcohol seeking behavior in a dose-related manner in male (left)
and female (right) mice. Values are mean ± s.e.m. (N= 10/group). Significantly
differs compared to males: ** (p< 0.01) Significantly differs from vehicle condition:
* (p< 0.05)
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Separate analysis of data from males revealed a significant effect of Dose
[F(3,35)= 5.22, p< 0.01] and post-hoc comparisons indicated that the highest
OXT dose tested (1 mg/kg) reduced responding compared to vehicle (p< 0.05).
In females, a main effect of Dose [F(3,34)= 4.54, p< 0.01] and post-hoc analysis
indicated that both 0.5 and 1 mg/kg doses of OXT significantly reduced alcohol
seeking behavior compared to vehicle (ps< 0.05).

Oxytocin Effects on Yohimbine-Induced Reinstatement of Alcohol Seeking in
Male Mice
Active and inactive lever responses, number of alcohol reinforcers earned,
and alcohol intake over the last 3 days of oral alcohol self-administration in males
are shown in Figure 4.2a, 4.2b, and 4.2c, respectively. Yohimbine treatment
increased alcohol responding during reinstatement testing and this effect was
blocked by pretreatment with OXT (1 mg/kg) (Figure 4.2d). Increased
reinstatement responding following injection of yohimbine did not significantly
differ as a function of dose of the drug. ANOVA revealed a significant main effect
of OXT Dose [F(1,17)= 22.15, p< 0.001], but the yohimbine Treatment x OXT
Dose interaction was not significant. This indicates that systemic administration
of OXT (1 mg/kg) reduced alcohol seeking behavior provoked by both yohimbine
doses to a similar extent.
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Figure 4.2. Effects of oxytocin on yohimbine-induced reinstatement in male
mice. Active and inactive lever responses (a), number of alcohol reinforcers
earned (b), and alcohol intake (c) over the last 3 days of oral alcohol selfadministration. Yohimbine treatment increased alcohol responding during
reinstatement testing and this effect was blocked by pretreatment with OXT (1
mg/kg) (d). Values are mean ± s.e.m. (N= 7-10/group) Significantly differs from
average last 3 days of extinction (ext): ** (p< 0.01). Significantly differs from
vehicle condition: ^ (p< 0.05).
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Figure 4.3. Effets of oxytocin on yohimbine-induced reinstastement in
female mice. Active and inactive lever responses (a), number of alcohol
reinforcers earned (b), and alcohol intake (c) over the last 3 days of oral alcohol
self-administration. Similar to males, yohimbine treatment increased alcohol
responding during reinstatement testing and this effect was attenuated by
pretreatment with OXT (1 mg/kg) (d). Values are mean ± s.e.m. (N= 7-10/group)
Significantly differs from average last 3 days of extinction (ext): ** (p< 0.01).
Significantly differs from vehicle condition: ^ (p< 0.05).
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Oxytocin Effects on Yohimbine-Induced Reinstatement of Alcohol Seeking in
Female Mice
Active and inactive lever responses, number of alcohol reinforcers earned,
and alcohol intake over the last 3 days of oral alcohol self-administration in
females are shown in Figure 4.3a, 4.3b, and 4.3c, respectively. As in males,
yohimbine treatment increased alcohol responding during reinstatement testing
and this effect was blocked by pretreatment with OXT (1 mg/kg) (Figure 4.3d).
ANOVA indicated that both doses of yohimbine produced a similar increase in
alcohol responding [F(1,26)= 1.62, p> 0.1], and OXT blocked this increase in
responding [F(1,26)= 23.52, p< 0.001]. The lack of a significant yohimbine
Treatment x OXT Dose interaction indicates that OXT was effective in reducing
elevated alcohol seeking produced by both doses of yohimbine.

DISCUSSION
Results from the present study demonstrate that systemic administration
of OXT reduces stress-induced reinstatement of alcohol-seeking behavior. In
Study 1, OXT attenuated predator odor (TMT)-induced reinstatement in a doserelated manner in both male and female mice. In Study 2, OXT attenuated
increased alcohol-seeking following administration of the pharmacological
stressor yohimbine in both sexes. Although OXT has been shown to effectively
reduce cue- and drug-primed reinstatement to alcohol and other drugs of abuse
(Baracz et al. 2015; Baracz et al. 2016; Cox et al. 2017; Ferland et al. 2016;
Hansson et al. 2018; Kohtz et al. 2018; Weber et al. 2018), to our knowledge,
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this is the first report to demonstrate that OXT attenuates stress-induced alcohol
relapse-like behavior in mice.
Our finding that OXT reduces stress-induced alcohol reinstatement
responding is consistent with other studies that have shown OXT decreases
stress-related relapse-like behavior to other drugs of abuse. Systemic
administration of OXT decreased methamphetamine-seeking behavior following
predator odor exposure (Ferland et al. 2016) and yohimbine administration (Cox
et al. 2013) in rats. In mice, centrally administered OXT (icv.) attenuated
reinstatement of methamphetamine conditioned place preference (CPP) induced
by restraint stress (Qi et al. 2009), and systemic administration of the oxytocin
analog, carbetocin, reduced the effects of forced-swim stress on reinstatement of
morphine-induced CPP (Zanos et al. 2014). Collectively, results from the present
study and related reports in the literature indicate that OXT treatment is effective
in attenuating relapse-like behavior provoked by various stress procedures.
The present study demonstrated OXT was effective in reducing the ability
of two different stress procedures (predator odor (TMT) exposure and systemic
administration of the alpha-2 noradrenergic antagonist yohimbine) to reinstate
alcohol-seeking behavior. While both stressors produced a significant increase in
alcohol-seeking behavior, the use of TMT and yohimbine as tools to induce
stress and fear responses are controversial (Blanchard et al. 2003; Chen et al.
2015; Endres and Fendt 2007; Fendt and Endres 2008; Mantsch et al. 2016;
McGregor et al. 2002). In rodents, TMT exposure reliably produces an elevation
in plasma CORT levels (Morrow et al. 2000) and elicits a number of autonomic
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and behavioral changes that are indicative of fear and anxiety (Endres et al.
2005; Fendt et al. 2005). However, it has been suggested that TMT is not a fearinducing stimulus but rather a generalized noxious odor (Fendt et al. 2005;
McGregor et al. 2002). Studies investigating the neural basis of TMT effects on
rodents demonstrate activation of the HPA-axis (Day et al. 2004; Myers and
Rinaman 2005) and increases in c-fos expression in brain regions shown to be
important in fear processing and stress-related responses, such as the
amygdala, BNST, LS, and hypothalamus (Day et al. 2004; Janitzky et al. 2015).
Thus, there is ample neural, physiological, and behavioral evidence indicating
that TMT exposure produces a stress-like state that may trigger alcohol-seeking
behavior in the operant conditioning reinstatement model.
The use of yohimbine as a stressor in this relapse model also has been
called into question (Chen et al. 2015). It is suggested that yohimbine may not be
exerting its effects on alcohol/drug seeking behavior by producing an aversive
(stress) state but, rather, merely potentiating cue-related responding. Further,
yohimbine was not found to induce conditioned place aversion, suggesting a lack
of stress-like effects (Chen et al. 2015). However, evidence from several studies
indicate that yohimbine engages critical components of stress circuitry that are
known to mediate stress responses, including reinstatement of alcohol/drug
seeking behavior (Buffalari and See 2011; Le et al. 2013; Shaham et al. 2003;
Shalev et al. 2010). Further, human studies indicate that yohimbine induces both
physiological and psychological stress-like responses (Greenwald et al. 2013)
and alcohol craving (Umhau et al. 2011). Taken together, there is sufficient
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evidence indicating that both stress procedures employed in the present study
produced an aversive state, and OXT was effective in attenuating their ability to
provoke alcohol relapse-like behavior in male and female mice.
While results from the present study demonstrated that OXT is effective in
attenuating stress-induced alcohol relapse-like behavior in both male and female
mice, it is difficult to conclude whether a sex-related difference in sensitivity to
this effect exists. Results from Study 1 suggest that females may exhibit greater
sensitivity to OXT than males (shift to the left in the dose-effect function).
Unfortunately, only a single dose was used in Study 2 and this dose (1 mg/kg
OXT) was equally effective in reducing stress-induced reinstatement of alcohol
seeking in both females and males. Other studies have provided evidence for
sex-related differences in sensitivity to OXT. For example, lower doses of OXT
were more effective in reducing cue-induced reinstatement of cocaine (Kohtz et
al. 2018) and sucrose (Zhou et al. 2015) responding in female rats compared to
their male counterparts. Further, sexually dimorphic expression of OXTRs in the
brain has been reported in several strains of rats and mice (Dumais et al. 2016;
Dumais et al. 2013; Dumais and Veenema 2016), although no such sex
differences were found in a study with C57BL/6J mice (Hammock and Levitt
2013). Oxytocin expression and signaling in the brain has been shown to be
modulated by gonadal hormones (Dumais and Veenema 2016; Ivell and Walther
1999; Patchev et al. 1993). Fluctuations in estrogen and progesterone levels
across the estrous cycle may influence sensitivity to OXT in females (Dumais et
al. 2013; Dumais and Veenema 2016). Although we did not assess estrus status
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in our studies, other reports have indicated that the effects of OXT on relapse-like
behavior are not dependent on phase of estrus at the time of testing (Cox et al.
2013; Leong et al. 2017; Leong et al. 2016). Thus, possible sex-related
differences in sensitivity to OXT as well as the role of sex hormones influencing
effects of OXT on alcohol relapse-like behavior remain to be determined.
The mechanism by which OXT decreased stress-induced re-invigoration
of alcohol responding is not well understood. Previous work in our laboratory
demonstrated that OXT doses less than 3 mg/kg reduced alcohol selfadministration in C57BL/6J mice without altering general locomotor activity (see
Chapter 2; King et al. 2017). Thus, it is unlikely that OXT reduced alcohol relapse
responding provoked by TMT or yohimbine exposure due to a nonspecific
sedative effect.
Oxytocin is known to exert anti-stress and anxiolytic effects (Jurek et al.
2015; Peters et al. 2014; Slattery and Neumann 2010). Oxytocin interacts with
CRF neurons and the peptide has been shown to dampen stress-induced HPAaxis activation (elevated CORT levels), as well as reduce stress-related
behavioral responses in animal models of anxiety and depression (Neumann et
al. 2000; Windle et al. 2004). Further, high levels of OXT and OXTR mRNA
expression are localized in forebrain regions such as the extended amygdala,
where OXT signaling can play a significant role in the regulation of anxiety,
stress, and reward-related behaviors (Dabrowska et al. 2011; Gimpl and
Fahrenholz 2001; Martinon and Dabrowska 2018; Veinante and Freund-Mercier
1997).
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Another potential mechanism by which OXT decreases reinstatement of
alcohol-seeking behavior may be through direct influence on reward signaling.
Oxytocin receptors have been identified in a number of brain regions known to
significantly contribute to drug-related reward and relapse-like behavior. This
includes the NAcc (Tan et al., 2017; Dolen et al., 2013), VTA (Peris et al., 2017)
and mPFC (Li et al, 2016; Nakajima et al., 2014). Intra-NAcc infusion of OXT has
been shown to attenuate drug primed- (Baracz et al. 2015; Baracz et al. 2016)
and cue- (Bernheim et al. 2017) induced reinstatement of methampethamine
seeking. Additionally, Leong et al. (2017) demonstrated that elevated Fos
expression in the mPFC, NAcc, and subthalamic nucleus (STN) in response to
cocaine associated cues was normalized by a systemic injection of OXT in rats.
Interestingly, direct infusion of OXT into the NAcc and STN reduced whereas
intra-PFC OXT increased cue-induced reinstatement of cocaine-seeking
behavior (Weber et al. 2018; Leong et al. 2018). A few studies have examined
the influence of OXT on alcohol-related reward effects. For example, acute icv.
infusion of OXT reduced alcohol consumption and elevated dopamine release in
the NAc in rats (Peters et al., 2017). Viral-mediated overexpression of OXTRs in
the NAc was shown to reduce alcohol drinking and alcohol-induced CPP (Bahi
2015; Bahi et al. 2016). Hansson et al. (2018) demonstrated increases in OXTR
mRNA and protein levels in PFC, striatal, amygdala, and hippocampal regions in
alcohol dependent rats after 3 weeks of abstinence, implicating similar brain
regions as the aforementioned studies. Thus, there is evidence to suggest that
the effects of OXT within brain reward circuitry may not only contribute to its
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ability to reduce alcohol self-administration, but also reduce alcohol relapse-like
behavior. Unfortunately, there are no studies investigating the effects of sitespecific administration of OXT on reinstatement of alcohol-seeking behavior
using operant conditioning procedures. Future studies are needed to investigate
specific brain regional changes that mediate the ability of OXT to blunt alcohol
relapse-like behavior.
Systemic administration of OXT raises the issue of blood-brain barrier
penetrance (Lee et al. 2018). A number of studies have recapitulated effects of
systemic OXT administration with direct (icv. or site-specific) intracranial
infusions across a number of behavioral tasks (Cox et al. 2017; Lee et al. 2018;
Love 2014; Ring et al. 2006; Slattery and Neumann 2010; Windle et al. 1997).
Additionally, peripheral administration of OXT has been shown to induce Fos
expression in OXT neurons in the PVN (Carson et al. 2010; Leong et al. 2017),
suggesting that peripheral administration may induce endogenous central
release. However, Lee et al. (2018) demonstrated that while OXT administered
through IN and IV routes of administration increased OXT levels in cerebral
spinal fluid, it did not activate a feed forward mechanism to elevate endogenous
OXT. Thus, the mechanism by which exogenous OXT delivered in the periphery
activates OXT signaling in the brain remains unclear. Further studies are needed
to address this issue, as it is relevant to the potential for OXT to serve as a
therapeutic for alcohol/drug addiction.
In conclusion, our findings reveal that systemic OXT administration
attenuates stress-induced reinstatement of alcohol seeking in male and female
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mice. Exogenous OXT decreased alcohol-seeking behavior in a dose-related
manner in response to acute challenge with a predator odor. The reduction in
reinstatement responding was similar between males and females, though
females showed a decrease in responding at lower doses of OXT compared to
males. Additionally, OXT administration produced a similar decrease in alcohol
relapse-like behavior triggered by the pharmacological stressor yohimbine in both
sexes. Taken together, these results indicate that OXT may be potential
therapeutic target for mitigating relapse initiated by stress in both males and
females.

122

CHAPTER 5. The Role of Oxytocin Receptor Signaling in StressInduced Relapse Behavior
The endogenous OXT system appears to be sensitive to both stressors
and long-term exposure to alcohol and thus, may develop compensatory
neuroadaptive changes in brain regions specifically involved in the addiction
process, including relapse (Lee & Weerts 2016). Work from our laboratory (see
Chapter 4; King and Becker 2019) demonstrated OXT reduces stress-induced
reinstatement of alcohol seeking in male and female mice. These data add to a
growing body of literature that has shown that both systemically and centrally
administered OXT decreases stress-related relapse-like behavior (Ferland et al.
2016; Cox et al. 2013; Qi et al. 2009; Zanos et al. 2014). However, the
mechanism by which OXT reduces relapse-like behavior remains unknown.
While there is some evidence to suggest that OXT attenuates the reinvigoration
of drug seeking via effects at its own receptor (Han et al. 2014; Baracz et al.
2013, Qi et al. 2009), other studies have shown that co-administration of OXT
and a selective OXTR antagonist was unable to reverse the modulating effect of
OXT on relapse-like behavior (Baracz et al. 2015; Baracz et al. 2016; Everett et
al. 2018; Dong et al. 2017).
Additionally, we have previously demonstrated (see Chapter 3) that the
effects of OXT on alcohol drinking do not involve peripheral OXTR signaling.
However, induced central and peripheral OXT release have been shown to be
coupled, especially in a situation of stress (Neuman, 2007; Wotjak et al. 1998). In
humans, higher levels of peripheral OXT secretion have been associated with
faster vagal recovery following acute stress (Engert et al. 2016), suggesting the
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involvement of peripheral mediated actions. As our model of stress-induced
relapse-like behavior involves exposure to predator odor (TMT), the specific
contribution of central versus peripheral OXTR signaling on the neuropeptide’s
attenuating effect on stress-induced reinstatement of alcohol seeking should also
be evaluated.
The OXT system is likely to interfere with the negative consequences of
withdrawal and protracted abstinence, such increased stress and negative
affectivity which contribute to susceptibility to stress-induced relapse (Bowen and
Neumann 2017; Koob and Volkow 2016; Koob et al. 2014). Hypothalamic OXT
projection fibers have been found in number of stress-related brain regions,
including those integral to the motivational effects of alcohol such as central
nucleus of the amygdala (CeA) (Knobloch et al. 2012; Bale et al. 2001). The CeA
receives input from a number of cortical, limbic and midbrain regions that release
several stress-related neuropeptides, including CRF, NPY, DYN, AVP and OXT
(Koob et al. 2014; Koob and Volkow 2016). Oxytocin receptors are present on
discrete populations of neurons in the CeA, thereby enabling OXT to contribute
to regulation of anxiety, stress and reward behaviors (Knobloch et al. 2012;
Huber et al. 2005) Indeed, OXT neurotransmission has been shown to play an
important role stress, fear and anxiety responses through actions in the CeA
(Bale et al. 2001; Knobloch et al. 2012; Ebner et al. 2005; Neumann et al. 2007)
and the PVN (Neumann et al. 2000; Bale et al 2001; van den Burg et al. 2015)
via inhibition of stress-induced CRF synthesis (Jurek et al. 2015). Additionally,
oxytocinergic circuits from the hypothalamus have been shown to modulate
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GABA signaling in the CeA (Huber et al. 2005; Viviani et al. 2011; Knobloch et al.
2012). This is especially compelling considering that the CeA plays a key role in
the aversive symptoms associated with alcohol withdrawal (Koob et al. 2014;
Koob 2015). Interestingly, a reduction in OXT-induced modulation of GABAergic
transmission has been implicated in depression- and anxiety-related behaviors
(Han et al. 2018) as well the acute effects of alcohol (Tunstall et al. 2018).
However, it is not known whether OXT, via OXTR signaling, acts in the CeA to
regulate stress-induced relapse-like behavior.
Studies in this chapter will examine the role of OXTR signaling in the
ability of OXT to modulate alcohol relapse-like behavior in male and female mice.
First, we examine the contributions of central versus peripheral OXTR signaling
on attenuation of stress-induced reinstatement of alcohol-seeking behavior.
Second, we investigate the role of OXTR signaling in the amygdala via coadministration of systemic OXT and intra-CeA infusion of a selective OXTR
antagonist.

MATERIALS AND METHODS
Animals and Housing
Adult male and female C57BL/6J mice (25 to 30 g) were obtained from
Jackson Laboratories (Bar Harbor, ME) at 9 to 10 weeks of age and were
acclimated to the experimental housing rooms for a minimum of 1 week prior to
the start of experiments. Male and female mice were group housed (4 per cage)
in the same colony room, but with males and females on separate racks. The
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animals were maintained under a 12-hour reversed light/dark cycle in an
AAALAC-accredited facility. All testing was conducted during the dark phase of
the circadian cycle. Mice were provided free access to food and water, except at
the start of operant oral self-administration training. All experimental protocols
were approved by the Medical University of South Carolina Institutional Animal
Care and Use Committee and consistent with guidelines of the NIH Guide for the
Care and Use of Laboratory Animals.

Drugs and administration
Synthetic human OXT (CellSciences, Canton, MA) and the OXTR
antagonists L-368,899 hydrochloride (Tocris) and Atosiban (Tocris) were
dissolved in 0.9% saline. Systemic administration of OXT (1 or 0.5 mg/kg), L368,899 (5, 10 or 20 mg/kg) and Atosiban (1 or 10 mg/kg), was delivered via
intraperitoneal (ip.) injection at a volume of 0.01 ml/g body weight for all
experiments. Doses were based on previous experiments (see chapters 2-4). For
direct brain infusion, L-368,899 hydrochloride (Tocris) was dissolved in PBS and
bilaterally microinjected (0.5µl over 2 mins) into the central nucleus of the
amygdala (CeA) to achieve a dose of either 1 or 2 ug/side. Injectors were left in
place for an additional 2 minutes to ensure drug diffusion before removal.

Surgical procedures
C57BL/6J mice were anesthetized with isoflurane and implanted with dual guide
cannulae (Plastics One) aimed at the central nucleus of the amygdala (AP -1.2
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mm, ML: ± 3.0 mm, DV: – 3.9 mm). When inserted, microinjector tips extended
0.5mm beyond the guide. Mice received surgery after establishing stable alcohol
lever responding and intake in operant conditioning chambers, about 2-3 weeks
into baseline (coordinates adjusted for age). Mice were allowed one week for
recovery before returning to daily sessions.

Operant Alcohol Self-Administration
Mice were tested in standard operant conditioning chambers, as
previously described in Chapter 2, 3 & 4. Briefly, mice were first trained to
respond for alcohol reinforcement under a fixed ratio-1 (FR1) schedule.
Response requirements were gradually increased until mice achieved stable
lever responding under a FR4 schedule of reinforcement (<15% variability across
3 consecutive daily sessions). Once stable baseline alcohol responding/intake
was established, mice entered into the extinction phase of the study. During daily
extinction sessions, responding on the “active” lever no longer had stimulus
consequences and alcohol reinforcement was no longer delivered. After 14 days
of extinction (when responding has reached <15% of baseline responding), all
mice were tested for stress-induced reinstatement of alcohol seeking behavior
(see Chapter 4).
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Experiment 1. Effect of pharmacological antagonism of oxytocin receptors
on oxytocin-induced attenuation of stress provoked relapse-like behavior
Mice were transferred to an enclosed chamber and exposed to predator
odor (2,3,5-trimethyl-3-thiazoline (TMT)) for 15 minutes, as previously described
in Chapter 4. TMT (0.03 ml; 1% v/v in saline) was placed on a gauze pad in a
weight boat in the chamber such that mice could not manipulate it. After the 15
minutes exposure period, mice were immediately place into self-administration
chambers to examine alcohol-seeking behavior under extinction conditions. At 30
minutes prior to the reinstatement test (15 minutes prior to TMT exposure), mice
were injected blood-brain barrier penetrant OXTR antagonist, L-368,899 (0 or
10mg/kg; i.p.), 45 mins prior to the reinstatement test session. At 30 min post
OXTR antagonist injection, mice were injected (ip.) with vehicle (saline) or OXT
(0.5 or 1 mg/kg). Each mouse received both doses of the OXTR antagonist in a
counterbalanced order with 1 week of extinction responding between tests.

Experiment 2. Effect of central versus peripheral oxytocin receptor
signaling on stress-induced relapse-like behavior
Since the results from the previous study indicated that 10 mg/kg dose of
OXTR antagonist, L-368,899, was not effective in reversing the effects of either
dose of OXT on stress-induced reinstatement in female mice, a follow up study
(Experiment 2a) was conducted to examine wider range of L368,899 doses
against a lower dose of OXT (0.5 mg/kg).
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To examine potential sex differences in peripheral OXTR signaling we
also investigated the effects of peripherally-restricted OXTR antagonist, Atosiban
(Experiment 2b). At 45 minutes prior to the reinstatement test (30 minutes prior
to TMT exposure), mice were injected blood-brain barrier penetrant OXTR
antagonist L-368,899 (0, 5, 10, 20 mg/kg; i.p.) or peripherally restricted OXTR
antagonist Atosiban (0, 1, 10 mg/kg; i.p.). At 15 min post OXTR antagonist
injection, mice were injected (i.p.) with vehicle (saline) or OXT (0.5 mg/kg). Tests
with L-368,899 (N=12 male/12 female) and Atosiban (N=12 male/12 female)
were conducted in separate groups of mice. Each mouse received all OXTR
antagonist (L-368,889 or Atosiban) doses in a counterbalanced order with 1
week of extinction responding between tests.

Experiment 3. Effect oxytocin receptor blockade in the central amygdala on
stress-induced relapse-like behavior
Following recovery from stereotaxic surgery (one week), mice returned to
daily oral operant self-administration sessions to re-establish stable baseline
responding for alcohol and intake levels over 2-3 weeks. Mice then entered into
the extinction phase of the study for 14 days. At 30 minutes prior to daily
extinction sessions mice received a saline injection and were handled to
acclimate them to the microinjection procedure.
On day 15, mice were tested for stress-induced reinstatement of alcohol
responding following the 15-minute stress (TMT exposure) procedure described
in Experiment 1. At 45 minutes prior to the reinstatement test session (30
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minutes prior to TMT exposure), mice received bilateral infusion of OXTR
antagonist L-368,899 or vehicle (PBS). Different doses of L-368,899, low;1
ug/side (N=14 male/8 female) or high; 2 ug/side (N= 23 male/ 20 female) were
tested in two separate cohorts. Following microinjection procedure (~15 minutes
prior to TMT exposure), mice injected (ip.) with vehicle (saline) or OXT (0.5
mg/kg). At the conclusion of Experiment 2, the mice were euthanized, and brains
were histologically examined for injector placement.

Statistical Analysis
The primary dependent variable analyzed was lever responses during
different phases of the studies. Lever responses were averaged over the last
three daily sessions of baseline alcohol self-administration and the last 3 days of
extinction testing prior to reinstatement testing. Number of reinforcers earned and
amount of alcohol intake (g/kg) averaged over the last three self-administration
sessions were also analyzed. For Experiment 1 & 2, lever responses, reinforcers
earned, and alcohol intake in male and female mice were analyzed by t-tests. For
Experiment 1, responses during reinstatement testing were analyzed by ANOVA,
with Sex (M,F) and Group (VEH, ANTAG) as a between-subject factors and OXT
Dose (0, 0.5, 1) and Time (Ext, Reinstate) as repeated measures. Analysis of
lever responding in Experiment 2 was also by ANOVA in which Sex (M,F) and
Group (VEH, OXT) served as a between-subject factors and Dose(2a: 0, 5, 10,
20 L368,899 or 2b: 0, 1, 10 Atosiban) and Time (Ext, Reinstate) were repeated
measures. Initial analyses for all studies in Experiment 1 and 2 also included

130

Order as a factor but since this variable did not significantly interact with the other
variables, data were presented and analyzed as collapsed over this factor. For
analysis of locomotor activity, distance traveled (cm) served as the dependent
variable and the factor Time served as a repeated measure. The design for
studies in Experiment 2 was 2 Sex (M,F) x 2 IP (VEH, OXT) x Micro (VEH,
ANTAG) x 2 Time (Ext, Reinstate). Analysis with ANOVA was preformed using
Sex, IP and Order as between-subject factors and Micro and Time as withinsubject variables. Post-hoc analyses (Newman-Keuls) were conducted when
appropriate. For all analyses, significance levels were set a p < 0.05, and all data
are presented as mean +/ standard error of the mean (SEM).

RESULTS
Baseline data including active lever and inactive lever responses, number
of alcohol reinforcers earned, and alcohol intake over the last 3 days of oral
alcohol self-administration in males and females can be seen in Table 3. All
animals demonstrated stable and preferential responding on the active lever.
Males and females did not significantly differ in responding on the active lever
and there was no sex-related difference in the number of alcohol reinforcers
earned. However, average alcohol intake was significantly higher in females
compared to males due to differences in body weight.
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Effects of Pharmacological Antagonism of Oxytocin Receptors on Stress-Induced
Relapse-like Behavior in Male and Female Mice
During reinstatement testing, TMT exposure significantly increased alcoholseeking behavior and OXT treatment significantly reduced this stress-induced
relapse-like responding in both males and female mice in a dose related manner
(Figure 5.1). Pretreatment with OXTR antagonist L368,899 reversed the effects
of 1 mg/kg OXT on stress-induced reinstatement in male mice, whereas
administration of the OXTR antagonist had no effect on reinstatement responding
in females. These results were supported by the overall ANOVA, with Sex (M,F)
and Group (VEH, ANTAG) as a between-subject factors and Dose (0, 0.5, 1
OXT) and Time (Ext, Reinstate) as repeated measures indicated a significant
main effect of Sex [(F(1,100) = 34.76, p< 0.0001], Dose [(F(2,100) = 26.17, p<
0.0001], Group [(F(1,100) = 6.09, p< 0.05] and Time [(F(1,100) = 191.15, p<
0.0001], as well as significant interactions between Time, Sex and Group
[(F(1,100) = 14.06, p< 0.0001], Time, Sex and Dose [(F(2,100) = 10.83, p<
0.0001], and Time, Group and Dose [(F(2,100) = 4.54, p< 0.05]. However, the
interaction between all test variables (Sex x Group x Dose x Time) did not reach
statistical significance [(F(2,100) = 1.90, p >0.1].
Separate ANOVA including Group (VEH, ANTAG), Dose (0, 0.5, 1) and
Time (Ext, Reinstate) were also conducted for males and females independently.
Analysis of lever responding during reinstatement test for males indicated a
significant main effect of Group [(F(1,52) = 14.89, p< 0.0001], Dose [(F(2,52) =
4.40, p< 0.05] and Time [(F(1,52) = 245.75, p< 0.001], as well as significant
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Table 3. Summary of Baseline Lever Responses and Ethanol Intake (g/kg)

Active Lever Responses
Experiment 1
Male
Female
Experiment 2
Male
Female
Experiment 3
Male
Female

Baseline
Inactive Lever Responses

Reinforcers

Ethanol Intake (g/kg)

67.1 (3.96)
75.32(4.52)

17.4 (3.45)
12.8 (1.40)

16.7 (0.89)
18.1 (1.03)

0.85 (0.05)
1.51 (0.09)*

80.8 (3.76)
72.6 (4.05)

15.1 (1.31)
10.6 (3.52)

20.2 (0.88)
18.3 (0.94)

1.17 (0.06)
1.49 (0.06)*

77.9 (5.50)
67.5 (5.52)

10.4 (1.94)
9.10 (1.16)

19.1 (1.23)
16.9 (1.31)

0.83 (0.08)
0.92 (0.06)

*denotes significant difference from corresponding (p < 0.05).
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Time x Group x Dose interaction [(F(2,52) = 4.38, p< 0.05] (Figure 5.1a). Post
hoc analysis based on these effects indicated that 1mg/kg OXT significantly
attenuated stress-induced reinstatement compared to both VEH and 0.5 mg/kg
OXT treated animals, whereas 0.5 mg/kg OXT was not sufficient to attenuate
stress-induced reinstatement of alcohol-seeking behavior. Pretreatment with
OXTR antagonist reversed the effects of 1mg/kg OXT on stress-induced
reinstatement but had no effect on lever responding during reinstatement test
when co-administered with VEH or 0.5mg/kg OXT.
For female mice, ANOVA revealed a significant main effect of Dose [(F(2,48) =
42.47, p< 0.001] and Time [(F(1,48) = 51.92, p< 0.001] and Dose x Time
interaction [(F(2,48) = 60.98, p< 0.001] (Figure 5.1b). These results indicate that
OXT administration similarly reduced stress-induced relapse-like behavior at both
the 0.5mg/kg and 1 mg/kg dose compared to vehicle and this effect was seen
regardless of pretreatment with VEH or OXTR antagonist.

Sex differences in the Reversal of the Oxytocin Effect on Stress-Induced
Reinstatement by Central, not Peripheral, Oxytocin Receptor Antagonist
ANOVA with Sex (M,F) and Group (VEH, OXT) as a between-subject
factors and Dose (0, 5, 10, 20 OXTR antagonist) and Time (Ext, Reinstate) as
repeated measures indicated a significant main effect of Sex [(F(1,80) = 55.80,
p< 0.0001], Group[(F(1,80) = 60.73, p< 0.0001], Dose [(F(3,80) = 3.28, p< 0.05]
and Time [(F(1,80) = 254.06, p< 0.0001], as well as significant interactions
between Time, Sex and Group [(F(1,80) = 9.718, p< 0.01] and Time, Group and
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Figure 5.1. Effects of pharmacological antagonism of oxytocin receptor on
oxytocin-induced attenuation of stress provoked relapse-like behavior in
male and female mice. Systemic OXT attenuates stress-induced reinstatement
of alcohol seeking behavior in a dose-related manner. Pretreatment with OXTR
antagonist, L368,899 (10 mg/kg), reverses the effect of OXT on relapse-like
behavior in (a) male mice but has no effect on level responding in (b) females.
Values are mean ± s.e.m (N=10/group) *p<0.001 VEH versus OXT, #p<0.001
VEH versus 0.5 mg/kg, ^p<0.001 VEH-1mg/kg versus VEH-10mg/kg
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Dose [(F(3,80) = 11.14, p< 0.001]. However, the interaction between all test
variables (Sex x Group x Dose x Time) did not reach statistical significance
[(F(3,80) = 0.803, p >0.1]. These results demonstrate that TMT significantly
increased significantly alcohol-seeking behavior during reinstatement test
compared to extinction in both male (Figure 5.2a) and female (Figure 5.2b)
mice. Reinstatement responding was significantly attenuated by OXT treatment,
though the magnitude of this effect was dependent on sex. Further, ability of the
selective OXTR antagonist, L368,899, to reverse the effect of OXT on stressinduced relapse-like behavior was dose-dependent.
Separate ANOVA including Group (VEH, OXT), Dose (0, 5, 10, 20) and
Time (Ext, Reinstate) were conducted for males and females independently. For
males, analysis by ANOVA of lever responding during reinstatement indicated a
significant main effect of Group [(F(1,52) = 14.89, p< 0.0001], Dose [(F(2,52) =
4.40, p< 0.05] and Time [(F(1,52) = 245.75, p< 0.001], as well as significant Time
x Group x Dose interaction [(F(2,52) = 4.38, p< 0.05] (Figure 5.2a). Post hoc
analysis based on these effects indicated TMT exposure provoked stressinduced relapse-like behavior in vehicle groups pretreated with 0, 5,10 20 mg/kg
dose of L368,899. This effect was significantly attenuated by 0.5 mg/kg OXT in
animals pretreated with 0 and 5 mg/kg L368,899, but not 10mg/kg or 20 mg/kg
L368,899. Additionally, VEH treated animals that received the highest dose of
L368,899 (20 mg/kg) demonstrated a significant reduction stress-induced
alcohol-seeking behavior compared to VEH-VEH treated animals, suggesting
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Figure 5.2. Effect of brain penetrant oxytocin receptor antagonist, L368,899,
on stress-induced reinstatement of alcohol-seeking behavior. Administration
of brain penetrant OXTR antagonist reversed the effect of OXT on stress-induced
reinstatement of alcohol-seeking behavior in male, but not female, mice.
Systemic OXT attenuated stress-induced reinstatement of alcohol-seeking
behavior and this effect was reversed by pretreatment with OXTR antagonist
L368,899 (10 mg/kg) in (a) male, but not (b) female mice. Additionally, higher
range doses of L368,899 administered alone (20 mg/kg in males, 10 and 20
mg/kg in females) reduced lever responding compared to VEH-VEH treated
groups. Values are mean ± s.e.m (N=6/group) *p<0.001 OXT versus VEH,
#p<0.001 versus VEH-VEH
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that high doses of L368,899 may have behavioral effects independent of OXT
treatment.
For female mice, ANOVA revealed a significant main effect of Group
[(F(1,40) = 63.31, p< 0.001] and Time [(F(1,40) = 31.98, p< 0.001] and Time x
Group[(F(1,40) = 49.66, p< 0.001], Group x Dose and [(F(3,40) = 5.05, p< 0.001]
and Group x Dose x Time [(F(3,40) = 4.48, p< 0.001] interactions (Figure 5.2b) .
Post hoc analysis revealed that TMT provoked relapse-like behavior in VEH
groups pretreated with 0, 5 and 10 mg/kg L368,899. Oxytocin treatment
attenuated stress-induced reinstatement of alcohol-seeking behavior in all groups
regardless of L368,899 dose. Additionally, pretreatment with 10 mg/kg and 20
mg/kg L368,899 reduced alcohol-seeking behavior compared to VEH groups that
received saline (VEH-VEH).

Peripherally Restricted Oxytocin Receptor Antagonist Does Not Block the Effect
of Oxytocin on Stress-Induced Reinstatement of Alcohol Seeking
TMT provoked relapse like behavior in male and female mice (Figure 5.3)
compared to extinction responding and systemic OXT administration attenuated
this behavior similarly across all three doses of peripherally restricted OXTR
antagonist, Atosiban (ATO). Pretreatment with ATO did not affect the ability of
OXT to attenuate relapse-like behavior in male or female mice. These
observations were supported by ANOVA with Sex (M,F) and Group (VEH, OXT)
as a between-subject factors and Dose (0, 1, 10 OXTR-A) and Time (Ext,
Reinstate) as repeated measures. Analysis indicated a significant main effect of
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Figure 5.3. Effect of peripherally restricted oxytocin receptor antagonist,
Atosiban, on stress-induced reinstatement of alcohol-seeking behavior.
Peripherally restricted OXTR antagonist, Atosiban, does not block the effect of
OXT on stress-induced reinstatement of alcohol-seeking behavior in male and
female mice. The ability of OXT to attenuate stress-induced alcohol relapse-like
behavior was not reversed by administration of peripherally restricted OXTR
antagonist in male (a) or female (b) mice. Values are mean ± s.e.m (N=6/group)
*p<0.001 OXT versus VEH
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Group[(F(1,60) = 101.18, p< 0.001], Dose [(F(2,60) = 5.09 , p< 0.001] and Time
[(F(1,60) = 115.31, p< 0.001], as well as significant interactions between Time x
Dose [(F(2,60) = 3.80, p< 0.05] and Time x Group [(F(1,60) = 90.92, p< 0.001].
Separate ANOVA including Group (VEH, OXT), Dose (0, 1, 10 ATO) and Time
(Ext, Reinstate) were conducted for reinstatement test for males (Figure 5.3a)
and females (Figure 5.3b) independently. However, the Time x Dose x Group
interaction did not achieve statistical significance in either sex.

Effect of Oxytocin Receptor Blockade in the Central Amygdala on Stress-Induced
Alcohol Relapse-Like Behavior
Initial analyses indicated that order of drug treatment did not significantly
influence treatment (L368,899 vs. PBS) effects, as indicated by nonsignificant
Order x Drug and Order x Drug x Time interaction. Thus, data were collapsed
over this variable (Order) for further analysis. Analysis by ANOVA was preformed
using Sex (M,F), IP (VEH, OXT) and as between-subject factors and Micro (VEH,
ANTAG) and Time (Ext, Reinstate) as within-subject variables. Analysis revealed
a significant main effect of IP [(F(1,14) = 4.56, p< 0.05] and Time [(F(1,14) =
11.47, p< 0.001], as well as a significant IP x Time interaction [(F(1,14) = 11.47,
p< 0.001]. These results indicate TMT produced a significant increase in lever
responding in VEH treated animals and OXT administration attenuated this
effect. Further intra-CeA infusion of OXTR antagonist, L368, 899, (1 ug/side) had
no effect on the ability of systemically administered OXT to attenuate stressinduced reinstatement of alcohol-seeking behavior, and this (lack of) effect was
similar in both male (Figure 5.4a) and female (Figure 5.4b) mice.
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Figure 5.4. Effect of oxytocin receptor blockade in the central amygdala on
stress-induced alcohol relapse-like behavior. Direct infusion of OXTR
antagonist, L368,899, (1 µg/ul) in the CeA does not block the effect of
systemically administered OXT on stress-induced alcohol relapse-like behavior in
(a) male or (b) female mice (N= 7/group M, 4/group F). However, intra-CeA
infusion of a higher dose of L368,899 (2µg/ul) reversed the effect of systemic
OXT treatment (0.5 mg/kg) on stress-induced reinstatement of alcohol-seeking in
(c) male, but not (d) female, mice (N= 11-12/group M, 9-11/group F). Values are
mean ± s.e.m *p<0.05 versus Ext, ^p<0.05 versus VEH-VEH
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In a follow up study in a separate cohort of mice we examined whether a
higher dose (2ug/side) of L368,899 directly applied to the CeA could reverse the
effects of systemically administered OXT on stress-induced reinstatement of
alcohol seeking. ANOVA revealed a significant main effect of Sex [(F(1,35) =
8.98, p< 0.01] and IP [(F(1,35) = 6.63, p< 0.05], as well as Sex x Time [(F(1,35) =
7.98, p< 0.01] and IP x Time [(F(1,35) = 10.61, p< 0.01] interactions. However,
Sex x IP x Time interaction was nonsignificant.
Separate ANOVA including IP (VEH, OXT) and Micro (VEH, ANTAG)
during reinstatement test were conducted for males and females independently.
For males, ANOVA revealed a significant main effect of Micro [(F(1,21) = 5.24,
p< 0.05]. The IP x Micro interaction did not reach statistical significance. These
results indicate that intra-CeA infusion of L368,899 (2ug/side) reversed the
effects of OXT on stress-induced reinstatement in male mice.
For female mice, OXT attenuated reinvigoration of lever responding to
stress relative to vehicle condition regardless of infusion (L368,899 or PBS) and
intra-CeA infusion of L368,899 (2ug/side) alone was sufficient to significantly
reduce lever responding compared to the VEH-VEH treatment group. These
results were supported by ANOVA which revealed a significant main effect of IP
[(F(1,18) = 13.76, p< 0.001] and significant IP x Micro interaction [(F(1,18) = 5.34,
p< 0.05].
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DISCUSSION
In agreement with previous studies, systemically administered OXT
reduced reinstatement of alcohol-seeking behavior provoked by stress exposure
in male and female mice. However, the mechanism by which OXT reduces
stress-induced relapse-like behavior remains unknown. To characterize OXT
neurotransmission in this behavior, we examined the effect of two different OXTR
antagonists across a range of doses applied systemically and infused directly
into CeA. In males, systemic and intra-CeA administration of brain penetrant
OXTR antagonist, L-368,899, blocked the ability of systemic OXT to reduce
stress-induced relapse-like behavior, though this effect appears to be dosedependent. Somewhat surprisingly, pretreatment with OXTR-A L,368,899
systemically or directly infused into CeA failed to prevent the action of oxytocin in
female mice. Additionally, high doses of L368,899 alone appear to reduce lever
responding in both male and female mice compared to vehicle-vehicle treated
groups. Pretreatment with a peripherally restricted OXTR antagonist (Atosiban,
ip.) did not reverse the effect of systemic OXT on stress-induced reinstatement in
either sex. Taken together, results from this study suggest that the effect of OXT
on alcohol relapse-like behavior is centrally, not peripherally, mediated and may
be independent of actions at the OXTR, especially in females.
Sex differences observed in the response to OXT are in congruence with
results from the previous studies (See Chapter 4) that show trend level
significance in sex-related differences in the behavioral response to OXT
treatment. In the current study, female mice exhibit greater sensitivity to both
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OXT (Experiment 1) and OXTR antagonist (Experiment 2a) than males. Sexually
dimorphic expression of OXTRs has been described in a number of brain regions
across multiple rodent species (Dumais et al. 2016; Dumais et al 2013; Dumais
and Veenema 2016), in which males consistently demonstrate higher OXTR
expression than females (Dumais and Veenema 2016). Currently, no such sex
differences have been identified in C57BL/6J mice (Hammock and Levitt 2013),
though this may be an artifact due to lack of comprehensive analysis (Dumais
and Veenema 2016). It is also important to note that OXT may not exclusively
bind to OXTRs (Manning et al. 2012), and therefore, sexually dimorphic
expression in related systems, such as vasopressin, could possibly mask or
contribute to sex differences in the sensitivity to OXT (Dumais and Veenema
2016). Further, the greater sensitivity to the effect of an OXTR antagonist on
alcohol-relapse like behavior in females may be reflective of differences in
endogenous brain OXT levels. Sex differences in OXT-immunoreactive neurons
have been identified in which OXT is typically higher in females compared to
males (Dumais and Veenema 2016). However, it is unclear whether sex
differences in brain OXT-immunoreactivity reflect differences in OXT release.
Thus, future studies are necessary to specifically link sexually dimorphic OXTR
expression and peptide levels to the OXT-modulation of relapse-like behavior.
The central mechanism by which OXT administration modulates
reinstatement of alcohol-seeking behavior remains relatively unknown. The
results from the current study corroborate previous reports (see chapter 3) that
demonstrate that systemic administration of a brain penetrant OXTR antagonist
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blocks the inhibitory effect of OXT on alcohol-related behaviors. However, there
are very few studies investigating the role of OXTRs on relapse-like behavior and
evidence for an OXTR-mediated mechanism are mixed, especially in regard to
site-specific infusion. In a series of studies by Baracz and colleagues, direct
infusion of an OXTR antagonist into NAcc or STh did not specifically block the
OXT-induced attenuation of methamphetamine-primed relapse behavior (Baracz
et al. 2015, Baracz et al. 2016). Interestingly, Everett et al. (2018) demonstrated
that prior systemic and intra-NAcc administration of a V1aR, but not OXTR,
antagonist attenuated the inhibitory effects of OXT on methamphetamine -primed
reinstatement (Everett et al. 2018) . In contrast, the same group demonstrated
that OXT dose-dependently modulated acute dopamine reward in STh through
actions at the OXTR (Baracz and Cornish 2013). Unfortunately, the above
studies regarding the effects of OXTR neurotransmission on drug- and alcoholseeking behaviors only involve males and therefore provide no insight to sex
differences in OXTR-mediated regulation of alcohol relapse-like behavior. Future
studies are necessary to provide insight into the receptor specificity of OXT’s
effect in reducing stress-induced reinstatement of alcohol-seeking behavior in
both males and females.
Discrepancies in OXTR function may be related to changes in the OXT
receptor system in response to drug or alcohol exposure. Indeed, it has
previously been shown that the OXT system is dysregulated following chronic
alcohol exposure (Stevenson et al. 2017; Silva et al. 2002, Hansson et al. 2018).
Specifically, in alcohol-dependent rats, Hansson et al. (2018) demonstrated an
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upregulation of OXTR mRNA and OXTR protein levels in PFC, striatal, amygdala
and hippocampal regions after 3 weeks of abstinence in contrast to a
downregulation of the same systems during intoxication. These data suggest that
OXTRs undergo dynamic neuroadaptations following the cessation of alcohol
exposure, with may alter their function and contribute to withdrawal and relapselike behavior. Additionally, it is also important to note that in addition to the known
OXTR, the existence of another uncharacterized OXTR subtype has been
proposed (Chan et al. 2003; Adan et al. 1995), which may also help to explain
the inconsistent effect of the OXTR antagonists on OXT modulation of
reinstatement behavior. Regardless, compensatory changes in OXTR expression
following alcohol exposure may explain why OXT has little effect through its own
receptor to modulate stress-induced reinstatement in females and may suggest
that exogenously administered OXT might interaction with other
neurotransmitters or neuropeptides in specific brain regions to modulation
behaviors associated with alcohol abuse.
Numerous studies have implicated a key role for the CeA in the transition
to alcohol dependence (Koob 2009; Koob and Volkow 2010). Results from the
present the study demonstrate that in males, intra-CeA infusion of a selective
OXTR antagonist blocked the attenuating effects of systemically administered
OXT on alcohol-relapse behavior. One potential mechanism by which this is
occurring is through interaction with GABAergic neurotransmission. Excessive
drinking appears to dysregulate numerous neuropeptide systems that converge
on GABAergic circuitry in the CeA, producing the negative emotional symptoms
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observed in alcohol abstinence (Roberto et al. 2004). Evidence suggests that
GABA transmission in the amygdala is regulated by OXT (Huber et al. 2005). An
infusion of OXT into the CeA has been shown to increase GABA activity in this
region (Huber et al. 2005) and decreases in OXTR expression have been
demonstrated to modulate presynaptic GABA release (Ripamonti et al. 2017).
Additionally, local application of OXT to the lateral CeA activates a subpopulation
of GABAergic interneurons that inhibit neurons in the medial CeA, the main
output of the CeA to the brainstem (Huber et al. 2005), thereby attenuating
behavioral fear responses (Viviani et al. 2011). In the context of alcohol
exposure, Tunstall et al. (2019) demonstrated that OXT decreased GABA
signaling in the CeA in both dependent and nondependent rats. However, OXT
neurotransmission may affect GABAergic signaling in the CeA through different
mechanisms in male and females. A recent study by Campbell-Smith and
colleagues demonstrated that administration an OXTR antagonist into the CeA
reversed OXT-induced suppression of fear responses in male rats (CampbellSmith et al. 2015). Further, another study showed that OXT rescued stressinduced depression and anxiety-related behaviors by acting on OXTR in the CeA
to enhance GABAergic transmission in male mice (Han et al. 2018). However, in
females, administration of GABAA, but not OXTR, antagonist in the CeA, blocked
OXT- mediated increases in social preference and anxiety-like behavior (Dong et
al. 2017). Therefore, the different effects of pharmacological antagonism of
OXTRs on stress-induced reinstatement observed in male and female mice may
relate to the fact that systemically administered OXT either does not act on
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OXTRs in the CeA, or that the effect of OXT on the CeA is offset by its activity in
other brain regions, e.g., BNST, PFC, NAc. Future studies are necessary to
alternative interaction with other neurotransmitter systems, as well as determine
specific brain regional contributions that mediate the ability of OXT to attenuate
relapse-like behavior.
A limitation of the current study, as discussed in Chapter 3, is the use of
the OXTR antagonist Atosiban. The specificity of Atosiban raises some concern
due to actions at both the OXTR and vasopressin V1a receptor. Vasopressin V1a
receptor signaling has been implicated in anxiety- and stress- behaviors (Wsol et
al. 2014; Gray et al. 2012; Hernandez et al. 2016). Oxytocin has been shown to
activate the V1a receptor, not its own, to modulate some prosocial and
autonomic effect in males that were previously attributed solely to the OXT
system (Bowen and McGregor 2014; Sala et al. 2011; Hicks et al. 2014; Wsol et
al. 2014). Interestingly, systemic administration of a V1a receptor antagonist,
SR49059, has been shown to block OXT-induced reduction in relapse to
methamphetamine-seeking behavior (Everett et al. 2018). Additionally, there is
some evidence to suggest that Atosiban may also act as a biased agonist
(Galandrin and Bouvier 2006) that favors Gi coupled signaling pathways over Gq
(Busnelli 2012; Vrachnis et al. 2011; Devost et al. 2008). Thus, a more
comprehensive spectrum of signaling pathways must be taken into consideration
when interpreting the present results. Data from the current study demonstrated
that blockade of peripheral OXTR and possibly V1aR, via OXTR antagonist
Atosiban, did not alter the ability systemically administered OXT to reduce
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alcohol relapse-like behavior. These results provide compelling evidence to
support a centrally-mediated mechanism of action, though it is unclear whether
these effects are due to action at OXTR or V1aR. Future studies investigating the
specific contribution of OXTR and V1aR signaling mechanisms on alcoholrelapse like behavior are necessary.
In conclusion, results from the present study provide new evidence
indicating a role for OXT/OXTR activity in the regulation of stress-induced
reinstatement of alcohol-seeking behavior. Our findings reveal potential sex
differences in OXTR signaling within the CeA to modulate stress-induced
reinstatement of alcohol-seeking behavior. The ability of OXT to attenuate
alcohol-relapse behavior is mediated by central, not peripheral, OXTR signaling
in male mice. Additionally, the present study is the first to demonstrate that
OXTR signaling in the CeA mediates, at least in part, the ability of systemically
administered OXT to attenuation stress-induced reinstatement of alcohol-seeking
behavior in male mice. However, in female mice systemic or direct CeA infusion
of OXTR antagonist L368,899 was ineffective in blocking the effects of OXT on
stress-induced reinstatement of alcohol-seeking behavior. Taken together, these
results indicate the OXT/OXTR system as a potential therapeutic target for
mitigating relapse initiated by stress in both males and females. Future studies
are necessary to provide greater insight into potential sex difference in the
engagement of the OXT/OXTR system to influence stress-related alcohol
relapse-like behavior.
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CHAPTER 6: Conclusions and Future Directions
Oxytocin and Alcohol Consumption
The current PhD dissertation has demonstrated that systemic
administration of OXT reduces alcohol consumption in a variety of drinking
models. Across a broad dose range systemic OXT reduced alcohol intake in a
binge-like model, 2-bottle choice drinking paradigm and a model that employs
operant self-administration procedures. Oxytocin decreased ethanol consumption
in a dose-related manner and the ability of OXT to reduce ethanol intake did not
appear to be related to nonspecific (e.g., sedation, antidipsogenic) effects.
Further, oxytocin reduced motivation to respond for alcohol at doses that did not
alter responding for a natural reward (sucrose). We also report that direct
activation of OXT+ neurons in the PVN via targeted expression of excitatory
DREADD (and systemic injection of CNO) decreased alcohol consumption in the
DID model, as well as lever responding and intake in oral operant selfadministion, mimicking the effects of exogenous OXT. Using the same approach,
we also demonstrate that activation of PVN OXT+ neurons decreased anxietylike behavior in an open field and this effect was not due to changes in locomotor
activity. Finally, the effect of OXT on alcohol consumption appears to be
mediated, at least in part, by action at the OXTR. This observation was
supported by the reversal of OXT’s effect on alcohol consumption by selective
brain penetrant OXTR antagonist, L368,899. Additionally, using pharmacological
and chemogenetic approaches, we demonstrate that the effect of CNO-induced
activation of PVN OXT+ neurons on alcohol consumption can be reversed with
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the (blood-brain-barrier penetrant) OXTR antagonist L368,899, whereas
peripheral administration of an OXTR antagonist that does not cross the bloodbrain-barrier (Atosiban) did not reverse this effect. Together, these data suggest
that the behavioral effects of OXT on alcohol drinking and anxiety-like behavior
are centrally mediated and implicate OXTR neurotransmission as a potential
mechanism of action.
One important limitation of the present work is that these studies were
conducted exclusively in males. Although very few studies have examined the
potential sex-related differences in the ability of OXT to modulate alcohol intake,
there is some evidence that female mice may be more sensitive to the behavioral
effects of OXT (King et al. 2018, Zhou et al. 2015, Kohtz et al. 2018). Thus, it
would be beneficial to examine a broad range of OXT doses in female mice.
In the chemogenetic studies, female Oxt-IRES-Cre mice were run
concurrently with males, however, systemic injection of CNO reduced alcohol
consumption in female mice harboring control virus (with no active DREADD
receptor) across several studies. These results suggest that CNO produced offtarget effects, making the data from female mice infused with excitatory
DREADD virus challenging to interpret. There are a number of considerations
that may help to explain off-target effects of this chemogenetic technique. First,
the ligand CNO used to activate DREADD receptors has been shown to be backconverted into clozapine (Gomez et al. 2017; Jendryka et al. 2019), an atypical
antipsychotic. Clozapine has been shown to suppress alcohol drinking in rodents
in a dose range (2-4 mg/kg; Green et al. 2004; Ingman and Korpi 2006) similar to
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the dose of CNO (3 mg/kg) used in the current investigation. However, we also
used DREADD agonist Compound 21, which is thought to be more selective, and
observed similar off-target effects in control mice. Data from our lab
(unpublished) demonstrated that the off-target effects of both DREADD agonists
(CNO and Compound 21) on alcohol consumption are not present in mice that
have not received stereotaxic surgery targeting the PVN. Thus, it is possible that
damage from surgery and/or viral infusion produced a larger inflammatory
response in females, compromising the integrity of the blood-brain-barrier. Future
studies utilizing IHC procedures to stain for inflammatory markers could help to
resolve this question. Finally, the issue may be related to the transgenic OxtIRES-Cre mouse itself rather than the DREADD virus or DREADD agonist. It is
possible that Cre recombinase was incorporated into target cells during
development in a sex-specific manner, such that the recombinase enzyme is
constitutively active in female mice. Therefore, studies investigating the pattern
of activation (by measurement of c-fos expression) of OXT neurons may help to
elucidate differences in male and female Oxt-IRES-Cre mice.
Another limitation of chemogenetic approach is that male Oxt-IRES-Cre
mice are larger and gain weight more quickly compared to C57BL/6J mice. This
represents a significant issue as the main output in many alcohol-related studies
is ethanol intake (g/kg is a body weight dependent measure). Although the mice
were backcrossed with C57BL/6J mice, Oxt-Cre males also drink less on a mL
basis compared to C57BL/6J mice, regardless of size. One factor that may
contribute to this observation is viral surgery targeting the hypothalamus (PVN)
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may damage areas involved in the homeostatic regulation of energy balance,
satiety, food and fluid intake.
Given these limitations this transgenic mouse model still provides an
excellent opportunity to investigate pathway specific OXT-modulation of behavior
in males. Studies to further elucidate the specific mechanisms involved in OXTmodulation of alcohol consumption could selectively activate OXT PVN neurons
projecting to discrete brain regions via direct infusion of CNO into the brain
region of interest (versus global activation of OXT+ containing neurons by
systemic injection of CNO). This approach may also help limit off-target effects.
Another way to selectively target PVN projection fibers to discrete brain regions
(i.e., BNST, CeA, PFC) would be through the use of a Cre-dependent
retrogradely transported AAV containing excitatory, inhibitory or control virus. In
this strategy, virus is taken up by presynaptic terminals at the site of infusion and
retrogradely transported to cell bodies expressing Cre-recombinase in the
hypothalamus. Finally, use of site-specific administration of OXTR antagonists in
conjunction with activation of PVN OXT+ containing neurons may provide
information about OXTR signaling.

Oxytocin and Stress-Induced Reinstatement of Alcohol-Seeking Behavior
In agreement with both preclinical and clinical literature, the data
presented in this dissertation demonstrate the efficacy of OXT administration in
attenuating relapse-like behavior. Oxytocin attenuated predator odor (TMT)- and
yohimbine-induced reinstatement in a dose-related manner in both male and
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female mice. In male mice, systemic and intra-CeA administration of brain
penetrant OXTR antagonist, L-368,899, blocked the ability of OXT to reduce
stress-induced relapse-like behavior and this this effect appears to be dosedependent. Additionally, pretreatment with a peripherally restricted OXTR
antagonist, Atosiban, did not reverse the effect of OXT on stress-induced
reinstatement in either sex. Taken together, results from this study suggest that
the effect of OXT on alcohol relapse-like behavior is centrally, not peripherally,
mediated and may be independent of actions at the OXTR, especially in females.
Although males and females may be similar on a behavioral level, they
often use different mechanisms to respond to challenges (i.e. stress) and social
and emotional cues (Bangasser and Valentino 2014; Palanza and Parmigiani
2017) Data obtained in males are often irrelevant for inferring the efficacy of
pharmacological treatments in females. In this vein, results presented in this
dissertation illustrate the importance of studying both sexes. Regarding the effect
of OXT on stress-related alcohol relapse-like behavior, future studies should
explore the possibility that OXT is interacting with other neurotransmitter systems
and receptors other than its own. There is evidence to suggest that OXT interacts
with multiple receptors including GABAA (Bowen al. 2015; Dong et al. 2017),
vasopressin V1aR (Everett et al. 2018), dopamine D2R (de la Mora et al. 2016;
Fuxe et al. 2012) and mGlurR2/3 (Bernheim et al. 2017) to regulate stress- and
reward- related behaviors, including reinstatement of drug-seeking behavior.
Thus, site specific co-administration of OXT and antagonists targeting the
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aforementioned receptors will provide insight into OXTR signaling in both males
and females.
Final Thoughts
A growing body of literature suggests that OXT plays a significant role in
alcohol (and other drug) addiction, as well as in stress-related neuropsychiatric
disorders that are often co-occurring in AUD. The current dissertation presented
strong evidence to suggest that OXT (exogenous administration or driving the
endogenous system) reduces alcohol self-administration and reinstatement
behavior. However, a number of questions remain unanswered about the
mechanism and circuitry underlying the ability of OXT to produce these effects.
Taken together, the OXT system may be a promising target for therapeutic
intervention of AUDs, though additional studies are necessary to establish its
clinical efficacy and further investigate the mechanisms and conditions by which
the OXT system regulates stress- and reward- related behaviors differently in
males compared to females.
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Figure 1. Chemogenetic activation of hypothalamic oxytocin-containing
neurons decreased alcohol consumption in female mice. (a) chemogenetic
activation of PVN OXT+ neurons reduced alcohol consumption in the first two
hours of the test session (0-2hr) and total alcohol consumption (b) Systemic
CNO (3 mg/kg) administration decreased drinking at all time points relative to
vehicle in animals harboring control virus (c) systemic administration of OXT (1
mg/kg) decreased alcohol intake at all timepoints relative to vehicle. Values are
mean ± s.e.m (N=10-12/group) *p<0.05 versus VEH

177

Lever Responses

e

Ethanol Intake (g/kg)

80
60
40

^

*

20
0
3 Day AVG VEH

CNO

100

d
Ethanol Intake (g/kg)

Lever Responses

c

b

100

80
60
40
20
0
3 Day AVG VEH

CNO

100
80
60
40
20
0
3 Day AVG VEH

^

*

OXT

f

1.5

1.0

0.5

0.0
3 Day AVG VEH

^

*

CNO

1.5

1.0

0.5

0.0
3 Day AVG VEH

Ethanol Intake (g/kg)

Lever Responses

a

CNO

1.5

1.0

0.5

0.0
3 Day AVG VEH

^

*
OXT

Figure 2. Effect of chemogenetic activation of hypothalamic oxytocincontaining neurons on oral operant alcohol self-administration in female
mice (a) chemogenetic activation of PVN OXT+ neurons reduced lever
responding and (b) alcohol intake in mice harboring excitatory virus compared to
vehicle and the average of the last 3 days of baseline responding prior to testing.
Administration of CNO had no significant effect on (c) lever responses and (d)
alcohol intake in mice that received infusion of control virus. Systemic OXT (1
mg/kg) also reduced (e) lever responding and (f) alcohol intake. Values are mean
± s.e.m (N= 8 /group Gq and N= 6/group CTL) *p<0.05 versus VEH, ^p<0.05
versus 3 day average
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Figure 3. Effect of chemogenetic activation of hypothalamic oxytocincontaining neurons on stress-induced alcohol relapse-like behavior in
female mice (a) Active and inactive lever responding during the baseline oral
operant alcohol self-administration. Animals harboring excitatory (Gq) DREADD
exhibited higher responding on the active lever than animals that received control
virus but there was no difference in (b) ethanol intake between groups. For
reinstatement, animals were exposed to predator odor (TMT) for 15 minutes and
then tested for alcohol-seeking behavior under extinction conditions (c) mice with
excitatory DREADD virus that received a vehicle injection demonstrated an
increase in lever responding (alcohol-seeking behavior) compared to the average
of the last 3 days of extinction. Activation of PVN OXT+ neurons via
administration of CNO (3 mg/kg) significantly reduced stress-induced relapse-like
behavior relative to vehicle. Similarly, in mice that received control virus (d) TMT
exposure reinvigorated alcohol-seeking behavior in both VEH and CNO treated
animals. However, animals treated with CNO exhibited a significant decrease in
stress-induced relapse-like behavior compared to VEH. Values are mean ± s.e.m
(N= 10 /group Gq and N= 8/group CTL) *p<0.05 versus Ext, ^p<0.05 VEH
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